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Protein identification and quantitation using mass spectrometry has evolved as the dominant technique 
for studying the protein complement of a system: cell, tissue or organism. The proteomics of body 
fluids is a very active research area as there is great potential for protein biomarker discovery; 
application of such technologies would revolutionise medical practice and treatment. Saliva, through 
its non intrusive nature of sampling, is an ideal body fluid for disease diagnosis, screening and 
monitoring. Gingivitis is a gum disease with symptoms including bleeding, swollen, and receding 
gums. After dental decay, gingivitis is estimated to be the most common disease worldwide, and 
around 40% of the population in the US are reported to have gingivitis. The end point goal of this 
project was to identify salivary biomarkers for gingivitis. 
This dissertation presents an investigation of: 1) the salivary proteome; 2) developments and 
applications of a mass spectrometry kinase assay; and 3) salivary biomarkers for gingivitis using 
proteomics and kinase activities.  
The soluble portion of the human salivary proteome (saliva supernatant) has been studied by several 
research groups but very few proteomic studies have been performed on the insoluble, cellular and 
bacterial portion of saliva. Presented here, is the first global proteomics study performed on the saliva 
residue and supernatant from the same test subject.  A total of 834 and 1426 proteins were identified 
in the saliva supernatant and residue, respectively. A global analysis of protein complexes in saliva 
was also performed and is the first study, to date, of such an analysis. KAYAK (‘Kinase ActivitY 
Assay for Kinome analysis’) was further developed for its application on a number of cell types, tissue 
types, and a variety of organisms. Proof of concept work for in-gel kinase activity/kinase abundance 
correlation profiling using blue native gels was performed, and experiments using anion exchange 
chromatographic kinase activity/kinase abundance correlation profiling were performed to identify 
kinase-substrate pairs. KAYAK applications included the analysis of kinase activities in 
Saccharomyces cervisiae, Drosophila, mouse, and human saliva in which significant kinase activity 
was detected in the saliva supernatant, a novel finding. Finally, gingivitis was induced in patients, and 
the saliva samples were analysed using proteomics and kinase activity profiling. Although this work is 
ongoing, preliminary data indicate that there are increases in various inflammatory proteins, certain 
bacteria and also in the activity of particular kinases as a result of the induction of gingivitis.  
The overall study provided insights into the salivary proteome for both the human and bacterial 
complement, as well as discovering the presence of significant kinase activity in saliva. In the induced 
gingivitis study, almost half of all the proteins identified in the residue were from bacteria (1274 
bacterial proteins, 198 species identified) and there may be more potential for biomarker discovery for 
certain diseases in the saliva residue than in the supernatant. A very large overlap was observed 
between the human proteins in the saliva supernatant and residue, indicating that many of the salivary 
proteins originate from lysed cells. The origin of the kinase activity in the saliva supernatant is not 
known but is also proposed to originate predominantly from lysed cells. A range of novel KAYAK 
applications have been investigated, demonstrating that KAYAK has a wide variety of future uses 
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1.1 Project overview and aims 
Until very recently medical practice has been based on generalised therapy in which a standard set of 
treatments are used to address a particular disease1-2. Only recently has the idea of ‘personalised 
medicine’ become feasible in which therapies are specifically tailored to an individual’s genetic 
makeup to yield optimal results3. With the dramatic reduction in the cost of DNA sequencing, in the 
future medical treatment in the developed world will become increasingly personalised and effective4-
5. Whilst the use of genetic markers are useful for gauging a patient’s potential responsiveness to 
various drugs or understanding genetic disorders, knowledge of an individual’s gene sequence alone is 
often inadequate for understanding and treatment of disorders related to transcriptional regulation, 
protein expression levels, and abnormal enzymatic activity6-7.  Protein biomarkers are able to detect 
abnormal cellular dynamics not revealed by DNA sequencing, and are likely to be a critical tool in 
personalised medicine8. Protein profiling and biomarkers are likely to play an increasingly significant 
role in screening, diagnosis, prognosis, and monitoring of patients in a wide variety of diseases. 
Classical proteomics focuses on protein identification and abundance whilst protein activity has been 
relatively unexplored9; the assessment of both will be necessary for fully understanding the human 
proteome. Drug development and testing in pharmaceutical companies may also be significantly 
benefited by continued progress in these fields10-11.  
It is important that any tool used for screening, diagnosis, or prognosis should use easily obtainable 
samples that provide robust information.  Saliva, as an easily accessible body fluid, fits these criteria 
and holds great promise as a diagnostic tool12. Despite the ease of access and non-invasive nature of 
saliva collection, the majority of biomarker efforts have been directed towards blood, and the salivary 
biomarker field has been relatively unexplored. Furthermore, most protein biomarkers have been 
validated, to date, using protein abundance approaches8, 13 and there is a great need for technologies 
that can comprehensively assess protein activities that may be more indicative of disease state than 
protein abundance9.   
This project analysed saliva using both proteomics and protein activity profiling in order to discover 
disease biomarkers. In this thesis, the salivary proteome was characterised and biomarkers were 
investigated from an induced gingivitis clinical trial. Developments and novel applications of 
KAYAK (Kinase ActivitY Assay for Kinome profiling) were investigated. This assay quantifies one 
specific type of protein activity (kinases) and offers great potential for cancer-diagnostics, treatment 
options, and lead compound drug evaluation. The strategy used in this kinase assay can also be 




The specific project aims were: 
i) To investigate the salivary proteome comprising both the supernatant and residue portion, 
including proteins of human and bacterial origin (Chapter 3). 
ii) To develop and apply a mass spectrometry-based multiplexed kinase assay and kinase 
activity/kinase abundance correlation profiling to a variety of different systems including saliva 
(Chapter 4). 
iii) To identify protein-abundance and protein-activity salivary biomarkers of gingivitis (Chapter 5). 
Prior to addressing these aims, a general overview of proteomics, mass spectrometry, saliva, and 
biomarkers will first be discussed. 
 
1.2 Proteomics 
The proteome can be defined as the total protein complement of an individual cell, tissue or organism 
under a given set of conditions14. Proteomics involves any large scale or systematic characterisation of 
the proteome, and represents the functional genome15. The aim of proteomics is to generate an 
overview of the characteristics and functions of proteins in a given biological system, at any particular 
time, to reveal information on cellular dynamics and cell-to-cell crosstalk16-17. The proteome is 
dynamic – proteins are modified and change in abundance and sub-cellular location with time. The 
dynamism of proteins is dependent on the state of the cell (metabolic, activation, pathological) and 
internal and external signals. The proteome reflects the state of the cell at the time of sampling, thus 
revealing the molecular mechanisms behind the control of all aspects of cell biology.  
Proteomics can be divided into two types in terms of scale: global and targeted proteomics18. The goal 
of global proteomics is to analyse all the proteins present in a cell. An extension of global protein 
analysis can involve examining differences in protein profiles under different conditions. Since 
differences will always be observed, the main challenge is to determine those that are biologically 
significant. On the other hand, targeted proteomics attempts to characterise a well-defined 
subproteome, for example phosphoproteins, glycoproteins, cell surface proteins, individual organelles, 
macromolecular complexes, and cellular machines19-20. The main challenge is the difficulty in 
reproducible isolation of subproteomes and differentiating relevant proteins from contaminants20-21. 
 
1.2.1 Protein identification by mass spectrometry 
There are two main approaches for protein identification using mass spectrometery (MS): ‘top-down’ 
and ‘bottom-up’. In the top down approach intact proteins are analysed directly by MS, whilst in the 
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bottom-up method the proteins are first digested into peptides before MS analysis. The main 
advantages of the bottom-up approach for sequencing are that the currently existing database search 
engines are more developed for the analysis of bottom up fragments, determination of the mass of 
peptides is more accurate than measuring the mass of whole proteins, and the bottom-up approach 
allows for higher throughput22. Only bottom-up approaches will be considered here. There are two 
main routes for protein identification using bottom-up approaches: Peptide Mass Fingerprinting 
(PMF) and tandem MS. 
1.2.1.1 Protein identification using peptide mass fingerprinting 
In the early days of proteomics (mid 1990s), peptide mass fingerprinting was used to identify proteins 
by obtaining and matching the masses of a group of peptides derived from a protein by sequence-
specific proteolysis against the masses of the peptides from in silico digested proteins in a database23-
24. Protein digestion by a sequence-specific protease generates peptides with predictable masses, 
which are generally unique for a specific protein, thus providing a mass fingerprint for the protein. 
Trypsin is often the protease of choice, and it cleaves proteins at the C-termini of arginine (R) and 
lysine (K) residues.  MS analysis of peptides results in a list of mass/charge (m/z) ratios. The 
experimentally derived m/z values are compared to a database of in silico digested proteins, generated 
using the same sequence-specific protease. An algorithm is then used to compare experimentally 
derived m/z ratios of peptides versus theoretically predicted peptide m/z ratios for each protein in 
database. Scores are assigned depending on the quality of the match and the number of matches of 
peptides to the protein. PMF is generally performed on MALDI TOF (Matrix Assisted Laser 
Desorption Ionisation Time Of Flight) mass spectrometers. In MALDI the analyte is embedded in a 
matrix that is dried and then volatilised in a vacuum under UV laser irradiation. It is often combined 
with a TOF analyser, where the mass-to-charge ratio of an analyte ion is deduced from its flight time 
through a tube of specified length under vacuum. 
1.2.1.2 Protein identification using tandem MS 
The use of peptide fragmentation spectra from tandem mass spectrometers has now replaced PMF as 
the main protein identification approach. Tandem mass spectrometers have two (or more) stages of 
mass analysis and they are able to fragment peptide ions and record the resulting peptide 
fragmentation spectra. There are various ways by which peptides can be fragmented, depending on the 
type of mass spectrometer, and this in turn dictates at what point in the peptide backbone the peptides 
are fragmented. The most common fragmentation method is CID (Collision Induced Dissociation) and 
is the usual process for triple quadrupole, ion trap, quadrupole-time of flight (QTOF) hybrids and 
LTQ Orbitrap mass spectrometers (discussed in more detail in Appendix B). In general, the peptide 
ion of interest is isolated from the rest of the ions from the source. The isolated peptide ion is then 
fragmented in a collision cell by collision with a non-reactive gas, such as helium or argon, and the 
fragment ions detected. The process of CID on each of the peptide ions can be automated. For 
complex mixtures of proteins, it is necessary to have very low flow rates (50-300 nL/min) into the 
mass spectrometer to allow time to isolate each of the peptides and to perform CID on them. Protocols 
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for automated, instrument-controlled precursor ion selection have been developed in which, in a 
particular time-frame, the ion with the greatest intensity is selected (data-dependent acquisition 
MS/MS) and CID is performed on it.25 The next most intense ion is then selected and so on. 
The majority of fragment ions from low-energy CID result from cleavage of the amide bond and are 
referred to as b and y ions (Figure 1.1). A b ion is formed when the positive charge associated with the 
parent peptide ions is retained by the amino terminal fragment side, whilst a y ion is formed when the 
charge is retained on the carboxy terminal fragment of the fragmented amide bond26. The subscript for 
b and y ions represent the number of amino acid residues present on the fragment ion counted from 












The information in the peptide fragmentation spectra can be used to identify proteins in two different 
ways. Firstly, de novo sequencing: amino acid residues can be determined from the mass difference of 
successive fragment ions of the same type (e.g. bn – bn-1)29. The advantage of de novo sequencing is 
that the search is not restricted to peptides contained in a database. However, there are several 
problems with this approach as it is generally difficult to correctly identify the whole amino acid 
sequence and the results are time-consuming to analyse manually. Another difficulty in de novo 
interpretation is that when using tandem MS spectra, not all fragment ions are detected and many of 
the intervening peaks may or may not belong to the series. Although there have been some attempts to 
automate this process, it remains an extremely difficult task30,31. The second approach for protein 
identification is the comparison of the m/z peaks in the CID spectra with theoretical in silico generated 
MS/MS CID spectra. This approach is easily automated and is the more prevalent method used today. 
Only a small fraction of the total number of possible peptide amino acid sequences occur in nature and 
therefore, whilst a tandem mass spectrum may not contain enough information for de novo 
sequencing, it often contains sufficient information to be matched to a peptide sequence in the 
database based on the observed m/z values of the fragment ions.  
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1.2.2 Quantitative proteomics 
To understand biological systems and their perturbations, measurement of changes in protein 
abundance as well as protein identification is important32. Quantitative proteomics involves the global 
analysis of changes in protein abundance in a particular system (cell, tissue or organism) under 
different conditions/treatments. Protein abundance can be determined using either relative (to other 
proteins in an experiment) or absolute quantitation, but in general, relative quantitation is more 
commonly used in large-scale proteomics experiments on account of ease and cost. In gel-free 
proteomics experiments, quantitation is normally calculated at the peptide level, rather than the 
protein level. However, the signal intensity of a particular peptide is not directly proportional to the 
protein amount due to varying ionisation efficiencies of different peptides, protease accessibility, and 
peptide solubility22. There are several approaches for quantitation using mass spectrometry (Figure 
1.2)33 including stable isotope labelling34-35 and label-free quantitation based on either the ion 









Figure 1.2   Schematic of  the  three main quantitation approaches  in LC‐MSMS proteomics. Quantitation using 
isotopic labelling (shown in red) uses the abundance of peptide A (sample X) versus the abundance of the heavy 
isotope labelled peptide A* (sample Y) for relative quantitation. Quantitation using spectral counting (shown in 
green)  relies on  the number of  times a peptide was  successfully  sequenced as a measure of peptide/protein 
abundance and compares this across different LCMS runs (sample X and sample Y). Quantitation using label‐free 




There are various strategies for quantification using LC-MSMS (liquid chromatography tandem mass 
spectrometry) (metabolic labelling, chemical modification, label-free) depending on the point in an 
experiment the quantitative information is generated, and on when the label is added. For example, 
metabolic labelling can be used to label during cell culture, chemical modification can label at either 
the protein or peptide level, whilst label-free methods rely on the mass spectrometer extracted ion 
intensity, or the spectral count, and require no labelling.    
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1.2.2.1 Stable isotope labelling 
Quantitative proteomics using stable isotope labelling was first reported in 1999 by several research 
groups39-40. Stable isotope labelling theory proposes that the relative signal intensity in a mass 
spectrometer of two analytes that are chemically identical but of different stable isotope composition 
(and thus distinguishable in a mass analyser) are a true representation of the relative abundance of the 
two analytes in the sample41. The differential stable isotope labelling approach allows relative peptide 
quantitation between two (or more) samples in the same LC-MSMS run. Two samples are 
differentially labelled with a light and heavy isotope and can be detected by their mass difference 
(Δm/z), resulting in a relative quantitation of the protein amounts. Absolute quantification using stable 
isotopes is also possible by comparison with a labelled synthetic peptide analogue that acts as an 
internal standard (e.g. AQUA)42, but will not be discussed further in this section. 
ICAT (isotope coded affinity tag)39 and iTRAQ (isobaric tag for relative and absolute quantitation)43 
are chemical modifications where the samples are treated with heavy and light forms of a reagent. 
Chemical modifications can be performed either on proteins or peptides, depending on the actual tag. 
ICAT analysis involves labelling proteins at cysteine residues with heavy and light ICAT labels prior 
to trypsin digestion. The ICAT reagent is attached to cysteine residues by a cleavable biotin group 
which allows rapid affinity isolation of cysteine containing tryptic peptides on an avidin column44. 
The heavy and light ICAT tag results in a 8 Da mass shift between the respective heavy and light 
peptides, and through comparing the peak area of the heavy and light peptide pairs in the MS survey 
scan can allow relative quantitation44. One of the disadvantages of ICAT is that only cysteine 
containing proteins can be analysed, although this can be advantageous in the analysis of a complex 
sample where the simplification of the analysis can often result in greater sensitivity45. 
The iTRAQ system is similar to ICAT but the labelling is performed following trypsin digestion and 
peptides, rather than proteins, are tagged. The amine group of a peptide is labelled with isobaric 
labelling reagents and fragmentation of the tag attached to the peptide generates reporter ions of 
masses 113-119 and 121 Da which are unique to the tag used46. By comparing the relative intensity of 
the reporter ions it is possible to obtain relative quantitation of the original protein amounts46-47. There 
are currently 8 iTRAQ labels, allowing 8-plex quantification47. Advantages of iTRAQ include 
multiple comparisons of different samples/treatments in the same experiment along with complete 
sample labelling48. A disadvantage of iTRAQ is that the chemical tag is introduced at a late stage of 
the experimental workflow. This means that many sample preparation steps must be performed prior 
to the labelling, increasing the risk of inadvertent errors due to differences in sample preparation. 
Another labelling technique is to use 16O/18O digestion labelling where peptides are labelled during or 
following trypsin digestion in the presence of H216O or H218O49. 
Metabolic labelling, where the label is introduced in vivo during growth, can be advantageous since 
sample preparation errors are reduced as the samples are isotopically labelled very early in the 
procedure prior to protein extraction, and hence any sample preparation errors performed post 
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labelling affect both the heavy and light labelled samples in parallel50. In general, metabolic labelling 
using 14N/15N is most commonly used and has been performed on many organisms including 
bacteria40, yeast51, plants52, cell culture53, Drosophila melanogaster54, Caenorhabditis elegans and 
rats55. The main disadvantage of metabolic labelling is that samples can only be labelled during 
growth, thereby excluding body fluids, clinical biopsies, and environmental samples from being 
analysed. Furthermore, the aim of achieving complete labelling can often result in long culture times, 
and incomplete labelling is common for complex multicellular organisms55. 
One popular metabolic labelling procedure is SILAC (Stable isotope labelling with amino acids in cell 
culture) which utilises two cultures of cells.56  One group of cells is cultured with unlabelled (natural 
isotopic abundance) amino acids and the other culture is fed with amino acids in which one amino 
acid, generally arginine or lysine, has been replaced with an isotopically (often 13C and/or 15N) 
labelled form. As the cultures grow, the cells incorporate the natural or heavy isotopes into their newly 
synthesised proteins. Following proteolytic digestion the ratio of peak intensities or peak areas in the 
mass spectra can be used to determine the relative abundances of the proteins. A disadvantage of 
SILAC, compared to 14N/15N labelling, is the possibility of quantitation errors through in vivo 
interconversion of isotopically labelled amino acids. Arginine is converted into proline in some cell 
lines and glycine can be converted to various amino acids57-59 leading to partial loss of labelling and 
unpredictable mass shifts.  
The main advantage of labelling methods is that they allow the relative quantitation of 
peptides/proteins from different samples in the same LCMS run, meaning that the method does not 
suffer from multiple measurement noise or errors from misalignment of chromatographic traces. For 
label-free analysis it is imperative that the chromatographic and mass spectrometry conditions are 
identical between runs. Disadvantages of labelling based quantitation include high reagent cost, 
increased time and complexity of sample preparation, difference in ionisation efficiencies of labels, 
incomplete labelling, the potential requirement of specific quantitation software, and the limitation of 
comparing only two samples. Consequently for experiments requiring the comparison of large 
numbers of samples, such a biomarker discovery, there has been increased interest in the application 
of label-free proteomics for quantitation. 
1.2.2.2 Label-free quantitation 
Label-free quantitation encompasses methods that use spectral counting as a measure of protein 
abundance, as well as methods that directly compare the signal intensity between different LCMS 
runs. The label-free approach is significantly less costly than the labelled approach because high-cost, 
heavy isotopic label tags are not necessary. As a result, the label-free approach is more suited 
comparing a range of different treatments in clinical samples and allows for retrospective comparison.  
1.2.2.2.1 Ion intensity 
Label-free quantitation based on the extracted ion intensity (EIC) quantifies proteins in separate 
8 
 
LCMS or LC-MSMS analyses through aligning the chromatographic total ion count (TIC) traces from 
MS survey scans and comparing the peptide relative peak intensities (peak areas or heights)36, 60-62. A 
challenge in label-free peptide ion intensity quantitation for complex peptide mixtures is that changes 
in the elution of the peptides may affect the quantitation. It is therefore critical that the same data 
acquisition conditions are performed for all experiments: same mass spectrometer method, same LC 
method, same column and temperature63. This becomes more problematic where multi-dimensional 
chromatographic separations are used, since even small variations in the chromatography will lead to 
irreproducible peptide separation64. Matching of peptide peaks between different MS analyses can be 
challenging on account of variations in both the LC retention time and the m/z65. The changes in LC 
retention time of the peptides are often not linear and accurate correction is difficult64. Minimal 
sample handling is preferred to reduce variations between samples and minimise errors65. 
Much of the published research using label-free ion intensity quantitation uses spectra with high 
resolution and high mass accuracy from FT-LTQ, LTQ Orbitrap and QTOF instruments with few 
reports using low resolution mass spectrometers such as ion traps63. Accurate matching of peptides 
between different runs is easier with greater accuracy m/z and the software packages are often 
optimised for the higher resolution mass spectrometers66. However, label-free ion intensity 
quantitation software is often designed to work with a particular mass spectrometer and may only give 
quality results with one particular instrument setup. For hybrid mass spectrometers it is possible to 
acquire LC-MSMS data, and hence quantitative information from the LCMS may be combined with 
identification information from the MSMS scans. However, linking the LCMS with the LC-MSMS is 
not straightforward and there is currently much software development in this area66. There are a wide 
variety of software packages available for label-free quantitation, both open source and 
commercial165,166,170,171 (Table 1.1).  
Most of the software packages have fairly similar workflows. Preprocessing algorithms are employed 
for smoothing and despiking the data and then peptide peaks are detected through their characteristic 
isotopic pattern. The chromatograms are aligned to account for changes in the retention time and the 
TICs are normalised based on a spiked in reference or the total TIC area. The EICs of each of the 
peptides are then compared between the different LCMS runs. Finally, MSMS information on the 
peptides can be linked through the m/z and retention time (Rt) to the peptides in the LCMS run. There 
are two main approaches for the combination of LCMS and LC-MSMS data. Firstly, MSMS 
information from a single LC-MSMS run can be used when quantitation LCMS information has 
already been extracted. However, because in one LC-MSMS run not all the peptides have MSMS 
data, another approach has been to incorporate MSMS information from several LC-MSMS runs or 
use inclusion lists which target peptides of interest33.  
1.2.2.2.2  Spectral counting 
There are various features that can be correlated with protein abundance, for example the number of 
identified peptides, the number of unique peptides, the sequence coverage, and the spectral count67. 
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The spectral count is the sum of all the acquired MSMS spectra and represents the identified peptides 
for a protein68. In spectral counting quantitation experiments, two or more samples are analysed using 
LC-MSMS independently with similar data acquisition parameters. Protein identification is performed 
on the individual samples separately and the spectral count of each protein is then compared between 
samples. A variety of different normalisation procedures can be used to account for both run-to-run 
variations69 and the variation in protein sizes. For example, normalisation is often performed using 
protein length or the expected number of proteolytic peptides. The normalised spectral abundance 
factor (NSAF) is a commonly used approach that effectively divides the total spectral count for a 
protein by its length70-71. 
One of the challenges with the spectral count quantitation method is the significant variability at low 
spectral counts (e.g. one to three peptides per protein)33. Shotgun proteomic experiments (high 
performance liquid chromatography combined with tandem mass spectrometry) favour the detection 
of the more abundant peptides, and the detection of peptides present at only low concentrations can be 
poor and irreproducible72.  Also, at high spectral counts saturation behaviour is often observed73. 
Spectral counting is very dependent on the accuracy of the MSMS peptide identifications, and 
consequently any errors made at the peptide level propagate though to the protein level33. Another 
source of error is that one peptide can be matched to several proteins leading to problems of 
redundancy at the protein level. 
In general, spectral counting is considered semi-quantitative, since the spectral count is an estimate of 
protein amount and the physicochemical properties of the peptides are not considered. Spectral 
counting assumes that all the peptides respond linearly with increased protein abundance, but this is 
not necessarily the case. Further, the peptide’s size, charge and hydrophobicity have a significant 
effect on the efficiency of ionisation65. Spectral counting is able to quantify proteins from many 
independent experiments and is suited to samples with large dynamic ranges38. Low resolution 
instruments are also suited to spectral counting because low resolution data are not ideal for other 
quantitation methods. Spectral counting has been widely used in many biological samples including 
biomarker discovery in urine74, saliva75 and lung cancer76. 
Despite the lower accuracy of label-free quantitation in proteomics, the absence of a need for 
expensive reagents and tags/labels, a greater dynamic range, and no limitation on the number of 
samples for analysis, means that label-free is the preferred technique in many studies. This is 
particularly true for those studies involving biomarkers where the analysis of numerous samples is 
required65, 70. 
1.2.2.3 Software packages for proteomics quantitation 
Data processing and bioinformatics are  major analytical challenges in quantitative proteomics and in 
the last five years, there has been a rapid increase in the number of commercial and open-source 
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Many of the software packages are dependent on the specific instrument type and labelling/label-free 
strategy. While there are a few software packages available, such as MaxQuant83, Trans-Proteomic 
Pipeline96 and Mascot v2.2 (Matrix Science, UK), in general, very few publically available software 
platforms exist for integrated data processing and analysis. Integrated data analysis allows consistent 






Subproteomics can refer to proteomics of a particular organelle, protein complex or body fluid, as 
well as a proteomics investigation of an affinity enriched sample such as the phosphoproteome or 
glycoproteome99. A greater depth of protein coverage may be obtained by focussing on a particular 
subproteome. This thesis involves the study of the salivary proteome as well as the phosphoproteome 
of saliva. A brief introduction to the proteomics of body fluids and phosphoproteomics is discussed 
below. 
1.2.3.1 Proteomics of body fluids 
One of the applications of proteomics is to identify disease biomarkers and, for this application, the 
proteomes of body fluids are likely to be the most useful and clinically relevant100. To achieve this aim 
for biomarker discovery, two phases of proteomic research have been proposed: a mapping phase and 
a scoring phase100. The mapping phase involves large scale, comprehensive analysis of the proteomics 
of body fluids and their subsequent organisation into databases (e.g. Global Proteome Machine101,102 
and Peptide Atlas103,104). The scoring phase involves quantitation of a core set of proteins that can 
effectively represent the whole proteome or a subproteome of particular interest100. Many human body 
fluids have been investigated using proteomics; including blood105, which has been the most studied, 
urine106, saliva107, cerebrospinal fluid108-112, tears113, and seminal fluid114.  The Human Proteome 
Organisation (HUPO) completed the first large scale study of human serum and plasma proteins in 
which 889 proteins were identified with high confidence115 from a total of 3,020 proteins which were 
identified with two or more unique peptides116. Since blood comes into contact with all the tissues, 
tissue specific proteins are secreted into it and hence plasma proteomics has the potential to diagnose 
many diseases affecting all parts of the body117. However, since the volume of blood is relatively 
large, the abundance of proteins secreted into the blood from any particular organ can be very low and 
there may be greater opportunity for biomarker discovery in ‘proximal fluids’ which are those fluids 
that come into contact with only a few tissue types100. The concentrations of tissue specific proteins 
that are indicative of the health/disease state of that tissue are likely to be higher in proximal fluids 
and therefore these fluids offer greater diagnostic value for certain diseases100. For example, CSF 
(cerebrospinal fluid) can give an indication of the biochemical environment of the brain as it is in 
continuum with the extracellular fluid of the CNS (central nervous system). There are various brain-
specific proteins present in low concentrations in CSF. However, more than 80% of the proteins in 
CSF are thought to originate from plasma108-112.  Furthermore, obtaining blood samples, while 
relatively commonplace, is more difficult than obtaining samples of other body fluids such as saliva.   
Urine analysis has particular relevance for the understanding of diseases that are related to the 
kidneys. Diseases of the kidneys and urological tract can often cause glomerular damage. For people 
with normal kidney function the walls of the glomerular capillaries in the kidney only allow proteins 
less than 65 kDa into the urine. Therefore, many renal diseases are diagnosed by the presence of larger 
proteins in the urine (e.g. proteinuria). Urine is a desirable fluid for analysis as it is convenient to 
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collect in large amounts. In a recent study, 1,543 proteins were identified from urine, with nearly half 
classified as membrane proteins by Gene Ontology (GO) analysis106. Extracellular, lysosomal and 
plasma membrane proteins were found to be highly represented in the urine, whereas other 
intracellular proteins were low. Urinary biomarker investigation has involved the study of many 
diseases including prostate cancer118, renal cell carcinoma119, bladder cancer and120, and urothelial 
carcinoma121.  
The sputome (sputum proteome) is an under-studied bodily fluid on which there is little published 
research. This is at least partly due to the technical difficulties involved in processing such mucin-rich 
samples. The highly crosslinked mucin matrix and the presence of highly charged mucins makes 
analysis by conventional 2DGE more difficult. The most extensive study carried out to date on the 
sputome used a combination of 2DGE and GeLC-MSMS and identified 258 proteins, of which 191 
were of human origin122. The proteins in sputum originate from many diverse sources such as the 
secretory products of the lower and upper airways, cellular products, and inflammatory cell derived 
products. Proteins from ‘contaminants’ such as saliva, epithelial cells and gastrointestinal products are 
also present. An analysis comparing the sputome with the proteins of BAL (bronchoalveolar lavage), 
NLF (nasal lavage fluid) and saliva found that the proteins in sputum overlap significantly with those 
found in BAL and saliva. It is not clear, though, whether the proteins identified in both sputum and 
saliva are due to contamination of sputum with saliva or whether it is possible that these proteins are 
produced independently in the lower airway mucous glands. Many more proteins have been identified 
in BAL than in sputum: 1,375 versus 258122. A possible explanation is that the process of BAL 
collection causes microvascular leakage leading to the presence of serum proteins in BAL, something 
which would not necessarily occur during collection of sputum122. Various proteomic studies have 
been performed on saliva and this is discussed in Section 1.4.3. 
One of the disadvantages of proximal fluid proteomic analysis is the restriction to diagnosis of certain 
diseases and that collection can be difficult in particular cases(e.g. CSF)100. However, it is thought that 
many of the biomarkers found in proximal fluids can be identified in blood plasma if a targeted 
approach is used100. Therefore, the strategy of using proximal fluids for preliminary biomarker 










Phosphorylation is one of the most common reversible posttranslational modifications (PTM) of 
proteins123 whereby a phosphate group is added to a protein molecule. Phosphoproteomics is the 
characterisation of the degree of phosphorylation of proteins. Phosphorylation can be observed most 
commonly on serine residues, and to a lesser extent on threonine and tyrosine residues. Protein 
kinases catalyse the phosphorylation of proteins whilst phosphatases dephosphorylate proteins. Genes 
coding these two enzyme types constitute around 2% of the human genome124. Phosphorylation plays 
a critical role in regulating many cellular processes including cell differentiation, many metabolic 
functions, and forms the basis of many signalling pathways. Phosphorylation also regulates enzyme 
activity, complex formation, subcellular localisation and the degradation of proteins. Chemically, the 
addition of a phosphate group generally makes a protein more hydrophilic. 
Prior to large scale mass spectrometry-based proteomic studies, the analysis of protein 
phosphorylation was challenging and often only focused on one phosphoprotein. Traditional methods 
included purification by phospho-specific antibodies which were very time consuming to generate123. 
Another approach used 32P labelled ATP in in vitro kinase reactions followed by the separation of 32P 
labelled phosphorylated peptides by TLC (thin layer chromatography) and subsequent MS analysis123. 
However, in vivo studies of phosphorylation can generally yield more useful information than 
studying phosphorylation in vitro, since nonspecific phosphorylation may occur in vitro. 2DGE or 
DIGE (followed by MALDI MS or immuno- or western blot with specific phosphoantibodies) can be 
used to map the phosphoproteome because phosphorylation of a protein leads to a decrease in its pI 
resulting in a change of spatial location on the gel. However, this approach is not suited to quantitative 
analysis on account of variability in the amounts of proteins transferred to the membrane and the 
selectivity and affinity characteristics of the antibodies. Alternatively, direct staining of 2DGE can be 
used with Pro-Q DiamondTM, a fluorescent phosphosensor dye, that is able to discriminate between 
phosphorylated and unphosphorylated proteins125. Another method is to compare gels treated with 
phosphatase to untreated gels in order detect changes in the proteome126,127.  
On account of the low abundance of phosphoproteins and/or the low phosphorylation stoichiometry of 
phosphoproteins, it is often necessary to perform phosphoprotein enrichment when studying the 
phosphoproteome123, 128. It is important to note that the phosphorylation sites on proteins might vary 
and, although it is often possible to identify the major phosphorylation sites, less abundant or highly 
transient phosphorylation sites might be missed.  
1.2.3.2.1  Methods for phosphoprotein enrichment 
For native purification of phosphoproteins/peptides there are four main strategies: immunoaffinity 
chromatography, immobilised metal affinity chromatography (IMAC), metal oxide affinity 
chromatography (MOAC), and strong cation exchange (SCX) chromatography123.  These strategies 
are also used for other sample separations and enrichments but can be tailored towards 
phosphoprotein/peptide enrichment.   
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In immunoaffinity chromatography, antibodies that specifically recognise phosphorylated residues 
irrespective of the surrounding sequence can be used to purify phosphorylated proteins and peptides. 
Antiphosphotyrosine antibodies are more commonly used123,129-130 than antiphosphoserines and 
antiphosphothreonines131. This is largely because antiphosphotyrosine antibodies are more specific 
than the other antibodies. Other phosphorylated amino acids can be analysed more easily using 
antibodies that specifically target a phosphorylated peptide sequence or consensus sequence motif for 
a kinase.  
IMAC is the most extensively used strategy for phosphoprotein/peptide enrichment. Negatively 
charged phosphate groups are ligands for transition metal cations such as Fe3+ and Ga3+. These 
transition metal cations are linked to a solid support, such as sepharose or poros by, for example, 
iminodiacetic acid (IDA). The main limitation with this approach is nonspecific binding of carboxyl 
groups (COO- of acidic amino acids and C-terminal carboxy groups) to the metal cation, although this 
can be reduced by using a low pH (COOH favoured)132, methyl esterification of the carboxyl group133 
and a relatively high percentage of organic solvent. Elution can be performed using sodium phosphate 
(pH 7.4) or EDTA (ethylene diamine tetra-acetic acid). 
The MOAC method uses metal oxides such as titania and zirconia to chelate phosphorylated peptides. 
This is based on a similar principle to IMAC, except that it is not necessary to chelate the metal to a 
solid support. Similarly to IMAC, the nonspecific binding of carbonyl groups of peptides remains a 
challenge with the approach. Non-specific binding can be reduced by the addition of 
dihydroxybenzoic acid134 or using phthalic acid135. Addition of dihydroxybenzoic acid is reported to 
reduce nonspecific binding by competition between non phosphorylated peptides and 
dihydroxybenzoic acid for binding sites on TiO2136.  
SCX is a common method for the purification and fractionation of proteins and peptides, where 
positively charged proteins/peptides are electrostatically attracted to anionic beads. By tuning the pH 
and ionic strength of the buffers it is possible to favour the binding of particular proteins. At low pH 
(2.7) tryptic phosphopeptides have less positive charge than other tryptic peptides and therefore elute 
earlier from SCX columns. Although SCX can be used as a standalone technique for phosphopeptide 
enrichment, it is generally more useful when it is used as a fractionation technique in combination 
with a subsequent phosphopeptide enrichment step. 
1.2.3.2.2 MS strategies for phosphoprotein analysis 
The bottom-up strategy is generally used for MS analysis of phosphoproteins. The C-phosphate bond 
is usually cleaved more easily than the peptide backbone during CID and therefore, if performing 
normal MSMS of peptides, the phosphate group is unlikely to be observed attached to the fragment. 
There are alternative approaches to analyse phosphopeptides including precursor ion scanning, neutral 




Cleavage of the phosphate group (PO3-) from a peptide by CID in negative mode generates a peak at 
m/z 79 in the MS/MS spectra. Using precursor ion scanning it is possible to generate an inclusion list 
on which MS/MS is to be performed, which can then be applied in the next run137. Another method 
involves the detection of m/z 79 in negative mode triggering a polarity switchover to positive mode 
MS/MS138-139. Similarly, loss of a phosphotyrosine immonium ion in positive mode CID at 216 m/z 
can be used as a marker ion for phosphopeptides137.  
The loss of various species involving phosphate (such as phosphoric acid) from precursor ions can be 
used as a trigger for peptide fragmentation such as in the neutral loss monitoring approach. It is 
possible to determine the number of phosphate groups on the phosphopeptides by observing the 
number of neutral losses from the precursor ion. Also, it is often possible to determine the 
phosphorylation sites by observing unique product ions and the fragment ion series. In positive 
ionisation, loss of H3PO4 (phosphoric acid) corresponds to a neutral loss of 98 Da from phosphoserine 
and phosphothreonine residues (through β-elimination), whilst loss of 80 Da corresponds to a neutral 
loss of HPO3 (metaphosphoric acid) from phosphotryrosine. A loss of 69 Da corresponds to 
dehydroalanine from phosphoserine and 83 Da corresponds to dehydroaminobutyricacid from 
phosphothreonine. 
Fragment ions in the MSMS spectra can be further fragmented by MS3 and the loss of neutral 
fragments (e.g. phosphoric acid) in MSMS can trigger MS3 fragmentation. This leads to better 
fragment ion spectra and consequently better identification of phosphopeptides138-139.  
Fragmentation techniques other than CID can be used for the analysis of phosphopeptides. Electron 
capture dissociation (ECD) and electron transfer dissociation (ETD) are particularly suited to the 
analysis of phosphopeptides because the phosphorylated group is not generally cleaved off, allowing 
direct determination of the modification site140-143. ECD involves the capture of low energy electrons 
by multiply protonated ions. Following the neutralisation of the charge, the radical cations dissociate 
forming c- and z-type fragment ions. ECD is primarily used in FTICR MS. ETD is similar to ECD and 
generates c- and z-type ions144. The main difference is that ETD uses radical ions for the transfer of 
electrons whereas ECD uses naked electrons. ETD is particularly suited to the fragmentation of large 
peptides and high charge states.  
Whilst large scale phosphoproteomic studies provide information about which sites on a protein are 
phosphorylated, no information regarding the identity or the activity of the kinase responsible for the 
phosphorylation event is obtained. This issue is addressed in the next section where a mass 





1.3 Mass spectrometry based kinase activity assay 
Classical proteomics experiments generally involve the identification of large protein sets with or 
without relative quantitation. The results of such proteomics experiments give an overview of the 
steady state chemical readout of protein abundance but there is no information regarding the activity 
of the proteins. For enzymes, quantifying the enzymatic activity is often of more interest than the 
enzyme’s abundance. Whilst there has been some work involving activity-based proteomics, the 
majority of studies on activity-based proteomics have focussed on the use of chemical tags that 
selectively label the active forms of enzymes145-149. There is currently no large scale mass-
spectrometry-based enzyme activity assay strategy established and adopted by the proteomics 
community. The development of KAYAK (Kinase ActivitY Assay for Kinome profiling)150-151 for 
kinase activity measurements, and its derivatives for other enzyme classes, offers such a strategy for 
global activity-based proteomic profiling.  
1.3.1 Kinases 
There are more than 500 genes encoding protein kinases in the human kinome and it is estimated that 
at least 30% of the human proteome is phosphorylated by kinases152-153. Protein phosphorylation (by 
kinases) and dephosphorylation (by phosphatases) are among the most significant regulators of 
signalling pathways in cells154. Hyperactivation of certain signalling pathways is a hallmark of most 
cancers155. The hyperactivation can be caused by the overexpression of growth factor receptors, such 
as Ras and PI3K, through the structural alteration of kinases such as Src and BCR-Abl, or through the 
loss of negative feedback control proteins such as PTEN156-159. During oncogenesis, rewiring of the 
cell signalling network occurs and the cell may reach a state whereby it becomes self-sufficient in 
growth signals and no longer responds to apoptotic signals155. Kinases are also the targets of many 
drug discovery programs including diabetes, autoimmune and neurological disorders160. 
Kinases generally comprise two domains: a catalytic and a regulatory domain. The catalytic domain 
binds ATP and the substrate, whilst the regulatory domain interacts with other proteins that modulate 
the activity of the catalytic domain. The kinase catalytic domain is highly conserved because all 
kinases bind ATP at common sites161. Many kinases have two major regions in which the ATP and 
substrate binding sites are situated. There is in a cleft linking the two regions where an activation loop 
keeps the substrate close to the ATP binding site. Changes in the location and conformation of the 
kinase activation loop affect the activity of the kinase.  
Kinase inhibitor drugs generally target the ATP recognition site or act through allosteric regulation. It 
is very difficult to achieve high-specificity ATP recognition site competitive inhibitors, and therefore 
unexpected off-target inhibition is a significant problem for pharmaceutical companies. Targeting 
allosteric sites is advantageous on account of higher specificity, minimising off-target effects, as well 




Kinases are divided into tyrosine kinases (TKs) and serine-/threonine kinases (STKs), based on the 
substrates they phosphorylate. Kinases are further divided into eight major groups based primarily on 















Various strategies have been traditionally used to both infer and directly measure kinase activities163-
166. The most common approach has been to use phosphospecific antibodies to observe 
phosphorylation of kinase substrates at a particular residue167. However, this approach does not 
directly measure the kinase activity. Instead, it measures phosphorylation at a specific site which is 
used as a surrogate of kinase activity. There is great need for high throughput techniques to screen for 



















1.3.2 KAYAK: Kinase ActivitY Analysis for Kinome profiling 
KAYAK is a technique recently developed by the Gygi laboratory to measure multiple kinase 
activities through absolute quantification of peptide substrate phosphorylation. The first version of 
KAYAK, reported in 2009168, was a ‘90 pot’ kinase reaction in which 90 synthetic peptide substrates 
were incubated individually with the sample (e.g. cell lysate, recombinant kinase) and ATP. 
Following quenching of the reaction, a known concentration of internal standard (the phosphorylated 
form of the substrate sequence labelled with stabled isotopes) was added. Each of the individual 
KAYAK reactions were then combined together, the phosphorylated peptides enriched using IMAC 
and then analysed using high-resolution LCMS. The absolute amount of phosphorylation is 
determined by comparing the peptide EIC of the light (phosphorylated substrate) peptide to the heavy 
(internal standard) peptide. The second modified version of KAYAK was reported in October 2009150, 
and further developed the assay into a multiplexed ‘one-pot’ kinase reaction where all 90 peptide 
substrates were incubated simultaneously with the sample (Figure 1.4). There are three main 
advantages with the improved KAYAK assay. Firstly, significantly less lysate (90-fold) is required for 
the reaction. Secondly, each peptide is at 20–fold lower concentration (5 µM instead of 100 µM), 
which enhances the sensitivity of the assay and utilises less substrate. Thirdly, the efficiency and ease 
of performing many reactions simultaneously is significantly increased, which was not possible with 




















1.3.3 Applications of KAYAK 
KAYAK can be used to determine the kinase activities in various sample types including cell lysates, 
tissue biopsies and recombinant kinases. By simultaneously monitoring the kinase activities of 
multiple kinases, an overall picture of kinase signalling pathways can be obtained. 
Kinase signatures of cell lines as well as their response to different treatments can be generated. For 
example, KAYAK was performed on various cell lines which were treated with and without 
epidermal growth factor (EGF). From the upregulated kinase activities it could be seen that EGF 
activates the Akt/PI3K and Ras/MAPK pathways in HeLa and HEK-293 cells. As well as 
investigating the effect of external stimulants, KAYAK can be used to investigate the effect of kinase 
inhibitors. Following the success of rapamycin, a kinase inhibitor of mTOR, there has been a great 
increase in research into kinase inhibitors as drugs for the treatment of cancer151. In vivo there may be 
many off-target effects of kinase inhibitors, and the KAYAK assay offers a way to investigate which 
kinases and pathways may be affected by such drugs150. KAYAK has been performed on normal and 
tumour tissue from patients with renal cell carcinoma, and it was shown that there is increased activity 
of Akt and RSK/ERK in the tumour tissue150. In the future, the KAYAK profile of a biopsy could be 
used to determine which kinase pathways are upregulated in a patient’s cancer, which can aid in 
determining optimum drug cocktails and provide increasingly personalised medicine. 
 
1.3.4 KAYAK correlation profiling 
Peptides can often be phosphorylated by multiple kinases. KAYAK correlation profiling is a new 
strategy to determine the kinase(s) responsible for a particular phosphorylation event. The sample (e.g. 
cell lysate) is fractionated at the protein level. Each fraction is analysed by KAYAK to determine the 
kinase activity, and by shotgun proteomics to determine the kinases involved. Correlation analysis of 
the kinase activities and kinase abundance in each of the fractions identifies kinase-substrate pairs. 
Shotgun analysis of the fractions identifies all proteins present and this technique may even identify 
regulatory partners in kinase complexes150. 
 
1.3.5 Comparison of KAYAK with current kinase activity assays 
A range of kinase assays have been developed169-173. It is difficult to compare KAYAK with other 
techniques since there is currently not a single ‘gold standard’ kinase assay with which to compare it. 
The main competitor is possibly the method in which substrate peptides or proteins are immobilised 
on microarrays and the kinase activity determined with phosphospecific antibodies or radioactive 
ATP173-175. Whilst these arrays allow high throughput analysis, it is not possible to gain site specific 
phosphorylation information. Assays based on radioactivity have been widely adopted as they do not 
require the generation of expensive phosphospecific antibodies. Disadvantages of assays based on 
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radioactivity include a fairly high background measurement, thus hindering accurate quantitation, and 
the high cost of waste disposal. 
In contrast, there are currently mass spectrometry methods following phosphoprotein enrichment that 
enable the identification of tens of thousands of phosphorylation sites. The amount of phosphorylation 
on these sites can even be compared between two samples for thousands of sites176-177. However, this 
analytical workflow is currently not high-throughput and requires significant amounts of starting 
material (in the region of 10-20mg), whilst only 20 µg per reaction is required for KAYAK.  
A disadvantage of KAYAK is that since it is an in vitro assay, the kinase activity obtained may be 
misleading due to the exclusion effect of regulatory mechanisms involving protein scaffold attachment 
and substrate competition in vivo. Whilst substrate competition does exist with the ‘one-pot’ reaction 
with multiple peptide substrates, this can never mimic the in vivo conditions. Also, kinase function is 
very dependent on its localisation in a cell, where the same kinase can have very different roles in the 
cytoplasm and the nucleus178-179. In the future it may be possible to perform KAYAK in vivo if 
KAYAK peptides can be engineered to cross the cell membrane. One of the advantages of the 
KAYAK method is that it can be adapted to other enzyme classes, such as phosphatases and proteases 
















1.4 Saliva  
Proteomics of body fluids is important for biomarker discovery and saliva has great potential on 
account of its ease of sampling12. A brief summary of the main components of saliva, different ways it 
can be collected, along with the main salivary proteomic studies that have been performed to date are 
discussed here. 
1.4.1 Saliva composition 
Saliva is an exocrine secretion that is slightly acidic (pH 6-7). It comprises a dilute aqueous solution 
of electrolytes, minerals, buffers and proteins and plays many physiological roles. It lubricates and 
cleans the oral cavity, facilitates speech, aids taste, chewing, and swallowing and aids digestion. As 
well as playing a significant role in oral homeostasis, it has antimicrobial activity and protects teeth by 
neutralising and buffering acids. It contributes to enamel pellicle formation and maintains a 
supersaturated solution of calcium phosphate (Figure 1.5)180. Some of the roles of proteins in saliva 
have been well studied whilst others are not known. For example, mucin is known to play several 
roles, including coating much of the surface in the mouth to aid lubrication, mastication and 
swallowing, and to protect against irritants and bacteria by regulating the adhesion of microorganisms 
to the oral surface181. Lactoferrin binds ferric iron and hence reduces the growth of certain bacteria, 












The fluids collected from the mouth are known as oral fluids or ‘whole saliva’, which is distinct from 
‘saliva’, which constitutes the glandular secretions. Oral fluids (or whole saliva) include stimulated 
and unstimulated saliva, gingival crevicular fluids, oral transudate, pathological exudates, nasal 
secretions, regurgitated gastric secretions, nonadherent oral bacteria and food debris, and traces of 
introduced chemicals or medications. Gingival crevicular fluid is secreted from the space between the 
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teeth and gums and the rate of secretion increases with damage to the gum/tooth interface. Nasal 
secretions pass into the back of the throat constantly. Gastric contents, particularly after drinking 
alcohol, will be regurgitated into the mouth. Saliva is produced by three major paired exocrine glands 
(Figure 1.6): the parotid (P), submandibular (SM) and sublingual (SL), as well as many minor salivary 
glands. Healthy humans produce around 1-1.5 litres of whole saliva a day, approximately 65% from 
submandibular, 20% from parotid, 7-8% from sublingual and less than 10% from the minor salivary 
glands182. Unstimulated saliva flow above 0.1 ml/min is considered as normal and the average is 0.3 
ml/min183. Saliva flow rate can be reduced by dehydration, fear, sleep, or use of some drugs such as 
atropine and opiates. Production is increased with chemical (gustatory or olfactory), physical (e.g 
chewing) or psychological stimulation. As with Pavlov’s dogs, where the association of a bell with 
food can make dogs drool, associations linked with food cause greater salivation in humans184. With 
stimulation, the percentage contribution from each of the glands changes, and the percentage 
contribution from the parotid gland increases from 7-8% to over 50%185. The maximum stimulated 
flow rate is around 7 ml/min, and up to 80-90% of the saliva produced a day may be stimulated185.  
There are three secretory pathways for saliva; the major-regulated pathway, the constitutive-like 
pathway and the minor-regulated pathway. The major-regulated pathway is regulated primarily by β-
adrenergic stimulation. Agonist binding to the β-receptor results in an increase in cAMP in the cell 
that activates PKA and an increase in exocytosis186. The major-regulated pathway is responsible for 
the high-abundance saliva proteins and provides most of the stimulated saliva during parasympathetic 
innervations187. On the other hand, the constitutive-like and minor-regulated pathways are mainly 
responsible for the production of unstimulated saliva during basal parasympathetic stimulation188. It 
appears that exosomes and apoptotic blebs are also secreted in saliva, and proteomics have been 
carried out on these membrane-bound vesicles187. 
In this project, whole saliva was collected, and consequently all the oral fluids were analysed together 
(Chapter 3). The rationale behind collection of whole saliva relates specifically to application of this 
work to ‘spit tests’ in the future; whole saliva is more convenient to collect than individual saliva 
components (e.g. individual saliva gland secretions). Furthermore, whole saliva collection is more 
comfortable for the patient and does not require a dentist for sample collection189. The main sources of 
proteins in oral fluid are the salivary glands, but there are also proteins in the other oral fluids 
mentioned above as well as from microorganisms (mostly bacteria), blood and oral tissues that could 
be important contributors, especially from people with poor oral health. In the literature, a distinction 
between saliva and oral fluids is generally not made, and the salivary proteome comprises oral fluids 
and often contaminants such as blood and bacteria.  
Saliva secretions are classified as serous, mucous or mixed. The parotid produces serous secretions, 
the minor salivary glands produce mucous secretions and the SM and SL have both serous and 
mucous secreting cells.185 The composition of saliva secreted is unique to each of the 3 different 
glands, and it is possible to collect secretions from individual glands by intraoral devices that are 
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capable of isolating a glandular duct. Because saliva is produced in acinar cells it is isotonic, but it 
changes to hypotonic on passing through the ductal network. This allows the mucin glycoproteins to 
hydrate and consequently expand to cover and protect the mouth tissues190. This is particularly 









Figure  1.6    Main  salivary  glands.  Saliva  is  secreted  from  three  main  paired  exocrine  glands:  sublingual, 
submandibular and parotid. The sublingual glands are located below the tongue, the submandibular are located 
below  the  lower  jaw  and  the  parotid  gland  is  located  anterior  to  the  external  ear  and wraps  around  the 
mandibular ramus. Adapted from Wong et al.189 
 
The SM and SL ductal orifices are close together, so obtaining secretions from individual ducts can be 
difficult. In some individuals these glands may share common ducts. In order to ensure the purity of 
SM and SL secretions, the Loo laboratory developed unique biomarkers that can be used to identify 
pure SM and SL secretions. Cystatin C was found to be unique to SM secretions and MUC5B mucin 
and Calgranulin B were found to be unique to SL secretions191. 
 
1.4.2 Salivary proteomics 
Salivary proteomics is a relatively new field and less work has been carried out on saliva than on other 
body fluids, such as blood and urine. The main reason for this is that the concentrations of proteins in 
saliva are generally lower than in blood but, with the advances in proteomics, the analysis of lower 
protein concentrations is now possible. There are various research groups investigating the salivary 
proteome with a view of cataloguing all the proteins present180, 189, 192-204. One of the main initiatives is 
by the National Institute of Dental and Craniofacial Research (NIDCR) to develop tools for disease 
diagnosis using saliva. In 2003 NIDCR funded three institutions – UCLA, USC and Scripps to 
catalogue the salivary proteome and to identify all the salivary proteins from the 3 major salivary 
glands. This initiative has 3 main aims; the first aim involved clinical acquisition of saliva from the 3 
major salivary glands (parotid, submandibular, sublingual) from a cohort of human donors. The 
second aim was proteomic analysis to decipher the complete salivary proteome and its associated 
complexes from the three major glands. The third was the biocomputational and bioinformatics 




cataloguing of the salivary proteome. The work was published in recently and the Salivary Proteome 
Knowledge Base is available on the internet205.  
A total of 1,116 proteins were identified in the ductal secretions of saliva: 914 in parotid and 917 in 
SM/SL. 57% were identified in both parotid and SM/SL secretions. The majority of proteins identified 
are linked to extracellular and secretory classes. The three research groups identified different 
numbers of proteins; however, 152 parotid and 139 SM/SL proteins were identified by all three 














Many of the proteins identified in saliva (from the three research study) were also present in plasma 
and tears (Figure 1.9)205, 207. 192 out of 657 plasma proteins were identified in saliva and 55% of tear 







Many studies have been performed on the saliva supernatant (Table 1.2). Most of the studies on ductal 
saliva have focused on the parotid187. Some researchers have also focused on subsets such as the 
salivary glycoproteome200, 202 but only one laboratory has recently considered the cellular portion of 
saliva211. 
Table 1.2   Main salivary proteome  results of  the saliva supernatant. The most comprehensive  list of proteins 
identified in whole saliva is from the Griffin lab where 2340 proteins were identified using a three dimensional 
peptide fractionation approach107. 










The proteome of parotid exosomes was investigated by the Yates group and 491 proteins were 
observed. 265 of these had previously been reported from parotid gland secretions and 72 had been 
identified in the proteomic analysis of urinary exosomes. Of the parotid exosome proteome, 43% were 
assigned to cytosolic proteins according to GO and KEGG pathway analysis, and 26% were integral 














Most of the salivary proteome studies reported in the literature have been searched against human 
databases. Few studies have searched their data against bacterial databases. One example identified 31 
bacterial species in saliva supernatant including Streptococcus mutans, Streptococcus pneumoniae, 
Streptococcus avermitilis, Porphyromonas gingivalis and Helicobacter pylori192 and another study 
identified around 30 bacterial species in the saliva residue211. 
The majority of work to date has focused on cataloguing the salivary proteome. The samples are 
generally pooled or taken from a single individual, and there does not appear to have been a thorough 
investigation of the amount of variation between individuals or the effect of circadian rhythm, health 
status, age, or gender. It is likely that the protein composition of saliva will change quite significantly 
with the above factors, along with the food consumption of the individual, the amount of physical 
exercise, and medication. Investigation of the salivary dynamic proteome is important for biomarker 
studies to determine the ‘normal’ amount of variation in the quantities of the various proteins. 
Although technologies such as MS and other protein separation techniques have been developed to 
identify and quantify proteins, there is no one universal strategy to identify all proteins in a biological 
sample. The main problem arises from the dynamic range of protein amounts and the structural 
complexity. The main steps are the purification and fractionation, identification of proteins and PTMs, 
followed by quantification.  
 
1.4.1 Salivary microbiome 
As a continuation of the Human Genome Project, the NIH sponsored the Human Microbiome Project 
(HMP) in December 2007. The microorganisms in five different regions of the human body are being 
investigated: gastrointestinal tract, oral cavity, nose, skin, and female urogenital tract214. The number 
of microorganisms present in the average human is estimated to exceed the number of human somatic 
and germ cells by a least 10:1. This NIH project aims  to produce 1000 sequenced bacterial genomes 













share a core microbiome and whether changes in the human microbiome can be correlated to disease 
states214.  
The Human Oral Microbiome Database (HOMD) was the first to go on-line in March 2008215 and the 
others are still in progress. There are currently 600 microorganisms known to live in the mouth215. The 
HOMD aims to categorise each microbe by its 16S rRNA sequence215. The mouth has many different 
environments each of which favours the growth of different suites of microorganisms: e.g. hard 
surface of the teeth, soft surfaces of the gums, tongue, lining of the mouth, crevicular pockets. The 
microflora of the mouth is a diverse community and one of the key populations is plaque, a biofilm on 
the surface of the teeth which has been proposed to be responsible for gingivitis and periodontitis216. 
The study of bacteria comprising plaque is critical for understanding the progression of gingivitis. In 
order to study the bacterial biofilm growth, a constant depth film fermentor (CDFF) can be used as a 
model mouth (Figure 1.11)217. This apparatus is maintained at body temperature (37°C) and comprises 
a glass vessel with stainless steel endplates and a rotating turntable contains holes which have plugs 
containing bovine enamel discs (modelling ‘teeth’) and which are recessed 50-500 µm to allow a 
biofilm to develop on the enamel discs. This system can be used to produce single and multispecies 
biofilms using artificial and/or human saliva218. This apparatus can be used to model the effect of 
different conditions and treatments on the structure and composition of the biofilm. For example, the 
effect of chlorhexidine219 and other antimicrobials on biofilms can be used, or gingivitis conditions 












Whilst many bacteria have been identified in plaque and on other mouth surfaces, very few studies 
have investigated the presence of bacteria in saliva. One recent study, looking at the cellular residue 
component of saliva, identified around 30 different bacterial species using proteomics211. In many 
diseases, there is a complex interplay between bacteria and the host response; therefore, it is important 
to consider as many aspects as possible in the discovery of disease causes and progression, which will 




Biomarkers are biological markers that can be used to indicate a specific state. The term can have 
various meanings depending on the area in which it is used. In medical terms, it is a substance or 
pattern of markers that can suggest and/or measure the progression of a disease state. Biomarker 
discovery is based on various ‘omics’ technologies including transcriptomics, proteomics, 
metabonomics, peptidomics, glycomics, phosphoproteomics and lipidomics (Table 1.3)220. 
Transciptomics involves studying the whole set of transcribed RNA products, and many profiling 
studies have been carried out which suggest that this area has great potential221,222. Proteomics, is the 
study of cellular proteins, is used in this project and has been previously discussed. Metabonomics is 
concerned with the quantitative metabolic response of multicellular systems to stimuli and relies on 
both NMR and MS methods. A few metabonomic biomarker studies have been successful in detecting 
liver cancer using urinary nucleosides as tumour markers223,224, but relatively few studies have been 
when compared to proteomic research. Peptidomics investigates all the expressed peptides and their 
PTMs (post translational modifications). The two main sources of peptidome biomarkers are 
fragments from protein molecules and cleavage products generated ex vivo following blood clotting.220 
Glycomics involves the study of all the glycan molecules in an organism: glycolipids, glycoproteins, 
lipopolysaccharides, peptidoglycans and proteoglycans. Several studies have shown promise for 
potential tumour biomarkers225. Finally, lipidomics is the characterisation of lipids and their 
interacting molecules. It has been reported that levels of LPA (lysophopsphatidic acid) and 
sphingolipids are altered in various cancers226,227.  
Ideally, it would be advantageous to utilise multiple ‘omics’ technologies to improve biomarker 
specificity and develop diagnostic tools which may work on a ‘personalised’ level. There have been 
several attempts to integrate various classes of biological data, such as linking transciptomics and 
metabonomics for neuroendocrine cancer124, and linking genomics, transcriptomics and proteomics 































1.5.1 Salivary diagnostics and biomarkers 
Proteins are commonly used in clinical assays for disease diagnosis and monitoring. In fact, over 100 
protein assays are currently used in clinical testing laboratories229. Most of these diagnostic tests 
current utilise blood samples, while use of other body fluids such as urine, cerebrospinal (CSF), 
amniotic, peritoneal, pleural and saliva are largely relegated to purely hospital use229.  
Despite the relative dearth of salivary diagnostic tools, saliva is easy to ship and store and it can be 
obtained at low cost and in sufficient quantities for many types of analysis. Furthermore, saliva 
collection is non-invasive, which provides a significant advantage over blood collection.  This is 
particularly true in certain populations such as children, the elderly, mentally handicapped and 
intravenous drug abusers. Unfortunately, saliva contains lower concentrations of protein than blood230, 
making analyses which require highly abundant proteins more difficult. However, the relative 
simplicity and lower dynamic range of the salivary proteome (when compared to blood) also allows 
for fewer complex protein interactions and would potentially allow for more straightforward, highly 
sensitive and specific, diagnostic tests to be developed.  
Various mouth diseases are known to affect salivary composition including oral cancer189,231-232 and 
periodontitis233. Periodontitis is a chronic bacterial infection of the tissues surrounding teeth. 
Symptoms include inflammation, connective tissue breakdown and alveolar bone destruction. There is 
a need to identify reliable markers for disease activity as a means to assess the effectiveness of 
treatments and for identifying the ‘at risk’ individuals who are particularly susceptible to destructive 
periodontitis233. Gingivitis, a milder, early form of periodontitis, is also highly prevalent and having 
biomarkers to identify it would allow for preventive measures to be taken before the disease worsens.  
This thesis will investigate potential biomarkers for gingivitis. 
Besides oral diseases, saliva tests are currently used in diagnosis of Sjogren’s syndrome234-236, HIV237-
238 and Hepatitis B and C239 as well as monitoring marijuana, cocaine and alcohol use240-243. Saliva can 
be used to help monitor various systemic conditions such as stress244, ovarian function245, ovarian 
cancer246,247, tuberculosis, gastric ulcers, liver dysfunction and sarcoidosis248-251,252,253,254. Saliva can 
also be used to test for illegal drugs, or monitor alcohol, steroid and antibody levels255-256. Many 
studies are currently aimed at discovering and validating salivary biomarkers for a range of 
diseases230, 236, 257. Many systemic diseases are known to affect the mouth and the salivary glands 
which makes searching for related salivary biomarkers a promising endeavour. Examples include 
diabetes75, Crohn’s disease258, Lambert-Eaton Myasthenic syndrome (LEMS)259 and 
Alzhemier’s260,261.  
With the development of proteomics protein biomarker pipelines, there is great potential for 
increasing numbers of protein biomarkers to be identified, validated and utilised8. Saliva offers an 
ideal body fluid for the diagnosis and monitoring of various diseases, particularly those that affect the 




This chapter has given an overview of protein identification and quantitation of proteins using mass 
spectrometry proteomics. Saliva, in the context of potentially useful body fluid biomarkers was 
introduced and a brief literature review of the work performed on the salivary proteome was included. 
The concept of a mass spectrometry based protein activity assay to measure kinase acitivies was 
outlined (KAYAK). Finally, a short introduction to biomarkers, with emphasis on saliva, was 
provided. The subsequent chapters of this thesis discuss work involving the investigation of the 
salivary proteome (Chapter 3), the further development and validation of the KAYAK technique 
(Chapter 4), and preliminary salivary biomarker discovery for gingivitis using both proteomics as well 





















2 Experimental and method development 
This Chapter outlines the experimental procedures used for sample preparation and mass spectrometry 
both at The University of Edinburgh (UoE) and at Harvard Medical School (HMS). Preparation of 
saliva for proteomic analysis was different in the two locations and different mass spectrometers were 
used. The mass spectrometers used at UoE included a quadrupole time-of-flight (QTOF Ultima, 
Waters), an ion trap (High Capacity Trap, HCT, Bruker) and a Fourier transform ion cyclotron 
resonance mass spectrometer (FTICR, Bruker). The mass spectrometers at HMS included an ion trap 
(LTQ, Thermo Fisher) and ion trap-Orbitrap (LTQ Orbitrap, Thermo Fisher). 
The procedure for the kinase assay is included along with the optimisation and developments made to 
the original assay. The procedure for correlation profiling using kinase activity/kinase abundance 
using anion exchange chromatographic separation is described. This technique is used to identify the 
kinase responsible for a specific phosphorylation event. As well as using in-solution chromatographic 
separation, gel separations techniques were investigated and the development and optimisation of in-
gel correlation profiling using blue native polyacrylamide gel electrophoresis is described. A 
description of the molecular biology techniques used is included. These procedures were performed 
for sample preparation for kinase assays and for validation experiments for putative kinase-substrate 
pairs following kinase activity/kinase abundance correlation profiling. 
 
2.1 Materials 
Unless stated otherwise, all chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Trypsin 
(mass spectrometry sequencing grade) was obtained from Promega (Madison, USA). Monocolonal 
anti-HA antibody (F-7, sc-7392) was obtained from Santa Cruz Biotechnologies. Purified human 
active kinases of PAK3, PAK2, EIF2AK2, PRKACA, MAPK14 and PRKCD were obtained from 
SignalChem. PBK was obtained from Cell Signaling Technologies and Cdc2/Cyclin B was obtained 
from Millipore. siRNA for PAK3, TP53RK, CDC2, MAPK14, PBK were obtained from Thermo 
Fisher. Peptides were synthesised by Cell Signaling Technologies (CST). Briefly, the MultiPep 
instrument from Intavis Bioanalytical Instruments AG was utilised in a 96 well-plate format using 
Fmoc chemistry, as described168. Unpurified peptides were obtained from CST and then purified 
individually using semipreparative HPLC on a C18 column and quantified using the 
spectrophotometric method based on the reaction of free amino groups in amino acids with 2,4,6-






2.2 Sample preparation at UoE (University of Edinburgh) 
2.2.1 Saliva preparation 
Whole saliva was collected on ice from healthy non-smoking subjects at least 2 h after eating. Saliva 
was expectorated through a pipette tip into a 15 mL centrifuge tube placed on ice. No stimulation to 
increase saliva flow was used. Protease inhibitor cocktail (Sigma, 1 μl/mL whole saliva) was added to 
minimise protein degradation. The saliva was centrifuged at 12,000 rpm at 4°C for 15 min and the 
residue discarded. Protein concentration was determined using a Bradford assay (Bio-Rad). The 
proteins in saliva were precipitated overnight using ethanol (5 x volume of saliva) at -20°C.  The 
mixture was centrifuged at 12,000 rpm at 4°C for 15 min, the protein pellet washed with 70% cold 
ethanol and dried by vacuum centrifugation. The protein pellet was redissolved in 50 mM ammonium 
bicarbonate (ambic, pH 7.8) containing 6 M urea. Dissolution was aided by sonicating on ice (10 
rounds of 20 sec each). The sample was reduced using 10 mM dithiothreitol (DTT) for 45 min at 
50°C, alkylated in the dark for 45 min using 50 mM iodoacetamide (IA), and further treated with 50 
mM DTT to quench excess IA. The sample was diluted with 50 mM ambic to a final urea 
concentration of 1M and acetonitrile (ACN) added to 10%. Trypsin (TrypsinGold, mass spectrometry 
grade, Promega) was added at a 1:20 (w/w) enzyme-to-substrate ratio and incubated overnight at 
37°C. After digestion, ACN was removed by vacuum centrifugation and purified using ZipTips 
according to the manufacturer’s instructions. Following vacuum centrifugation the purified peptides 
were resuspended in 0.1% formic acid (FA) for MS analysis. Percentages are referred as ‘by volume’ 
(v/v) unless otherwise specified. 
 
2.2.2 Saliva bacteria preparation 
Whole saliva was centrifuged at 1500 rpm at 4°C for 15 min. The supernatant was removed and the 
residue washed twice with PBS (phosphate buffered saline, pH 7.4). The cell pellet was resuspended 
in PBS (20 mL) and lysed using a Cell Disruptor Machine (Constant Systems Ltd.) at a pressure of 30 
kPa, or using detergents (RIPA buffer containing 1% Tritron X100). The lysed sample was 
centrifuged at 13,000 rpm at 4°C for 45 minutes and the residue discarded. The supernatant was 
precipitated overnight using ethanol (5 x volume of sample) at -20°C and then centrifuged at 13,000 
rpm, at 4°C for 15 min and the supernatant discarded. The protein pellet was resuspended in 50 mM 
ambic containing 6 M urea. Dissolution was aided by sonicating on ice (10 rounds of 20 seconds each) 
and then reduced, alkylated and digested as described in Section 2.2.1. Although very effective, the 
disadvantage of using the Cell Disruptor Machine for bacterial cell lysis is that a minimum volume of 





2.2.2.1 Culturing of saliva bacteria 
LB broth (200 mL) was inoculated with 1 mL of saliva and incubated at 37°C with stirring for 16 
hours. The bacteria were collected by centrifuging at 5,000 rpm. The bacterial pellet was washed 
twice with PBS and then resuspended in PBS. The bacteria were lysed in a Cell Perturbator machine 
at a pressure of 30 kPa. The lysed bacteria were then processed as described above.  
2.2.2.2 Strong cation exchange fractionation (SCX) 
Digested salivary bacteria were fractionated by SCX chromatography (Ultimate 3000, Dionex-LC 
Packings, Hercules, CA) system using a PolySulfoethyl A column (2.6 × 200 mm, 5 μm, 300 Å, Poly 
LC Inc., Columbia, MD). Peptides were reconstituted in 400 μl of SCX buffer A (10% ACN, 100 mM 
formic acid, pH 3) and loaded onto the column at 200 μl /min flow rate. An isocratic gradient of SCX 
buffer A for 20 minutes was used, followed by a 20 minute linear gradient from 0–50% SCX buffer B 
(100 mM ammonium formate, 10% acetonitrile, pH 6), followed by a 20 minute gradient from 0-
100% SCX buffer C (600 mM ammonium acetate, 10% acetonitrile, pH 6) at a constant flow rate of 
200 μl /min. Fractions were collected at 1 min intervals and those at the beginning and the end were 
combined. 
 
2.2.3 Saliva phosphoprotein enrichment  
Whole saliva (20 mL) was collected on ice as described in Section 2.2.1. Tris acetate buffer and urea 
were added to saliva to final concentrations of 50 mM and 6 M respectively. This mixture was 
centrifuged at 13,000 rpm at 4°C for 20 min to remove debris and filtered through 0.2 µm filters 
(SpinX, Costar). The protein and peptide double IMAC method used in this study was adapted from 
Collins et al.137 Fast-flow Sepharose with iminodiacetic acid chelating groups (Amersham 
Biosciences) was charged with GaCl3. The filtered saliva (20 mL, 12 mg) was incubated with 1 mL of 
the gallium charged resin with mixing at room temperature for 1 hour. The resin was washed with 50 
mM tris acetate containing 6 M urea (10 column volumes) and the phosphoproteins were eluted with 
50 mM tris acetate containing 6 M urea, 100 mM EDTA and 100 mM EGTA and concentrated in a 
spin column (Vivaspin 500,Vivascience). The phosphoproteins were diluted with 25 mM ambic 
containing 1M urea and 5 % ACN and digested with trypsin (Promega) in a ratio of 1:20 (w/w) 
trypsin-to-substrate at 37°C overnight and then dried in a vacuum centrifuge. A portion of the digested 
protein IMAC purified sample (200 µg) was desalted, dried in a vacuum centrifuge, and reconstituted 
in 200 µL buffer (pH 2.5-3) comprising 34% water, 33% methanol and 33% acetonitrile. Self Pack 
POROS® 20 MC media (Applied Biosystems) was charged with GaCl3. The peptide mix was then 
incubated with 200 ul of POROS-Ga slurry for 1 h at room temperature. The resin was then loaded 
into a spin column and washed with 10 column volumes of buffer comprising 34% water, pH 2.5-3, 
33% methanol and 33% acetonitrile. Phosphopeptides were eluted with 1 x 100 µL of 200 mM 
Na2HPO4 and 1 x 100 μl of 100 mM EDTA. The purified phosphopeptides were desalted using Zip 
tips and reconstituted in 0.1% FA prior to MS analysis. 
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2.3 Sample preparation at HMS (Harvard Medical School) 
2.3.1 Saliva preparation 
Whole saliva was collected on ice from healthy non-smoking subjects at least 2 h after eating. Saliva 
was expectorated through a pipette tip into a 15 mL centrifuge tube placed on ice. No stimulation to 
increase saliva flow was used. Protease inhibitor cocktail (complete protease inhibitor 1x, Roche) was 
added to minimise protein degradation. The saliva was centrifuged at 12,000 rpm at 4°C for 15 min 
and the residue discarded. Protein concentration was determined using a Bradford assay (Pierce). The 
proteins in saliva were purified using a methanol/chloroform precipitation method263. Briefly, for 100 
µL of protein sample, 400 µL of MeOH were added. After vortexing and centrifuging (12,000 rpm, 1 
min), 100 µL of chloroform was added. After vortexing and centrifuging (12,000 rpm, 1 min), 300 µL 
of water was added. Phase separation occurred following centrifuging (9,000 rpm, 1 min), and the 
upper aqueous layer was discarded. 300 µL of MeOH were added to the lower phase and the sample 
vortexed vigorously. The protein was pelleted by centrifugation for 2 min at 9,000 rpm and the 
supernatant removed. The protein pellet was washed twice with ice-cold acetone and dissolved in a 50 
mM Tris-Cl pH 7.5 buffer containing 8M urea, 50 mM EDTA and 0.005% n-dodecyl β-D-maltoside. 
The proteins were reduced with 10 mM DTT at 37°C for 20 mins and alkylated with 20 mM 
iodoacetamide for 45 min in the dark and the reaction quenched with 10 mM DTT. The concentration 
of urea was diluted to 1 M and the proteins digested with trypsin at a 1:100 (w/w) enzyme to substrate 
concentration at 37°C for 16 hours. The digestion was stopped using formic acid, (final concentration 
5%) and the peptides were purified using StageTips.264  The purified peptides were reconstituted in a 
5% formic acid solution containing 5% ACN prior to MS analysis. 
 
2.3.2 Lysis of human and bacterial cells in saliva 
Whole saliva was centrifuged at 1500 rpm at 4°C for 15 min. The supernatant was removed and the 
residue washed twice with PBS (phosphate buffered saline, pH 7.4). The cell pellet was lysed by 
bead-beating at 4°C (4 cycles of 30 s, with 60 s breaks in between) in a buffer containing 10 mM 
K2HPO4 pH 7.5, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM β-glycerophosphate, 0.5% 
Nonidet P-40, 0.1% Brij 35, 0.1% deoxycholic acid, 1mM sodium orthovanadate, 1mM 
phenylmethyl-sulfonyl fluoride, 5 µg/mL leupeptin and 5 µg/mL pepstatin A. The protein extract was 
separated from the beads and the lysate was centrifuged at 10,000 rpm for 10 min to remove insoluble 
material. The clear supernatant was aliquoted out, snap frozen with liquid nitrogen and then stored at -





2.3.3 In-gel protein digestion 
Where appropriate, proteins were reduced and alkylated prior to running on a gel. Where this was not 
desirable (i.e. with blue native PAGE where the sample is not denatured), the proteins in the gel were 
reduced and alkylated prior to digestion. The general procedure for in-gel digestion with reduction and 
alkylation is given below. The sample was loaded onto a precast bis-tris SDS PAGE gel (mini-gel 
Invitrogen, 4-12%). The proteins were visualised using colloidal Coomassie. The gel lane was excised 
into 20 bands, each of which was cut into ca. 1 mm cubes and transferred into 1.5 mL eppendorf 
tubes. The procedure for in-gel digestion was similar to that described previously265. Briefly, the gel 
cubes were destained using 50 mM ambic/50% ACN, dehydrated using ACN, the disulfide bonds 
reduced with 25 mM DTT at 56°C for 30 minutes and the free sulfhydryl groups then alkylated with 
10 mM IA at 25°C for 45 minutes in the dark and then washed with 50 mM ambic to remove excess 
IA. The peptides were digested overnight with a solution of 12.5 µg/mL trypsin in 50 mM ambic. 
Following extraction of the peptides with 50% ACN containing 5% FA, the peptides were dried by 
vacuum centrifugation, purified using StageTips264 and frozen at -80°C.   
 
2.4 Mass spectrometry at UoE 
2.4.1 Ion trap mass spectrometry 
The majority of HPLC (High Performance Liquid Chromatrography) separation was performed using 
a Dionex 3000 HPLC system (Dionex, UK). Some of the LC-MS/MS runs were carried out using a 
Proxeon Easy nanoLC system and an Eksigent nano pump LC system, but in those cases the gradient 
settings were the same. Two different platforms were used: nano ESI and regular ESI. 
2.4.1.1 nESI-LC-MS and LC-MSMS 
LC-MS/MS of peptide mixtures was performed on a RP HPLC (Ultimate 3000, Dionex, UK) with a 
High Capacity Trap mass spectrometer (HCT Ultra, Bruker) with a nanoelectrospray interface. The 
samples were first loaded onto a C18 pepmap precolumn (Dionex, UK) and washed for 3 min with the 
loading solvent, 0.1% FA. The samples were then loaded onto a PepMap capillary column (75 μm x 
15 mm; particle size 3 μm, Dionex, UK) for nano-LC separation at a flow rate of 350 nL/min. The 
buffers used for the LC were (A) 2% ACN/98% H2O/0.1% FA and (B) 80% ACN/20% H2O/0.1% 
FA. A linear gradient was utilised from 0% B to 50% B in 150 min, and then from 50% to 100% in 20 
min. After 10 min at 100% B, the column was re-equilibrated in buffer A for 20 min before the next 
run. For online MS and MS/MS analyses, a metal tip (Proxeon) with an internal diameter of 50 μm 
was used. The instrument was externally calibrated using Agilent Tune mix. MSMS data was acquired 
using data dependent software (HCT Ultra, Esquire Control, Bruker Daltonics). The acquisition 
parameters for the instrument were as specified in Table 2.1. Different gradient lengths were also 
used, for example, a 20 minute gradient was often used during label-free optimisation. In this case 
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gradient was utilised from 0% B to 50% B in 20 min, and to 100% in 2 min. After 10 min at 100% B, 
the column was re-equilibrated for 10 min before the next run. The method was otherwise the same as 




















2.4.1.2 ESI-LC-MS and LC-MSMS 
Similar settings to those specified for nanoESI were used except for the following conditions 
described. A High Capacity Trap mass spectrometer (HCT Ultra, Bruker) was used with an 
electrospray interface. The samples were loaded onto a monolithic PS-DVB (polystyrene-
divinylbenzene) column (500 μm x 5 cm, Dionex, UK) for LC separation at a flow rate of 20 μLmin-1. 
The buffers used for the LC were (A) 2% ACN/98% H2O/0.1% FA and (B) 80% ACN/20% 
H2O/0.1% FA. A linear gradient was utilised from 0% B to 30% B in 150 min, and to 100% in 20 
min. After 10 min at 100% B, the column was re-equilibrated in buffer A for 20 min before the next 
run. MSMS data was acquired using data dependent software (HCT Ultra, Esquire Control, Bruker 
Daltonics). The acquisition parameters for the instrument were as specified in Table 2.3 except for the 
following adjustments:  capillary voltage 4000 V; nebuliser 17 psi, drying gas flow rate of 5 litres/min 
and a source temperature was 310°C. 
 
2.4.2 Fourier transform ion cyclotron resonance mass spectrometry 
LC-MS of peptide mixtures was carried out on a reversed phase HPLC (Ultimate 3000, Dionex, UK) 
with an Apex Ultra Qh Fourier Transform Ion Cyclotron Resonance mass spectrometer equipped with 
a 12T superconducting magnet (FTICR, 12T, Bruker) and a 6 cm Infinity Cell® (Penning trap). As 
with the ion trap, two set ups were employed: nESI and standard ESI. nESI was performed using a 
TriVersa Nanomate (Advion Biosciences, Ithaca, NY) and ESI using an ESI source from Bruker 
Daltonics. The LC conditions were the same as those described above for the HCT. The mass spectra 
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were externally calibrated using ES tuning mix (Agilent) and data was acquired using HyStar 3.4 
software and mass spectrometry parameters are specified in Table 2.2. Fast fourier transforms were 
performed using DataAnalysis software (Bruker Daltonics). 








2.4.3  Data processing and quantitation 
The raw data from the HCT was processed using Bruker DataAnalysis Version 3.4 to generate peak 
lists in Mascot Generic Format (MGF) for submission to Mascot. A signal to noise threshold of 5, an 
area threshold of 10, and an intensity threshold of 10 were used. Database searches (NCBI-nr version 
NCBInr_20071130) were performed using the MASCOT database search engine 2.2.1 (Matrix 
Science, London, UK). The parameters specified in Mascot included trypsin as the enzyme and up to 
two missed cleavages, charge states  2+ and 3+,  mass tolerance in MS mode +/- 1 Da, and for MSMS 
data a tolerance 0.6 Da. Carbamidomethylation of cysteines was specified as a fixed modification and 
oxidation of methionine was included as an optional modification. At least 1 unique peptide sequence 
for each protein hit (required Red Bold in Mascot) and a score greater than the Significance Level in 
Mascot was required. For label-free quantitation the raw data was converted to mzXML files using 
CompassXport (Bruker).  
 
2.5 Mass spectrometry at HMS 
2.5.1 LTQ Orbitrap 
Samples were analysed on various different variations of LTQ/Orbitrap: LTQ, LTQ XL, LTQ 
Orbitrap, LTQ Orbitrap XL, LTQ Orbitrap Discovery and LTQ Orbitrap Velos (Thermo Fisher). The 
methods for these instruments were very similar and so just one general method is described. Various 
different gradient lengths were used depending on the particular experiment. In general, for in-depth 
proteomic profiling, 2 hour analyses were collected for each fraction.  
The samples were analysed on an LTQ Orbitrap mass spectrometer equipped with a Nanospray II 
electrospray ionisation source (Thermo Fisher, San Jose, CA) coupled to an Agilent 1100 series binary 
pump (Agilent Technologies, Palo Alto, CA). Dried peptides were reconstituted in water containing 
5% FA and 5% ACN and 1-4 µL loaded onto a hand-pulled fused silica microcapillary with an 
internal diameter of 125 µm, 18 cm long, packed with a C18 reversed-phase resin (Magic C18AQ, 
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particle size 5 µm, pore size 200 Å, Michrom Bioresources, Auburn, CA) using a Famos autosampler 
(LC Packings, San Francisco, CA). The needle tip had an internal diameter of approximately 5 µm. 
Once loaded, the peptides were separated across a 45 minute linear gradient of 10-37% solvent B 
(0.125 % FA in ACN) at a flow rate of 300 nL/min provided across a flow splitter by the HPLC 
pumps. Buffer A comprised 0.125% FA and 3% ACN in water. Data was collected in a data-
dependent mode using the TOP10 strategy where the high resolution MS survey scan was followed by 
10 MS/MS scans in the linear ion trap for the top 10 most abundant precursor ions266 with other mass 


















2.5.2 Data processing 
The database search parameters and processing parameters varied according to the particular 
experiment. RAW files were converted to mzXML files using the program ReAdW 
(http://sashimi.sourceforge.net/software_glossolalia.htmL). MS/MS spectra were searched using the 
SEQUEST search algorithm (version 27, revision 12)45 against a concatenated target and decoy 
human International Protein Index (IPI) protein database (ftp.ebi.ac.uk/pub/databases/IPI/current/)267 
using a precursor mass tolerance of 50 ppm. Search parameters for post translational modifications 
comprised a static modification of 57 Da on cysteine (carboxyamidomethylation) and dynamic 
modifications of 16 Da on methionine (oxidation). Protein hits were filtered at the peptide level using 
Xcorr, ΔXcorr, mass accuracy and peptide length using in-house software to false discovery rates of 
less than 1% using the target-decoy approach as described previously268. 
 
2.5.3 Quantitation 
Various different quantitation methods were performed depending on the particular experiment 
including spectral counting, SILAC and isotope-labelled peptides. 
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Spectral counting was employed for the relative quantitation of proteins present in each of the gel 
bands. The number of spectra observed per protein (number of spectra observed for all the peptides 
identified in a particular protein) was used as a rough estimate of protein abundance.  
SILAC was used in a pulse-chase type of experiment to determine the rate of degradation of various 
proteins in HeLa cell nocodazole arrested cell lysate. Peptides were quantified using the Vista 
program.269 Filtering was based on the predicted isotopic distribution and a tolerance window of ± 20 
ppm from the theoretical mass. The background noise was subtracted from each ion chromatogram 
and the ratio between the area of the heavy and light peptides was calculated. For accurate 
quantitation, S/N > 3 was required for both heavy and light peptides.  
Absolute quantification of peptide phosphorylation was carried out through comparison of heavy 
labelled same-sequence phosphopeptides (described in Section 2.7.5).  
 
2.6 Molecular biology 
Several molecular biology techniques were employed during this project. Cell culture was used to 
produce cells for analysis of lysates for kinase activities. Molecular cloning and transfection were 
used to overexpress several kinases for validation experiments to help identify kinase-substrate pairs. 
2.6.1 Cell culture 
HeLa cells (cervical cancer) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% dialysed fetal bovine serum (FBS) (HyClone).  For cell lysis, the media was 
removed, the cells harvested by scraping, the cell pellet was washed with ice-cold phosphate-buffered 
saline (PBS) and then lysed with ice-cold lysis buffer (10 mM K2HPO4 pH 7.5, 1 mM EDTA, 10 mM 
MgCl2, 50 mM β-glycerophosphate, 5 mM EGTA, 0.5% Nonidet P-40, 0.1% Brij 35, 0.1% 
deoxycholic acid, 1mM sodium orthovanadate, 1mM phenylmethyl-sulfonyl fluoride, 5 µg/mL 
leupeptin and 5 µg/mL pepstatin A).  The lysate was centrifuged at 10,000 rpm for 10 min to remove 
cell debris. The clear supernatant was aliquoted out, snap frozen with liquid nitrogen and then stored 
at -80°C. Protein concentration was determined by the Bradford assay (Pierce). For the cell cycle 
studies, HeLa cells were treated with nocodazole (0.2 µg/mL) until 90% of the cells were rounded up 
for G2/M (second gap/mitosis) arrest. The nocodazole-arrested cells were collected by mitotic shake-






2.6.2 Kinase overexpression 
Various kinases were overexpressed using Gateway cloning for KAYAK experiments to determine 
the effect of kinase overexpression on the phosphorylation of particular kinase substrates (Sections 
4.3.1.2 and 4.3.4.4). 
2.6.2.1 Background information to Gateway cloning 
The Gateway cloning system is based on the site specific recombination of bacteriophage lamda270-271. 
It was commercialised by Invitrogen in the late 1990s and allows the efficient transfer of DNA 
fragments between plasmids. This is carried out using two proprietary enzyme mixes (BP clonase and 
LR clonase) and a proprietary set of recombination sequences, termed the ‘Gateway Att’ sites. There 
are two main steps: the BP clonase reaction and the LR clonase reaction. 
Firstly, the Gateway entry clone (pENTR) is made. Att B1 and att B2 sequences are added to the ends 
of the gene fragment of interest. The PCR product with flanking att B sites is mixed with BP clonase 
which inserts the att B sequence into the att P sites in the Gateway Donor vector, forming the Gateway 
Entry clone with att L sites flanking the gene of interest. Secondly, the Gateway Entry clone is 
transferred into a Gateway Destination vector using LR clonase. The Destination vector contains attR 
recombination sequences, promoters and tags. This forms an Expression clone which contains the 
gene of interest with flanking at B sites.272 The Gateway cassette is a unique sequence which is cloned 
into the Destination vector. It contains a chloramphenicol resistance gene. This gene is replaced by the 
gene of interest during the LR clonase reaction, and hence the desired Destination clone can be 
selected by culture with chloramphenicol since the Destination clones will not be chloramphenicol 
resistant. The ORFs for the genes in pDONR223 were recombined into the Gateway destination 
vector: MSCV-N-Flag-HA-IRES-PURO using λ recombinase. HEK 293 T cells were maintained in 
DMEM supplemented with 10% FBS. Open reading frames (ORFs) for the kinases of interest were 
cloned using the Gateway cloning system and transfected into HEK 293T cells. The experimental 
protocol is described below 
2.6.2.2 Experimental procedure for Gateway cloning 
A total of 22 kinases were overexpressed using Gateway cloning: AKT1, CDK7, CHEK2, MAPK14, 
MAPK6, MAPKAPK3, PAK2, PKN1, PLK1, PLK2, PRKAA1, PRKCB1, PRKCD, PRKCG, 
PRKCH, PRKCI, PRKCZ, PBK, TP53RK, CDC2, PRKAA2, AURKB. The Gateway Entry clones 
with att L sites flanking the desired genes had previously been made by the Harper laboratory at HMS 
(pDONR223). The Gateway cloning procedure was carried out for the ORFs of 22 kinase genes of 
interest. The Gateway Entry clone plasmid in E. coli was added to 3 mL of LB Broth containing 
spectinomycin and incubated overnight at 37°C with mixing. Miniprep DNA (Qiagen) was carried out 
on each culture according to the manufacturer’s instructions.273 Briefly, the bacteria were pelleted (20 
s, 15,000 rpm) and resuspended in 250 µL buffer P1.273 250 µL of lysis buffer P2273 was added and 
mixed thoroughly. 350 µL of buffer N3273 was then added to neutralise the basic P2 solution. After 
centrifugation (30 s, 13,000 rpm), the lysate (supernatant) was transferred to the QIAprep spin 
41 
 
columns. The flow through was discarded after centrifugation (30 s, 13,000 rpm) and the QIAprep 
spin columns was washed with 750 µL of buffer PE273. The DNA was eluted using 50 µL of Buffer 
EB273. 
The LR clonase reaction to transfer DNA fragments from the entry clones to the destination vectors 
was carried out according to the manufacturer’s instructions272. Briefly, 1 µL of the purified plasmid 
DNA from the entry clone was combined with 1 µL of LR buffer, 1 µL of LR clonase enzyme and 1 
µL of phage vector and the recombination reaction was allowed to proceed for 2 h.  
The product from the LR recombination reaction was used to transform E. coli using heat shock. 
Briefly, 22 µL of recombinant E. coli was added to the reaction mixture from above and placed on ice 
for 20 min. 225 µL of LB broth containing spectinomycin was added to allow the E. coli to divide 
approximately 3 times. After 1 hour, the E. coli were plated on Agar plates and incubated overnight at 
37°C. After overnight incubation, 1 colony from each plate was picked out and incubated with LB 
broth with carbomycin overnight at 37°C with mixing.  
DNA was extracted, as described previously using the Qiagen DNA miniprep kit.273 Part of the DNA 
was digested using 2 enzymes (HINDIII and BAMH1) to check that the correct protein had been 
transfected. The digested DNA was run on a 1% agarose/ethidium bromide gel (120V). The DNA 
plasmids were then transfected into HEK 293T cells using Lipofectamine 2000 according to the 
manufacturer’s instructions274.  
 
2.6.3 Western blotting 
Lysates from the 22 kinase overexpression experiment were run on 4 to 12% SDS/PAGE and 
transferred onto Protran membranes (Whatman). The membrane was blocked with 5% milk in tris 
buffered saline with tween (TBST, 10mM tris, pH 7.4, 0.9% w/v NaCl, 0.1% Tween-20 detergent) for 
1 h at RT, incubated with a 1:2500 dilution of primary antibody in 0.5% milk for 1 h at RT, washed 4 
x with TBST for 15 min each. The washed membrane was then incubated with a 1:10,000 dilution of 
secondary antibody for 1 h at RT. The membrane was then washed as before. The bands were 
visualized using ECL solution (SuperSignal West Pico, Thermo Fisher). 
2.6.3.1 Kinase knock down using siRNA 
HEK 293T cells were cultured in DMEM medium supplemented with 10% FBS. Each of the four 
siRNAs (siGENOME®, Dharmacon, Thermo Scientific) for each gene were resuspended in RNAase 
and DNAase-free water (100 µL) and pooled for each gene of interest (1 µL from each siRNA stock). 
The genes of interest included: PBK, TP53RK, CDC2 and MAPK14. Reverse transfection was 
performed using 1 µL of the pooled siRNA and RNAiMax (Invitrogen) and Opti-MEM® (Invitrogen) 
according to the manufacturer’s instruction in a 12 well plate. Scrambled siRNA (SiCK) was used as a 
control. The cells were lysed 48 hours after transfection, as described in Section 2.6.1 
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2.7 Kinase activity assay and optimisation 
In this Section, the KAYAK procedure to profile kinase activities is described along with the new set 
of substrate peptides that are used in the K60 assay. The terminology Knumber refers to the number of 
substrate peptides in a particular kinase assay. Various developments that have been made to the 
original KAYAK assay, allowing greater sample throughput, are discussed. The procedure for 
correlation profiling using kinase activity and kinase abundance is described using anion exchange 
chromatrography as a separation technique. The development and optimisation of an in-gel kinase 
assay and correlation profiling using blue native polyacrylamide gel electrophoresis is described.  
 
2.7.1 KAYAK peptide numbering scheme 
To aid data interpretation, a new numbering scheme was devised based on dividing the peptide targets 
into categories according to the predicted kinase thought to be responsible for their phosphorylation 
Table 2.4. Previously the peptide codes were based on their location in the synthesis plate150. A list of 






































Table 2.5   The K60 KAYAK substrate peptide set. The peptide sequence and protein from which  it  is derived  is 
given.  Lowercase  s/t/y  in  the  peptide  sequences  denotes  the  phosphorylation  site.  Both  the  new  and  old 
numbering system for peptide numbering is provided.   
 
Peptide  New code for peptide  Sequence  Protein Name 
A3  KK1  RPRAAtFPFR  Aktide 
A6  PP6  RPGPQsPGSPPFR  Neutrophil cytosol factor 1 
A9  MM2  EPLtPSGEAPPFR  EGF receptor 
A12  MM3  PSTNSsPVLKPFR  Separase 
B2  CC1  KKAsFKAKKPFR  PKC substrate peptide 
B4  PP5  IPINGsPRTPPFR  Rb 
B6  BB2  PKRKVsSAEGPFR  Non‐histone chromosomal protein HMG‐14 
B11  PP7  LKLSPsPSSRPFR  Lamin‐B1 
C2  PP4  IPTGTtPQRKPFR  Kinesin‐like protein KIF11 
C6  BB3  TKRSGsVYEPPFR  Phospholylase b kinase reguratory subunit beta 
C10  XX1  AENAEyLRVAPFR  EGF receptor 
C11  AA1  NKRRGsVPILPFR  Erythrocyte membrane protein band 4.2 
D4  CC9  LKIQAsFRGHPFR  Neurogranin 
D7  PP9  NLLPLsPEEFPFR  STAT1 
D11  XX2  REVGDyGQLHPFR  Tyrosine‐protein kinase JAK2 
E1  YY1  EPEGDyEEVLPFR  Hematopoietic lineage cell‐specific protein 
E4  PP1  LLRGPsWDPFPFR  Heat shock 27 kDa protein 
E5  AM1  LKRSLsELEIPFR  Serum response factor 
E11  RR2  RKRLIsSVEDPFR  TSC2 
F6  RR1  RIRTQsFSLQPFR  Nitric oxide synthase, endothelial 
F7  YY2  EPENDyEDVEPFR  Hematopoietic lineage cell‐specific protein 
F12  YY3  VKRRDyLDLAPFR  Proto‐oncogene tyrosine‐protein kinase receptor ret 
G1  CC3  VLLRPsRRVRPFR  Somatostatin receptor type 3 
G2  YY9  ELQDDyEDLLPFR  Band 3 anion transport protein 
G10  CC8  KKKRFsFKKSPFR  Myristoylated alanin‐rich C‐kinase substrate 
H2  CC2  WPWQVsLRTRPFR  Plasminogen 
H5  WW9  EYDRLyEEYTPFR  PI3K regulatory subunit alpha 
H8  ZZ1  IYKNDyYRKRPFR  Proto‐oncogene tyrosine‐protein kinase ROS 
J7  PP10  TKRNStPPPSPFR  B10(position in the first plate) 
J10  AA10  NKRRGtVPILPFR  C11(position in the first plate) 
K5  BB4  LKRSLtELEIPFR  E5(position in the first plate) 
K11  KK2  RIRTQtFSLQPFR  F6(position in the first plate) 
L3  AA9  SKRRNtEFEIPFR  G5(position in the first plate) 
L12  AM2  AMARAAsAAALPFR  AMPKinase substrate AMARA peptide 
M5  BB8  KARSQsGTLDPFR  Tuberin 
M10  KK8  RGRSRsAPPNPFR  Bad 
N3  PP2  YSRAKsPQPPPFR  Heterogeneous nuclear ribonucleoprotein U  
N6  KK9  RKRSLsESSVPFR  Zinc Finger Protein 106 
N9  WW10  HTDDGyMPMSPFR  IRS1 
N10  QQ2  APVPSGsQSGGRGPFR  Mediator of DNA damage checkpoint protein 1 
O4  AA2  KIRRLsASKQPFR    
O7  WW1  MDTEVyESPYPFR  Tyrosine‐protein kinase SYK 
P3  WW8  YDDDNyDYIVPFR  Dual specificity tyrosine‐phosphorylation‐regulated kinase 1A 
P5  MM1  STSTPTsPGPRTHPFR  Ataxin‐2‐like protein 
P6  DD9  ALDVSAsDDEIARPFR  Acylamino‐acid‐releasing enzyme 
P8  GG2  TASGsSVTsLDGTRPFR  similar to NDRG1 PROTEIN 
P9  QQ1  NVKYSSsQPEPRTPFR  CHK1 checkpoint homolog 
P10  PP3  EVLRPEtPRPVDIPFR  Caspase‐9 
P12  GG1  HSsPHQsDDEEEPPFR  GYS1 protein 
Q1  CC4  LLATAsFTKSSRPFR  AT‐hook‐containing transcription factor 1 
Q2  OO9  LERNDsWGSFDPFR  Nuclear fragile X mental retardation protein interacting protein 2 
Q11  PP11  FEEEEsPKKKPFR  YY peptide1 
R8  BB1  RRRslLELH  Polo‐like kinase 1 delta 
R9  CH1  ALKLVRYPsFvITKKK  chk1tide 
R10  CH2  AARLERQDsIFYpKKK  chk2tide 
R11  WW2  GGEAIyAApFKK  DBR1 
S1  WW3  ETDDyAEIlP  FAK 
S2  BB9  RRPsYRKLL  ATF‐1 
T1  OO2  YDDFKLNSsIVEpKEPA  Nuclear factor NF‐kappa‐B p100 subunit 
T2  OO1  SIEKLNSsLHFlQQE  Calmodulin‐regulated spectrin‐associated protein 1‐like protein 1 
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2.7.2 Sample preparation for kinase activity analysis 
Cell lysates and tissue homogenates were prepared in an ice-cold lysis buffer: 10 mM K2HPO4 pH 7.5, 
1 mM EDTA, 10 mM MgCl2, 50 mM β-glycerophosphate, 5 mM EGTA, 0.5% Nonidet P-40, 0.1% 
Brij 35, 0.1% deoxycholic acid, 1mM sodium orthovanadate, 1mM phenylmethyl-sulfonyl fluoride, 5 
µg/mL leupeptin and 5 µg/mL pepstatin A. Following lysis/homogenization, the lysate was 
centrifuged at 10,000 rpm for 10 min at -4°C and the supernatant was snap frozen with liquid nitrogen 
and stored at -80°C. The number of freeze-thaw cycles was monitored since this affects the kinase 
activity. Kinase activities were always determined on lysate that had only been frozen once following 
harvesting. Protein concentration was determined by the modified Bradford assay (Pierce).  
 
2.7.3 KAYAK procedure 
Four KAYAK procedures were used in this study; classical, dilute and shoot, 96 well, and in-gel.  
2.6.2.1. Classical procedure 
Synthetic peptide substrates, each at 5 µM, were incubated with  20 µg samples (e.g. cell lysate) and 
kinase reaction buffer containing Tris-Cl (25 mM, pH 7.5), ATP (5 mM), MgCl2 (7.5 mM), EGTA 
(0.2 mM), β-glycerophosphate (7.5 mM), Na3VO4 (0.1 mM) and DTT (0.1 mM). After incubation for 
45 minutes at room temperature, the reaction was quenched with 100 µL of 1%  trifluoroacetic acid 
(TFA). A known amount (5 pmol) of internal standard phosphorylated stable-isotope labeled peptides 
were spiked into the quenched reaction. The solution was desalted using Sep-Pak C18 50 mg 
cartridges (Waters) and dried using vacuum centrifugation. The phosphopeptides were enriched using 
IMAC. In detail, IMAC resin (PHOS-Select iron affinity gel, Sigma) was washed twice with a 
solution containing 25 mM formic acid and 40% acetonitrile. Washed IMAC beads were diluted 6-
fold with 25 mM formic acid containing 40% acetonitrile and 90 µL of this suspension was added to 
the dried peptides and incubated for 1 hour at room temperature. After incubation the suspension was 
transferred to a pre-equilibrated StageTip containing a C18 Empore solid phase extraction disk (3M) 
and the resin washed twice with the resin wash solution (25 mM formic acid, 40% acetonitrile) and 
once with 0.1% TFA. Phosphopeptides were eluted onto the Empore disks using three washes of 
potassium phosphate (500 mM, pH 7.0). Bound peptides on the Empore disk were washed first with 
0.1% TFA and then 1% formic acid. The desalted purified phosphopeptides were then subsequently 
eluted with a solution containing 50% acetonitrile and 1% acetic acid. The eluted peptides were dried 
by vacuum centrifugation and resuspended in 8 µL of 5% formic acid of which 4 µL was then 
subjected to analysis by mass spectrometry (see Section 2.5.1). In general, a set of 60 substrate 
peptides was used, termed K60. However, for some optimisation experiments, only a subset of 




2.7.3.1 KAYAK mass spectrometry analysis 
The peptides from the KAYAK assay, dissolved in 5% formic acid, were analysed on an Orbitrap 
mass spectrometer. Various different Orbitraps were used, depending on availability (LTQ Orbitrap, 
LTQ Orbitrap XL, LTQ Orbitrap-Discovery). In general, only full MS scans were obtained. If the 
localisation site of the phospho group on the peptide was not certain, MSMS scans were also collected 
in the LTQ. The HPLC system and the buffers used have previously been described in Section 2.5.1. 
A 32 minute gradient was used and data were collected from 400-1,500 m/z full MS with a resolution 
setting of 60,000, AGC setting of 106, ion fill time maximum 1 second. 
 
2.7.4 KAYAK data processing 
The amount of substrate phosphorylation was determined by comparing the area of the light 
phosphorylated substrate peptide with that of the heavy phosphorylated internal standard peptide. The 
phosphorylated substrate peptides are chemically identical to the heavy internal standard and therefore 
should have the same chromatographic characteristics and ionisation efficiency. The procedures was 
as described151. Briefly, extracted ion chromatograms were generated from the survey full MS scan 
with ± 10 ppm mass accuracy around the monoisotopic peak of the most abundant charge state. The 
extracted ion chromatograms were integrated using Quan browser (Xcalibur 2.0.5, Thermo Fisher). 
Whilst Quan browser generates the area of the extracted ion chromatograms semi-automatically, each 
chromatogram required manual inspection to ensure that the correct boundaries had been selected. 
Where this was not the case, the peak boundaries were manually altered in Quan browser. It was 
required that heavy and light peptides co-elute perfectly for accurate quantitation. Measurements were 
excluded where the peak height (extracted ion count) was less than 104 or where the peak area was 
less than 1% of the internal standard (50 fmol). Since a known amount of internal standard was added 
to the reaction (in general, 5 pmol) prior to purification, the absolute amount of product formed could 
be determined. The product formed/kinase activity was usually presented with units of fmol/µg/min. 
The ratio of the light to heavy peptide area was divided by the amount of lysate (usually 20 µg) and 
the time of the reaction (usually 45 min). For correlation profiling studies, the amount of sample was 
not considered and the units are expressed as fmol/min. For recombinant kinase assays, the amount 
formed was not divided by the kinase amount or the reaction time and the units are expressed as fmol. 
 
2.7.5 Development of high throughput KAYAK 
The three parts of the KAYAK assay: the sample preparation, analysis on the mass spectrometer, and 
the data analysis are time consuming. For a standard assay of 12 samples (3 replicates, 36 KAYAK 
reactions), the sample preparation takes approximately 13 hours. Analysis on the mass spectrometer 
takes 1 hour per sample, totalling 36 hours. Analysis time using Quanbrowser and manual checking 
then takes approximately 1 day. Typically, the whole process takes around five days for 36 KAYAK 
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reactions. Various methods to increase throughput were trialled. The ‘classical’ KAYAK reaction is 
carried out in Eppendorf tube format. SepPak purification is performed using individual SepPak 
cartridges, and IMAC is carried out using StageTips in a centrifuge format.  
2.7.5.1 96 well plate format 
For large batches of samples, a 96 well format was developed. The KAYAK reaction was carried out 
in 96 well plates. Following reaction completion, the samples were desalted using SepPak 96 well 
plate and a vacuum manifold. After SepPak purification the peptides could be dried down by vacuum 
centrifugation in the 96 well plate. IMAC beads were then added to the 96 well plate and incubated by 
attaching the 96 well plate to a vortex. The IMAC purification was performed in a 96 well plate using 
a 96 well C18 Empore (3M) extraction plate. Following IMAC, the purified peptides were dried down 
by vacuum centrifugation in the 96 well plate, reconstituted, and then the same 96 well plate was put 
on the mass spectrometer, thereby reducing the time taken transferring samples to autosampler vials. 
These steps dramatically reduce the sample preparation time. Sample preparation of 96 samples using 
the classical eppendorf format takes approximately a week whilst the 96 well plate format can be 
prepared in a day. A few of the steps for the 96 well plate KAYAK required optimisation. During the 
IMAC purification with the 96 well extraction plate and manifold it was critical to centrifuge the 
extraction plate to fully remove all the salt, otherwise the salt was not fully removed by solely relying 
on the vacuum. To reduce cross contamination during use of the vacuum manifold for the SepPak 
purification elution step, P200 pipette tips were added to each of the ‘columns’ on the 96 well plate to 
ensure that the a sample did not contaminate other sample wells - which occurred when pipette tips 
were not added to the columns. 
2.6.2.2. ‘Dilute and shoot’ method 
A significant proportion of the sample preparation time involves the IMAC purification stage of the 
phosphopeptides. For KAYAK experiments which only required low substrate amounts of 1 µM to 
0.1 µM, and/or where lower amounts of lysate were required (for example 6 µg rather than the normal 
20 µM), the IMAC purification stage could be excluded, effectively reducing the sample preparation 
time by half. This method was termed ‘dilute and shoot’ since, following the Sep-Pak cleanup, the 
sample only required reconstitution (‘dilute’) prior to MS analysis (‘shoot’).    
2.7.5.2 Decreasing LC-MS method time 
The normal KAYAK reaction with 60 substrate peptides takes approximately 1 hour with a 32 minute 
gradient. For KAYAK experiments involving only a few peptides, gradient time could be reduced. For 
particular experiments where only one or two peptides were being quantitated, various parameters 
were optimised to achieve a very short LC-MS analysis time. A column with a 250 µm ID was used, 
rather than the standard 125 µm, and packed with only 3 cm of resin (rather than the standard 15 cm) 
to allow a higher flow rate. To accommodate the higher flow rate, the capillary was set to a higher 
voltage of 2.5 kV rather than the standard 1.8-2 kV. Initially an isocratic elution was investigated, at 
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both 30 and 50% B; however, the elution peak was very broad so this approach was discontinued. 
Instead, a very short gradient was used. Gradient lengths from 0.5 min to 8 min were tried and a 
length of 2 min was found to give optimum intensity for a single peptide. The LC-MS method for 1 
peptide takes in total 7 mins. 
KAYAK is in the process of being transformed from the ‘classic KAYAK assay’150 which was time 
consuming to a much more high throughput analysis where  four batches of 96 KAYAK (384) 
reactions can be prepared in two days (which for the classical method takes two weeks). There is still 
room for further development and the possibility to move to 384 well plates, in which case the time 
limiting aspect will switch from sample preparation time to mass spectrometer time. Other 
technologies to incorporate the phosphopeptide enrichment ‘online’ could also prove useful in the 
future. As well as increasing the speed various new substrate peptides were also investigated using 
peptide libraries (Appendix C).  
 
2.7.6 Kinase activity/kinase abundance correlation profiling 
Kinase activity/kinase abundance correlation profiling is a technique recently developed by Dr. 
Kubota150 to determine kinase-substrate pairs. Briefly, the sample (cell lysate) is fractionated at the 
protein level using anion exchange chromatography. For each protein fraction, both the kinase activity 
and kinase content are determined by KAYAK and shotgun proteomics respectively (Figure 2.1). The 
correlation profiles between the kinase activity and the kinase spectral count are compared and those 











































HeLa cell lysate (10 mg), prepared as described in Section 2.6.1, was dialysed in anion AEX buffer: 
HEPES (20 mM, pH 7.5), NP-40 (0.5%), Brij 35 (0.1%), deoxycholic acid (0.1%), EGTA (1 mM), 
MgCl2 (5mM), β-glycerophosphate (5mM), Na3VO4 (0.1mM), DTT (0.1mM), protease inhibitor 
cocktail (Complete, Roche Applied Science) and glycerol (20%). The dialysed lysate was centrifuged 
to remove debris and separated at the protein level using AEX on a monoQ column (5/50 GL, GE 
Healthcare) with a gradient from 0-0.5 M NaCl in AEX buffer. The lysate was separated into 40 
fractions, 500 µL each. Each fraction was aliquoted and analysed by KAYAK and shotgun 
proteomics. For KAYAK analysis, 30 µL of each 500 µL fraction were used and analysed with a K60 
substrate set. 
For shotgun proteomics, 100 µL of each fraction were used. For normalisation purposes, 500 fmol 
BSA were added to 100 µL of each fraction and the proteins were precipitated using the 
methanol/chloroform method.263 The precipitates were washed with ice-cold acetone and dissolved in 
a Tris-Cl pH 7.5 buffer (50 mM) containing urea (8 M), EDTA (50 mM) and n-dodecyl β-D-maltoside 
(0.005%). The proteins were reduced with DTT (10 mM, 37°C, 20 mins) and alkylated with 
iodoacetamide (20 mM, 45 min, in the dark).The reaction was quenched with DTT (10 mM). The 
concentration of urea was diluted to 1 M and the proteins digested with trypsin (5 ng/µL, 37°C, 16 
hours). The digestion was stopped using formic acid and the peptides were purified using 
StageTips.264   
The relative protein abundance in each of the 42 fractions was determined using spectral counting. 
The spectral count was normalised to the amount of BSA in each of the fractions as BSA had been 
added to each of the fractions prior to precipitation. The protein abundance and kinase activity profiles 
were compared using Pearson correlation150. A Pearson correlation coefficient gives a measure of the 
linear dependence between two variables and has a value from -1 to +1 where ‘+1’ denotes the highest 
positive correlation, 0 denotes no correlation and ‘-1’ the highest negative correlation. The Pearson 
correlation coefficient is defined as the covariance of two variables divided by the product of their 
standard deviation. A Pearson correlation coefficient was determined for each protein (5,626 proteins 
in total) against each kinase activity profile across the fractions. Fractions that contained less than 5% 
of the maximum kinase activity were not included in the correlation. The substrate peptides were then 
ranked with the proteins with the highest ranked Pearson correlation coefficients.  
 
2.7.7 Development of in-gel kinase activity/kinase abundance correlation 
profiling 
Kinase activity/kinase abundance correlation profiling is an approach that can identify kinase-
substrate pairs and relies on anion exchange chromatography (AEX) to separate proteins (kinases). 
The protein profiles are subsequently compared with the kinase activity profiles and the correlation is 
used to predict kinase-substrate pairs. Whilst this approach is very successful, one of the drawbacks is 
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that the use of AEX is generally not suited to high-throughput analyses; thus, to enable the kinase 
activity/kinase abundance correlation profiling method to be more attractive to the wider biological 
community, a gel-based approach for protein separation would be a more efficient workflow and 
would allow multiple samples to be separated simultaneously. Proof of concept work was performed 
to determine if an in-gel kinase activity/kinase abundance correlation profiling was possible. For 
kinase activity/kinase abundance, it is critical that the kinases remain active and are not denatured, and 
therefore blue native (BN) polyacrylamide gel electrophoresis (PAGE) was investigated.  
BN PAGE was developed by Shägger and von Jagow in 1991275 and uses Coomassie G-250 
(Invitrogen) as a charge-shift molecule which confers a negative charge to the protein without 
denaturing it. The use of Coomassie results in much higher resolution than native PAGE. Native 
PAGE is incompatible with nonionic detergents, which are often needed for protein solubility, and 
also the native PAGE Tris-Glycine system has a high operative pH which may affect pH sensitive 
proteins. One of the advantages of BN PAGE is that G-250 can reduce protein aggregation: proteins 
with large regions of hydrophobic surface exposed are less susceptible to aggregation in the presence 
of G-250 as the dye binds non-specifically to hydrophobic sites, hence converting them to negatively 
charged sites. Also, the lower pH of the BN PAGE gels (pH 7.5-7.7) is likely to help the proteins 
retain their structure and activity276. 
2.7.7.1 Proof of concept experiments 
Initial proof of concept work firstly involved determining whether protein complexes remained intact 
following BN PAGE, and secondly whether kinase activity could still be observed. HeLa cell 
nocodazole arrested lysate was separated by BN PAGE, fractionated into 10 slices and analysed by 
LC-MSMS, and protein abundance was measured using spectral counting. Around 2,600 proteins 
were identified (protein FDR 1.5%, peptide FDR 0.15%). To determine whether complexes were still 
present following BN PAGE, the protein profiles for proteins known to comprise the ribosome and 
proteasome were plotted for the 10 gel slices. The ribosome comprises two main subunits: the larger 
60S subunit (RPL proteins) and the smaller 40S subunit (RPS proteins).   The RPL proteins that 
comprise the large 60S ribosomal subunit were most abundant in the first fraction (red lines, Figure 
2.2a), whilst the small 40S subunit proteins were most abundant in the second fraction on the BN 
PAGE (yellow lines, Figure 2.2a). It was clear that the two ribosomal protein complexes remained 

















Figure 2.2   Protein profiles  from BN PAGE  for  (a)  ribosomal proteins and  (b) proteasomal proteins. HeLa cell 
lysate  (100µg)  was  fractionated  into  10  fractions  each  of  which  was  analysed  using  LC‐MSMS.  Protein 





The proteasome is the protein machinery responsible for the degradation of misfolded and damaged 
proteins in the cell. The proteasome consists of a core particle (CP) and a regulatory particle (RP). The 
CP comprises four stacked rings where the inner two rings comprise seven β subunits and the outer 
two rings comprise seven α subunits. The regulatory particle comprises 19 subunits and is responsible 
for unfolding ubiquitin protein conjugates and translocating them into the proteasomal core particle 
where the proteins are degraded. The abundance profiles of proteins in the core particle (PSMA, 
PSMB) are similar and peak in the third gel piece (yellow line, Figure 2.2b). Similarly, the abundance 
profile of proteins in the regulatory particle (PSMC, PSMD) are similar, and peak in the first gel piece 
(red line, Figure 2.2b). The data confirm that the proteasome complexes have remained intact on the 
BN gel. Interestingly, the work gave further evidence of the BP1 complex278 which comprises 
PSMD5, PSMD2, PSMC2 and PSMC1 and are found to be highly abundant in the 4th fraction of the 
BN gel (blue line, Figure 2.2b), as described in more detail in Appendix A.  
The second proof of concept experiment was to determine whether kinase activity was present in the 
blue native gel following electrophoresis. To achieve the objective, the KAYAK assay was performed 
on gel pieces and kinase activity was determined. The presence of kinase activity was observed 
following BN PAGE, but there was poor resolution and this was evidence for the need for a rigorous 





























2.7.7.2 Optimisation of BN PAGE protein separation conditions 
The two main problems encountered with BN PAGE were precipitation and streaking. Precipitation 
occurred in the loading well and also at the 3% to 8% junction (Figure 2.3 a and b). A variety of 

































Streaking of protein bands increased with increasing amounts of protein sample loaded in the wells of 
the gels (Figure 2.3 a-c). However, streaking was also observed at lower concentrations. The presence 
and concentration of detergent had a major effect on protein streaking. When no detergent or G-250 
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complexes had very low intensity (low solubility). As the percentage of the detergent was increased, 
the streaking also increased. It was critical to centrifuge or filter the samples after the addition of the 
G250, as protein precipitation sometimes occurred following the addition of G250 to the sample. 
Also, by manually removing the well dividers and loading several lanes, less streaking was observed 
(Figure 2.3 c). However, it was challenging to remove the well dividers resulting in a completely flat 
well. Flat wells were necessary for the protein to be loaded evenly to reduce streaking, and any ridges 
resulted in inconsistent wave-like patterns in the protein bands. 
The final optimised protocol was as follows: Sample additive G250 (Invitrogen) was added to the cell 
lysate (50 µg) which was filtered to remove any precipitation that may have formed. The well dividers 
in between gel lanes were removed and the protein loaded across several gel lanes. ‘Light’ cathode 
running buffer (Invitrogen) containing Coomassie blue dye was used and electrophoresis was run 
initially at 50 V until the dye front had reached roughly half way and then increased to100 V. 
2.7.7.3 Optimisation of in-gel KAYAK assay 
Following optimisation of the BN PAGE running conditions, the in-gel KAYAK assay was optimised. 
The length of time for the KAYAK reaction was evaluated: 11 substrate peptides were used and three 
gel bands were subjected to an 11 peptide KAYAK assay (K11). The gel was loaded with four 
samples to allow the KAYAK reaction to proceed for reaction times of 45, 90, 135 and 180 min. The 
rate of phosphorylation (product formation) was close to linear from 0-90 min (Figure 2.4). For some 
peptides, at times greater than 90 min the reaction rate decreased and a plateau was observed. To 
determine whether the reaction rate was linear for shorter reaction times another experiment assessed 
shorter time periods where sampling occurred at 10, 20, 45 and 90 min (Figure 2.5). The kinase 
activity was not linear from 0 to 90 minutes, presumably due to a delay in uptake of peptides into the 
gel piece. This was particularly evident for the peptides displaying high activity, for example B2, C2 
and E11 in gel band 2 and E5 in gel band 3 (Figure 2.5). A 90 min assay time was selected as the final 
assay time since kinase activity was not linear at times over 90 min (plateau was observed), and also 
non linear kinase activity was observed at shorter reaction times. At the longer reaction times (>90 
mins), the substrate concentration could become a limiting factor.  The optimised KAYAK in-gel 

























Figure 2.4  Optimisation of in-gel KAYAK reaction time. In-gel KAYAK with 11 substrate peptides was performed 














Figure 2.5  Optimisation of in-gel KAYAK reaction time. In-gel KAYAK with 11 substrate peptides was performed 


































































































































































































































2.7.7.4 In-gel BN PAGE kinase activity/kinase abundance correlation profiling  
Following the successful proof of principle experiments and optimisation of the BN PAGE running 
conditions and the in-gel KAYAK assay, a correlation profiling experiment was performed with 10 
fractions and a K60 substrate set (Figure 2.6).  
The lysate (100 µg) was mixed with Coomassie (G-250) and NativePAGE sample buffer (Invitrogen) 
according to the manufacturer’s instructions and loaded onto a precast Bis-Tris nativePAGE gel 
(mini-gel, 3-12%, Invitrogen) at 4°C. The gel was run at 50 V until the sample had run at least 2 cm 
into the gel. The voltage was then increased to 100 V for the remainder of the gel electrophoresis (ca. 
5 hours). The gel was washed with distilled water and the lane was cut up into 10 equal-sized slices. 
Each of the slices was further cut up into 1 mm3 and 100 µL of KAYAK reaction buffer containing 5 
µM of K60 substrate peptides was added to the diced gel pieces. The KAYAK reaction was allowed 
to proceed at room temperature for 90 minutes. All the above steps were performed at 4°C until the 
KAYAK reaction which took place at room temperature. The kinase reaction was terminated with the 
addition of a final concentration of 0.75% TFA. The reaction mix was then purified by Sep-Pak C18 
columns and analysed by shotgun proteomics for protein correlation profiling as described in Section 
2.7.6. After Sep-Pak purification the procedure was the same as that described for the classical 










purified  using  the  classical  KAYAK  procedure.  The  same  gel  piece  that  had  been  used  for  the  in‐gel  kinase 
reaction was then subjected to in‐gel trypsin digestion and analysed by LC‐MSMS to obtain protein abundance 
profiles of  the proteins present. The protein abundance was determined using  spectral  counting. The kinase 
abundance  profiles  obtained  from  the  spectral  counting  and  the  kinase  activity  profiles  obtained  from  the 
KAYAK assay were compared using Pearson correlation to identify kinase‐substrate pairs.   
 
Resolution was a major issue and as a result, it was a challenge to match up the putative kinase-
substrate pairs. One of the main problems was due to the low spectral counts of the kinases from the 
sample
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shotgun LC-MSMS experiments. The kinase activity profiles covered many gel slices, whilst the LC-
MSMS often only characterised the kinase in a fewer fractions on account of their low abundance. 
There are various ways that the kinase quantitation could be improved, including purification 
procedures to increase the abundance of kinases, and heavy isotope labelling strategies such as using 
AQUA for absolute quantitation or dimethylation labelling of alternate fractions. However, the 
solution sought in this project was to improve the abundance of spectral counts, and hence 
quantitation accuracy, by the utilisation of an inclusion list for the m/z of the tryptic peptides derived 
from the kinases. As proof-of-concept for this approach, the m/z of the tryptic peptides for which the 
kinases had already been identified were used. The list of proof-of-concept candidates comprised 
peptides from around 100 kinases that had previously been detected with mass spectrometry150. This 
‘target list’ approach resulted in the identification of approximately 30% more kinases and the 
observation of many more spectral counts (Appendix D).  
The profiles of the kinase activity (Figure 2.7a) and the kinase abundance (Figure 2.7b) were 
compared using Pearson correlation (Figure 2.8). Several known kinase-substrate pairs had fairly good 
correlation coefficients (Figure 2.9) but the profiles spread across several gel bands on account of poor 
gel resolution.  
Figure  2.7    In‐gel  BN  PAGE  KAYAK  correlation  profiling  on  nocodazole  arrested  HeLa  cell  lysate.  Gel  was 
fractionated into 10 slices and analysed by KAYAK K60 for its kinase activity and by shotgun LC‐MSMS for kinase 
abundance.  (a) Kinase activity profiles across 10  fractions.  (b) Kinases abundance profiles across 10  fractions. 





















































































































































































































map  of  Pearson  correlation  coefficients  between  the  Kinase  activity  profile  (labelled  ‘KAYAK  peptide’  on 
diagram)  and  Kinase  abundance  profile  labelled  ‘Kinase’  on  diagram)  across  the  10  BN  PAGE  fractions. 



























































































































































































































KAYAK activities are plotted  for each BN gel  fraction. The Pearson correlation coefficient  (ρ)  for each kinase‐
substrate pair is given above each plot.    
 
The low resolution of the BN PAGE along with the limited accuracy of the spectral count kinase 
quantitation due to the low sample loading capability of the gel reduce the accuracy of the kinase 
activity/kinase abundance correlation profiling. Whilst the targeted inclusion list greatly improves the 
quantitation, the spectral counts were still low and the method was ultimately biased towards the 




genome could be included. A disadvantage of this gel-based method, compared to an in-solution phase 
separation such as anion exchange chromatography (AEX), is the absence of any internal 
normalisation. With AEX, a standard protein can be spiked into the separated fractions prior to trypsin 
digestion, but with the in-gel digestion such normalisation is not feasible.  
Proof of concept work for in-gel BN PAGE kinase activity/kinase abundance correlation profiling was 
performed. The presence of protein complexes and kinase activity was confirmed following BN 
PAGE and whilst various known kinase-substrate pairs were identified, the procedure suffered greatly 
from poor BN PAGE resolution. Further kinase activity/kinase abundance correlation profiling 
experiments performed (described in Chapter 4) used AEX protein separation on account of the 
greater resolution. However, for future multidimensional correlation profiling experiments, in-gel BN 
PAGE kinase activity/kinase abundance profiling could prove useful as the second dimension. 
A wide variety of techniques have been used throughout this project. Whilst the methods have mostly 
involved mass spectrometry, a range of molecular biology techniques have also been used and the use 
of such methods for verification of results obtained by large scale mass spectrometry studies will 

















3 Salivary Proteomics 
3.1 Introduction 
An aim of this PhD was to identify salivary biomarkers for gingivitis. Work at Edinburgh focused on 
the development of a work-flow for biomarker discovery which could be applied to saliva samples 
from gingivitis clinical trials. The work in this chapter is divided into two main topics: proteomic 
analysis of saliva and label-free quantitation. Proteomic analysis of saliva was performed to catalogue 
the proteins present in different saliva fractions with a view to determine which fraction 
(SN/res/human/bacterial) would be optimal for subsequent biomarker discovery using label-free 
proteomics. In parallel, an evaluation and optimisation of label-free quantitation software packages 
was performed in order to develop a workflow for salivary biomarker discovery. Simple peptide 
mixtures were initially used to optimise the software parameters prior to analysing saliva samples. The 
comparison of saliva from gingivitis patients and healthy individuals is covered in Chapter 5 (Salivary 
biomarkers for gingivitis), whilst this chapter provides the background, methods and preliminary 
results that set the foundation for the analysis of clinical trial samples. 
3.1.1 Proteomics of saliva 
A great deal of research, both past and present, has gone into characterising the protein composition of 
body fluids210, 279-282. Analysis of body fluids is currently used for disease diagnosis and their 
prevalence is expected to increase as robust biomarker discovery and profiling efforts continue. 
Cellular proteins from numerous tissues are secreted into various body fluids and, by monitoring the 
relative abundances of these proteins during particular disease states, cellular-level information may 
be gained that could benefit diagnosis, prognosis, and drug/treatment evaluation117, 182, 283-284. 
To determine the diagnostic potential of saliva, it is critical to first comprehensively identify and 
characterise the contained proteins. Approximately 20% of salivary proteins are also observed in 
plasma205 and, whilst both fluids have comparable disease-linked protein profiles, saliva appears to 
have higher diagnostic potential for a subset of diseases including cancers, infections, and 
haematological, gastrointestinal, inflammatory, and respiratory diseases107. However, plasma is 
currently the preferred diagnostic fluid due to its higher protein concentration. Plasma protein 
concentration is around 50 mg/mL whilst saliva is approximately 1 mg/mL. As with plasma, the large 
dynamic range of protein abundances in saliva hinders protein identification. Around 10 proteins in 
saliva account for almost 98% of the salivary proteome, making the analysis of less abundant proteins 
difficult285. Despite these drawbacks, saliva samples are much easier to obtain than plasma, which 
increases its usefulness as a diagnostic specimen.   
Proteomic studies of saliva have largely focused on analysis of the saliva supernatant211. Analysis of 
the residue fraction of saliva has been relatively unexplored, and we believe that protein abundance 
information of significant value may be found from examination of this fraction.  Proteins with very 
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low abundance in saliva may originate from lysed cells in the mouth. Therefore, analysis of the 
proteins present in the saliva centrifugation residue (largely unlysed cells and bacteria), and the 
comparison of these proteins to the species present in the saliva supernatant, can provide an insight 
into the contribution of proteins from lysed cells to the whole salivary proteome.  
Considering different fractions of saliva separately reduces dataset complexity and allows for 
determination of the fraction which contains the most diagnostic value when comparing samples from 
healthy individuals and those suffering from gingivitis. In this study, different fractions of saliva were 
analysed using proteomics, including the supernatant, residue, and the phosphoprotein enriched 
portion of the saliva supernatant. Although the salivary supernatant has been extensively studied, very 
few proteomics studies to date have considered these other potentially important fractions211.  
It is unknown whether gingivitis causes a change in bacterial populations or vice versa286-287. It may be 
possible to gain insight into this question by observing changes in the bacterial portion of saliva in 
sufferers and healthy individuals. Several possibilities exist for the relationship between bacterial and 
host responses during gingivitis. Changes in bacterial populations (or a specific bacterial species 
group, species or subspecific variant) in the plaque and/or saliva could lead to changes in the saliva 
human protein composition and thus contribute to the development of gingivitis. Alternatively, 
changes in the ‘quality’ of saliva (for instance, fewer mucins) with environmental factors or ageing 
could lead to changes in the bacterial population. Interactions of salivary proteins with oral bacteria 
include aggregation, adherence, cell-killing and inhibition of metabolism, and such interactions would 
be expected to influence oral biofilm ecology288. For example, aggregation of bacteria by salivary 
proteins causes precipitation and is presumed to help in the clearance of the bacteria from the 
mouth289. Regardless of the mechanism, changes in both the bacterial and human proteome are likely 
to be observed, and therefore studying both proteomes will determine in which portion the most 
significant changes occur and potentially in which portion the onset of gingivitis can be first observed. 
Another area of salivary proteomics which has been relatively unexplored is phosphoproteomics. 
There are a few phosphoproteins that have been characterised in saliva and they are known to be 
important in protecting tooth enamel and integrity. For example, phosphorylation of APRPs (acidic 
proline rich proteins) maintains the ionic calcium concentration in saliva, and prevents the growth of 
hydroxyapatite crystals.  Phosphorylation of statherin prevents calcium phosphate precipitation290. 
However, to date, a salivary phosphoproteome has not been documented. It is likely that many 
phosphoproteins are present in gingival crevicular fluid (GCF) due to its contact with bone, which is 
known to contain extracellular matrix phosphoproteins291. Periodontitis is associated with alveolar 
bone loss from the tooth socket292 and it is therefore expected that there may be a higher abundance of 
phosphoproteins observed in saliva which could potentially act as biomarkers for periodontitis. This 
project will involve the first initial investigation of the salivary phosphoproteome to evaluate whether 




3.1.2 Salivary protein complexes 
Various salivary proteins are known to interact with each other in such a way as to enhance their 
interaction with oral bacteria289, 293. For example, secretory immunoglobulin A (sIgA) has been 
reported to bind to mucins. Mucins contain hydrophobic domains and sialic acid and sulphate residues 
which gives them a propensity for homotypic and heterotypic complex formation294. There are two 
major mucins secreted from the SM/SL glands: MG1, a highly glycosylated, high molecular weight 
mucin; and MG2, a single-glycosylated peptide chain mucin with a low molecular weight181.  MG1 
strongly adsorbs to the surface of the tooth, forming part of the enamel pellicle and protecting the 
tooth from acid. MG1 is known to form complexes with other proteins such as amylase, proline rich 
proteins (PRPs), statherin and histatin as well as various bacteria. Interestingly, an MG2-sIgA protein 
complex was found to bind to the oral bacteria Pseudomonas aeruginosa and Staphylococcus aureus 
whilst MG2 alone was found not to bind294. 
A complex interaction between the molecular contents of saliva and bacteria present on the tooth and 
gum surfaces is likely to play a role in gingivitis. It is therefore of interest to look at the protein 
complexes that may be present in saliva. Whilst a number of protein complexes have been identified 
in saliva, to date, there has not been a global proteomics analysis of saliva complexes. Proof-of-
concept experiments were performed in this study to investigate the presence of complexes in saliva 
and to determine their composition. A novel technique combining blue native gels with protein 
correlation profiling was used to look for putative salivary complexes. 
 
3.1.3 Label-free protein quantitation 
The composition of different fractions of saliva were analysed in this thesis. As well as identifying the 
proteins present in saliva it is critical to quantitate differences in protein abundance for biomarker 
discovery. A number of strategies are available for protein quantitation and an overview was given in 
Section 1.2.1. Label-free approaches for quantitation, rather than labelling techniques, were chosen 
due to their ability to analyse large numbers of samples for biomarker discovery and their relative 
cost-savings when compared to labelled techniques such as iTRAQ. This section introduces the label-
free software packages that were investigated in this thesis. 
Three software packages were evaluated in this study: XCMS, MS-Xelerator and Progenesis. This 
work was performed at the University of Edinburgh. Initially in the laboratory, no quantitative 
proteomics platforms were set up for either labelled or label-free approaches, and therefore it was 
necessary to evaluate a variety of software packages. The first label-free software investigated was 
XCMS. Despite the benefit of being open-source software, at the time of the commencement of this 
project, XCMS was not able to link LCMS quantitation with the identification LC-MSMS data. Two 
other software packages were also investigated: MS-Xelerator and Progenesis. It is important to note 




XCMS was developed at the Scripps Centre for Mass Spectrometry by Smith and coworkers295 and is 
available through the Bioconductor bioinformatics project and the Metlin Metabolite Database98. 
Although it was originally designed for LCMS metabolite data it can also be applied to LCMS peptide 
digests. XCMS comprises three main processing steps for each sample: peak detection, peak matching 
and retention time alignment. For peak detection, the LCMS filtering algorithm generates EICs 
(extracted ion chromatograms) in each of the 0.1 m/z bins. Peaks are detected based on the signal-to-
noise (S/N) cut-off which can be altered by the user, as well as a limit of 5 peaks per chromatographic 
slice (see Appendix E.1 for more information). XCMS can be used on both low and high resolution 
instruments and can be adapted for both centroided and profile data. Following peak detection the 
peaks are matched between the different samples to enable relative quantitation. Peak matching is a 
rough way to group the peaks for a more refined retention time alignment to be then performed. Well 
behaved peak groups are used as temporary standards to calculate a nonlinear retention time profile. A 
well behaved peak group is defined as a group which does not have many extra or missing peaks and 
this number may be specified by the user. The retention time deviation profile is then used to warp all 
the peaks into alignment and peak matching is performed once again to provide a set of reproducible 
peak groups. The relative intensities of the EIC peaks are then compared between the two groups of 
samples and a univariate t-test is used to identify peaks which are significantly different between the 
two samples. Samples are subsequently ranked by ascending p-value.  
3.1.3.2 MSX 
MS-Xelerator (MSX) is commercially available from MsMetrix (Netherlands)296. MSX comprises 
four modules: Browser, MPeaks, IPeaks and MSCompare. MPeaks can compare 2 different samples 
and alignment is based on a peak based algorithm. MSCompare allows the comparison of a series of 
LCMS samples and chromatographic alignment is a feature-based, rather than peak-based, algorithm. 
Currently LCMS and LC-MSMS linking capability is only possible in the MPeaks module. Future 
versions of the MSCompare module will implement the peak based algorithm and LCMS and LC-
MSMS linking. Pre-processing algorithms include smoothing, despiking and baseline correction, and 
alignment algorithms include offset shifting, correlation optimized warping (COW), and reference 
peak warping. Normalisation of the total area of specific peak area is possible. For ratio calculation, 
the intensity (peak height) of the EIC or the peak area can be used. For complicated samples, it is 
generally advisable to use the peak height since this appears to be less susceptible to overlapping 
peaks and misalignment (see Appendix E.2 for more information on MSX)296. 
3.1.3.3 Progenesis 
Progenesis LC-MS is commercially available from Nonlinear Dynamics (UK)297. The LCMS 
chromatographic alignment is based on algorithms previously developed for alignment of spots in 2D 
gels (SameSpots) and involves the addition of alignment vectors. Progenesis allows for manual editing 
of the peaks picked and to adjust the area over which the integration is calculated. Multiple options 
exist for viewing the data, either in 2D or 3D, and peptides are ranked by ANOVA p-value. 
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Progenesis uses a normalisation strategy that is based on the assumption that the abundance of at least 
50% of the peptides in two given samples is unchanged. The software uses these peptides, for which 
abundance is unchanged, for normalisation, allowing many data points to be used for normalisation 
and ignoring outliers. Progenesis has the potential to link LCMS and LC-MSMS data, although this 
was still under development at the time experiments were performed (see Appendix E.3 for more 
information). 
These three software packages were optimised and evaluated using a range of sample types of varying 






















3.2 Experimental Procedures 
Most of the saliva preparation and mass spectrometric analysis procedures are detailed in the 
Experimental Procedures (Chapter 2). A brief overview is given below. 
 
3.2.1 Saliva preparation 
Saliva supernatant was prepared and collected as described in Sections 2.2.1 and 2.2.2 at Edinburgh 
and HMS respectively. Saliva residue was prepared as described in Sections 2.2.2 and 2.3.2. Saliva 
was analysed using in-solution digestion (Section 2.2.1), SCX (Section 2.2.2.2) and GeLC-MSMS 
(Section 2.3.3), and analysed on various mass spectrometers including HCT (Section 2.4.1.1) and 
LTQ Orbitrap (Section 2.5.1). The phosphoprotein portion of saliva was purified using both protein 
IMAC and peptide IMAC (Section 2.2.3). The bacterial portion of saliva was prepared without 
culturing (Sections 2.2.2 and 2.3.2) and with culturing (Section 2.2.2.1). The bacterial biofilm was 
obtained from Dr. David Spratt from an experimental mouth set up at the Eastman Dental Institute, as 
described298, and processed in the same way as the bacterial portion of saliva (Section 2.2.2). Saliva 
(20 µg) was run on BN gel with the optimised conditions specified in Section 2.7.7.2 and analysed 
using LC-MSMS protein correlation profiling with quantitation using spectral counting (section 
2.7.7.4). 
 
3.2.2 Mass spectrometry and data analysis 
Mass spectrometry LC-MSMS was performed using an ion trap (HCT) (Section 2.4.1.1) and LTQ-
Orbitrap (Section 2.5.1) and the data processed and searched using Mascot (Section 2.4.3) or Sequest 
(Section 2.5.3). For protein annotation analysis, protein lists were filtered at a 1% FDR at the protein 
level and analysed for relative enrichment in MetaCore™ Analytical suite version 4.5 (GeneGo, Inc, 
St. Joseph, MI). MetaCore™ is a web-based computational platform designed for the analysis of high 
throughput experimental omics data. Enrichment analysis was carried out across various functional 
ontologies including Gene Ontology (GO) biological process (BP), GO cellular component (CC), GO 
molecular function (MF). The results were ranked by p-value which was calculated using a 
hypergeometric distribution as described299, where the p-value represents the probability of a mapping 
event arising by chance given the number of genes in the list of interest relative to all the proteins in 
the background protein list (whole proteome) for a particular ontology. Further protein function 
annotation using GO was performed using the Proteome Bioknowledge® Library (BKL) Retriever 
version 2.4.2300. Comparison of the number of proteins assigned to each GO category for both saliva 
supernatant and residue was carried out. Only the major categories with a p-value < 0.05 were 




3.2.3 Optimisation and comparison of label-free software packages 
Samples used for optimisation of the label-free software packages included a mix of standard peptides 
(bradykinin, enkephalin, angiotensin 2, glu-fibrinopeptide and melittin, each at 5pmol/µl) (Sigma 
Aldrich), BSA digest and ‘wake-up’ (WU) and ‘after toothbrushing’ (T) saliva samples. WU saliva 
was collected immediately after waking up in the morning after at least 6 hours sleep. No liquid or 
food was consumed prior to producing the saliva sample. T saliva was collected 30 minutes after teeth 
had been brushed. No food or liquid was consumed in the 30 minutes between toothbrushing and 
expectoration of saliva. Standard peptides were injected into the mass spectrometer at 150, 300 and 
600 pmol. BSA digest was injected into the mass spectrometer with amounts from 100 fmol to 5 
pmol. Peptides and BSA digest were spiked into saliva samples at 150 and 300 fmol. 
For optimisation and comparison of the software packages with different samples, triplicate LCMS 
analyses were performed for each sample. LCMS analyses were acquired using an ion trap (HCT, 
Bruker) and an FTICR (12T, Bruker) with 20 and 150 minute gradients on a Dionex 3000 HPLC 
system (Sections 2.4.1.2 and 2.4.2). ESI with a flow rate of 20µl/min was used rather than nESI as a 
more stable spray was obtained with the higher flow rates. For label-free analysis using the EIC, 
LCMS data was processed manually using Bruker software (DataAnalysis), and with the three label-
free software packages: MS-Xelerator, Progenesis and XCMS. Analysis using Progenesis was mainly 
performed by the company Nonlinear Dynamics since, at the time, we only had access to the earlier 
version of their software which was not suitable for low resolution data. A variety of settings were 
investigated in attempt to optimise performance (Table 3.1). 
 





























3.3 Results and Discussion 
Work was performed on cataloguing the salivary proteome for both the saliva supernatant and residue 
considering proteins of human and bacterial origin and is discussed in the first part of this chapter. The 
phosphoproteome of the saliva supernatant was also investigated. In parallel, three label-free software 
packages were evaluated and optimised with standard mixtures and then used to compare saliva 
samples and this is discussed in the second part of this chapter (Section 3.3.4). 
 
3.3.1 Proteomics of saliva 
This section is divided into the analysis of the human proteins in the saliva supernatant and residue, a 
short study analysing the phosphoproteome of the human proteins in the saliva supernatant, and an 
investigation of the bacterial proteins in saliva. In addition to cataloguing the proteins identified in 
saliva, gene enrichment analysis of the proteins in the different saliva fractions was performed to 
determine categories that were significantly overrepresented in saliva compared to the human 
proteome. 
3.3.1.1 Proteomics of human saliva in the residue and supernatant 
Saliva supernatant was digested in solution and analysed by LC-MSMS on the HCT (Bruker) ion trap 
mass spectrometer. Around 60 proteins were identified in one LC-MSMS run. The goal was to 
identify as many proteins as possible in one LC-MSMS run. One LC-MSMS run was preferred due to 
ease of label-free quantitation and the expectation of large numbers of clinical samples. Considering 
over 1000 proteins have been identified in saliva206, the number of proteins identified here was very 
low. The presence of a few very abundant proteins in saliva, such as amylases and immunoglobulins, 
dominate the protein mixture and, without sample prefractionation, mask lower abundance proteins.  
To identify more proteins in saliva it was necessary to fractionate the saliva. Saliva was fractionated 
by SDS PAGE into 20 fractions and analysed by LC-MSMS on an LTQ-Orbitrap. A total of 834 
proteins were identified with a FDR (false discovery rate) <1% at the protein level, where 4,657 
unique peptides and 30,670 total peptides were identified. This was lower than the number of proteins 
identified by the NIDCR salivary proteome consortium. However, the NIDCR study involved a very 
large number of fractionations and the combined efforts of 3 research groups205. 
Whilst many research groups have investigated the proteomics of the soluble (supernatant) fraction of 
the saliva, very few have considered the saliva residue (that is obtained following saliva 
centrifugation) using large scale proteomics. One of the main symptoms of gingivitis is inflammation 
of gingival tissue, and therefore it might be expected that the cells that are sloughed off into saliva 
from the gingiva may contain markers for gingivitis. It is thought that the majority of these cells 




For the same saliva sample for which the supernatant had been analysed, the corresponding saliva 
residue was analysed by GeLC-MSMS. The sample was fractionated into 20 gel slices and analysed 
on an LTQ-Orbitrap. A total of 1,426 proteins were identified with a FDR <1 % at the protein level, 
where 7,865 unique peptides and 39,751 total peptides were identified. A greater number of proteins 
were identified in the residue portion of saliva on account of the lower dynamic range of protein 
abundance compared to the saliva supernatant.  
The proteins identified in the residue and the supernatant were compared. The overlap between the 
supernatant and the residue was very high: 75% of the proteins identified in the supernatant were also 
identified in the residue and 44% of the proteins identified in the residue overlapped with those 
identified in the supernatant (Figure 3.1). The large overlap implies that a significant portion of the 
proteins in saliva originate from lysed epithelial or gingival cells from the inside of the mouth.  
Whilst there could be contamination of the saliva residue by salivary proteins from the supernatant, 
which is more common for ‘sticky’ proteins such as mucins, the salivary residue pellet was washed 
with PBS to reduce such contamination. Therefore, it is unlikely that a large proportion of the 







Figure 3.1   Overlap of proteins observed  in  the salivary supernatant  (SN) and  reside. Analysis was performed 
using GeLC‐MSMS. SDS PAGE was performed on 20µg of saliva SN and residue respectively and each gel was 
fractioned  into 20 bands, digested  in‐gel with  trypsin and analysed on an  LTQ Orbitrap. Of  the 834 proteins 




The spectral count (SC) distribution of co-occurring proteins which were identified in both fractions 
(residue and SN) was subsequently compared to the SC distribution of proteins in the individual 
fractions (the SN and residue fractions separately). This was performed to determine whether the co-
occurring proteins had low or high spectral count with respect to their counterparts in the supernatant 
or residue (Figure 3.2a and b). If the large overlap observed between the supernatant and residue 
proteins was due to contamination during sample preparation, the majority of co-occurring proteins 
would be expected to be found with low spectral counts in the corresponding sample.  However, since 
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the spectral count distribution of co-occurring proteins in the supernatant and residue was fairly 

















and  SN) against all  the proteins observed  in  the  individual  samples  (SN and  residue  separately).  (a)  Spectral 





Whilst many studies dedicated to profiling the salivary proteome have concentrated on extensive 
fractionation and pretreatment of the sample to remove the most abundant proteins in order to identify 
large numbers of salivary proteins, the approach here was to develop a simple, reproducible method 
whereby many samples could be processed and compared. One of the disadvantages of removing 
abundant proteins is reduced reproducibility. A promising new approach using Proteominer beads 
(Biorad) has been shown to identify a very large number of saliva proteins without the need for 
removal of abundant proteins107. For future studies, the reproducibility of data obtained using these 










































3.3.1.2 Protein annotation analysis of human saliva 
In the allocation of proteins to different gene ontology (GO) categories, the greatest number of 
proteins for both the saliva supernatant and residue were allocated to the cellular process category for 
GO biological process (Figure 3.3). For GO cellular component, the greatest number of proteins was 
assigned to the cytoplasm, and for GO molecular function, binding had the highest number of protein 
hits. The distribution of the protein profiles across the GO categories was fairly similar for both the 
saliva supernatant and residue. The largest difference is the greater relative abundance of extracellular 

















annotation by biological process.  (B) GO  annotation by  cellular  component.  (C) GO  annotation by molecular 
function. Performed using Proteome Bioknowledge Library (Section 3.2.2). 
 
GO enrichment analysis was performed on the identified human salivary supernatant and residue to 
determine which categories were significantly represented (Figure 3.4). 
  Saliva supernatant  Saliva residue 














































































































For the GO Biological Process categories, catabolic processes were the most enriched in saliva and the 
saliva residue. This is expected since many catabolic enzymes are present in saliva, and one of saliva’s 
main functions is to initiate the digestion of foodstuffs. The categories ‘response to wounding’, ‘acute 
inflammatory response’ and ‘defence response’ were also highly enriched in both saliva and saliva 
residue. The abrasive nature of food mastication can lead to many small injuries to oral epithelial 
tissues and may explain the increased abundance of wound-response and inflammatory proteins. For 
many mammals, the licking of wounds is common practice and has been shown to speed up the 
healing process and reduce bacterial infection; this is consistent with the finding of saliva enriched in 
defense-response proteins. The categories ‘response to stress’ and ‘response to stimulus’ were also 
highly enriched in both the supernatant and residue. The categories ‘generation of precursor 
metabolites and energy’, ‘transport’ and ‘establishment of localisation’ were highly enriched in the 
saliva residue but not in saliva, presumably due to the low cellular content of saliva.  
For the GO Molecular Function, the categories ‘peptidase inhibitor activity’ and ‘enzyme inhibitor 
activity’ were the most enriched in the saliva supernatant. ‘Protein binding’ was highly enriched in 
both the saliva supernatant and the residue. Many other ‘binding’ categories are highly enriched, 
especially in the saliva supernatant and to a slightly lesser extent in the residue. This highlights the 
role of salivary proteins binding to bacterial proteins and foodstuffs. ‘Oxidoreductase activity’ was 
highly enriched in the residue, whilst it was only moderately enriched in the supernatant.  
For the GO Cellular Component, the category ‘extracellular region’ was highly enriched in the saliva 
supernatant, much more so than in saliva residue. The ‘cytoplasm’ and other cell constituents 
including ‘mitochondrion’ and ‘cytosol’ were more enriched in the saliva residue compared to the 
supernatant, as would be expected. 
Since there was a large degree of overlap between the proteins observed in the saliva supernatant and 
residue, similar GO profiles would be expected. GO analysis was also carried out on the subset of 
proteins in the supernatant which were not observed in the salivary residue (Figure 3.5). The SN-only 
proteins were highly enriched for immune response pathways, cell adhesion, blood coagulation and 
proteolysis. Enrichment analysis against diseases yielded the ‘pure’ salivary supernatant to be 
enriched for proteins involved in thrombosis, amyloidosis and hypertension. The diseases for which 
the associated proteins were enriched are particularly interesting since they provide a starting point for 
potential conditions that might be diagnosed in saliva. The processes which were enriched in the SN-
only proteins were much more similar to what would be expected for saliva compared to that obtained 
when comparing all the proteins obtained in the whole saliva supernatant. It is likely that the SN-only 




















3.3.1.3 Human salivary phosphoproteome 
To further characterise the salivary proteome and determine whether many phosphoproteins can be 
identified in saliva, the phosphoprotein fraction of saliva was investigated with a view to determine 
whether this enrichment would be a useful step in saliva biomarker discovery. Analysis of the saliva 
supernatant following enrichment for phosphoproteins using IMAC identified 66 phosphorylation 
sites in 39 proteins (Table 3.2). This is the first report, to date, of the analysis of the salivary 
phosphoproteome. It is interesting to identify the phosphorylation of PRKCD, which could be an 
activation event, since PKC activity was observed in saliva (discussed in Section 4.3.2.2). The 
proteins found to be phosphorylated were investigated using enrichment analysis (Figure 3.6). 
On account of the small number of proteins identified, accurate enrichment analysis was difficult. 
However, salivary phosphoproteins appear to be enriched for processes involving the cytoskeleton. 
Processes involving interleukin production and other immune processes such as neutrophil mediated 
immunity were also enriched. Enrichment of proteins involved in immune processes may be expected 
on account of the mouth (saliva) being one of the main points of entry to the body of bacterial and 
viral pathogens. Furthermore, the natural bacterial flora in the oral cavity must be constantly 
monitored and regulated by host defences, giving credence to the high abundance of immune-related 
proteins. Enrichment for cell adhesion is also consistent with the known interaction between salivary 
proteins and bacterial proteins. However, it is not immediately clear why processes involving the 
cytoskeleton were enriched. One possible explanation is that the cells in the mouth are highly 
mitotically active on account of constant cell sloughing and the  turnover rate of the sulcular 
epithelium is one of the highest of the various epithelial tissues in the body302.The increased cellular 







Gene Symbol  Protein name  Sites  Sequence 
AMY2B  Alpha‐amylase 2B  1  K.TGS#GDIENYNDATQVR.D 
ARHGEF6  Rho guanine nucleotide exchange factor 6  1  R.MS#GFIYQGK.I 
BTN3A3  Butyrophilin subfamily 3 member A3  1  R.ILT#LEPT#ALTICPIPK.E 
DNAJC3  DnaJ homolog subfamily C member 3  1  K.LIES#AEELIR.D 
EFHA1  EF‐hand domain‐containing family member A1  3  K.DIEDTLS#GIQTAGCGS#T#FFRDLGDK.G 
FAM65B  Protein FAM65B  1  R.SQS#FAGFSGLQER.R 
GREM2  Gremlin‐2  1  K.EVLASS#QEALVVTER.K 
HMGA1  High mobility group protein HMG‐I/HMG‐Y  3  R.KQPPVS#PGTALVGS#QKEPSEVPTPK.R 
R.KQPPVS#PGTALVGSQK.E 
R.KQPPVSPGT#ALVGSQK.E 
HNRNPA3  Heterogeneous nuclear ribonucleoprotein A3  1  R.SSGSPY#GGGYGSGGGSGGYGSR.R 
HS3ST4  Heparan sulfate glucosamine 3‐O‐sulfotransferase 4  1  R.TPLAPSEMITAQS#ALPER.E 








IQSEC3  IQ motif and SEC7 domain‐containing protein 3  1  K.T#VLSVPHR.R 
LCP1  Plastin‐2  1  R.GS#VSDEEMMELR.E 
LMO7  LIM domain only protein 7  1  R.S#WASPVYTEADGTFSR.L 






LPP  Lipoma‐preferred partner  1  R.VLT#AKASTDL.‐ 




MYL9  Myosin regulatory light polypeptide 9  2  R.ATS#NVFAMFDQSQIQEFK.E 
R.AT#SNVFAM*FDQSQIQEFK.E 
MYO1F  Myosin‐If  1  R.GPPSTSLGAS#R.R 
MYO9B  Myosin‐IXb  1  R.RTS#FSTSDVSK.L 
NADK  NAD kinase  1  R.SLS#ASPALGSTK.E 
OR2AK2  Olfactory receptor 2AK2  1  K.M*AVS#FLS#QSK.T 
PIKFYVE  1‐phosphatidylinositol‐3‐phosphate 5‐kinase  1  K.ILLDS#VQLK.D 
PKP1  Plakophilin‐1  1  R.FSSYS#QMENWSR.H 




PRKCD  Protein kinase C delta type  1  R.SDS#ASSEPVGIYQGFEK.K 
RAB11FIP2  Rab11 family‐interacting protein 2  1  R.NNMTAS#MFDLSMK.D 
ROS1  Proto‐oncogene tyrosine‐protein kinase ROS  2  K.YAQLLGS#WT#YTK.T 
RRBP1  Ribosome‐binding protein 1  1  K.LQS#SEAEVR.S 
S100A9  Protein S100‐A9  1  K.MHEGDEGPGHHHKPGLGEGT#P.‐ 
SCAMP2  Secretory carrier‐associated membrane protein 2  1  R.AASS#AAQGAFQGN.‐ 
TBC1D10B  TBC1 domain family member 10B  1  R.AAGGAPS#PPPPVR.R 
THRAP3  Thyroid hormone receptor‐associated protein 3  1  R.IDIS#PSTFR.K 
VIM  Vimentin  1  R.S#LYASSPGGVYATR.S 
VTN  Vitronectin  1  R.DS#WEDIFELLFWGR.T 
WIPF1  WAS/WASL‐interacting protein family member 1  2  R.NLS#LSSSTPPLPS#PGR.S 
R.NLS#LSSSTPPLPSPGR.S 
ZYX  Zyxin  1  R.S#PGAPGPLTLK.E 
 
This short preliminary study of the salivary phosphoproteome indicated that several phosphoproteins 
are present in saliva. However, the enrichment protocol was considerably long and did not lend itself 
to parallel processing of samples, an important factor for biomarker discovery and analysis of clinical 
samples and phosphoprotein enrichment of saliva was not included in the analysis of clinical trial 
samples. Future in depth analysis of the salivary phosphoproteome will be performed using larger 
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amounts of saliva and using alternative enrichment protocols as described303 to determine whether a 
greater number of phosphoproteins can be identified in saliva and whether this could be a useful 

















3.3.2 Proteomics of bacteria in human saliva 
Very few studies have investigated the bacterial or human cellular proteins in the saliva residue and 
the first proteomic study of the saliva residue was only published recently211. Proof-of-concept 
exploratory studies were therefore performed at Edinburgh to determine whether bacterial proteins 
could be identified in saliva using proteomics.  
Various initial studies were performed in Edinburgh. From an in-solution digest of the saliva residue 
in one LC-MSMS analysis (HCT, Bruker) only four eubacterial proteins were identified. Obtaining a 
pure bacterial saliva sample was a challenge since the separation of bacterial cells from human cells 
and mucins was problematic. In order to increase the proportion of bacteria vs. human proteins to 
enable more detailed analysis, saliva was cultured in LB broth at 37°C for 24 hours and then analysed. 
This approach greatly increased the number of bacterial proteins identified and reduced the proportion 




MSMS run (HCT, Bruker). To investigate the composition further, SCX fractionation (30 fractions) 
was performed on this cultured sample, resulting in 487 eubacterial proteins and 37 archaebacterial 
proteins. From the published proteomic literature, no archaebacteria have been reported in saliva. 
According to the HOMD (Human Oral Microbiome Database) one archaebacterium is reported to be 
present in the oral cavity150, and no archaebacteria have been hypothesised to contribute to human 
disease304. This suggests that the bacterial flora of the mouth may be more diverse than originally 
anticipated, and that a proteomic analysis may provide insight into this unexplored population. 
Furthermore, the majority of saliva proteomics experiments have concentrated on the supernatant and 
have not included bacterial databases in their searches, presumably on account of the unwieldy size of 
the bacterial database. To the author’s knowledge, no published research has been performed in which 
salivary proteins have been searched against archaeal databases. With a view of obtaining a ‘purer’ 
bacterial sample under more mouth-like culturing conditions, bacterial biofilm samples from an 
experimental mouth model (Section 1.4.1) were analysed. A total of 59 eubacterial and 6 proteins 
from archaea were identified in a single LC-MSMS analysis with no fractionation. 
These initial proofs-of-concept studies demonstrated that saliva residue is an abundant source of 
bacterial proteins. A more comprehensive global analysis of the bacteria in saliva was subsequently 
performed using GeLC-MSMS analysis on an LTQ-Orbitrap. In the proof-of-concept work, lysis was 
performed using a Cell Perturbator machine (Section 2.2.2) whereas bacterial sample preparation in 
this global analysis involved lysis with detergents (Section 2.3.2). For the same saliva sample for 
which the supernatant and residue had been analysed for human proteins (Section 3.3.1.1), 20 
fractions were analysed and the spectra were searched against a composite database including 
eubacteria, archaea and human proteins. A total of 1,365 proteins were identified with a FDR <1 % at 
the protein level with 6,685 unique peptides and 34,107 total peptides being identified. Of the 1,365 
proteins, 1,233 matched to human, 130 matched to eubacteria and 2 matched to archaea. For the 
supernatant 810 proteins were identified with a FDR <1 % at the protein level with 4,001 unique 
peptides and 26,425 total peptides. Of the 810 proteins, 736 matched to human, 70 matched to 
eubacteria and 4 matched to archaea. On account of the large size of the composite database, only 1 
missed cleavage was specified in the search criteria to reduce search time. This explains the slight 
decrease in the number of human proteins observed when the dataset was searched solely against the 
human proteins with a missed cleavage of 2 (1,426 proteins). Combining the bacterial identifications 
for residue and supernatant resulted in the proteins mapping to 97 bacterial species and 16 species 
with ≥ 2 proteins per species. 
The majority of bacterial proteins comprising the saliva supernatant were gram-negative 
Proteobacteria, followed by gram-positive Actinobacteria and Firmicutes (Figure 3.7). In the saliva 
residue, the distribution of proteins between the different phyla was more evenly distributed. Whilst 
Proteobacteria also comprised the largest proportion, the contribution of both Firmicutes and gram-
negative Bacteriodetes accounted for 50% of the identified proteins. Interestingly, Bacteriodetes were 








Figure  3.7    Distribution  of  bacterial  proteins  across  the major  phyla  identified  in  saliva  (a)  residue  and  (b) 
supernatant. Taxonomic analysis performed using protein descriptions from Uniprot. 
 
Most of the species identified would be expected to be present in human saliva215, however, some 
species were unexpected. For example Bradyrhizobium, a soil bacterium, and Desulfovibrio, a 
water/soil bacterium were found in saliva. Since many of the organisms in the mouth have not yet had 
their genomes fully sequenced215, it is likely that hits from other species may occur where the protein 
in different species have similar sequences. A total of 97 species were identified based on one protein 
and 16 species identified with at least 2 proteins for each species (Table 3.3). 
 
This work investigating the bacterial complement of the salivary proteome indicates that many 
different bacterial species can be identified and that the bacterial portion of saliva may serve as a 
useful realm of information for future biomarker studies. 
Table 3.3  Bacterial species identified in saliva residue and supernatant from one individual subject. The number 
of proteins and the total spectral counts for each bacterial species are given. A total of 16 bacterial species were 






   Residue  Supernatant  Residue  Supernatant 
Bacteroides fragilis  4 0 8 0 
Bacteroides vulgatus   4 0 9 0 
Fusobacterium nucleatum  4 2 8 4 
Veillonella dispar   4 0 5 0 
Actinomyces odontolyticus   3 6 11 12 
Bacteroides caccae   3 0 13 0 
Pseudomonas aeruginosa  3 1 3 2 
Selenomonas flueggei   3 1 17 3 
Bacillus subtilis  2 0 2 0 
Bacteroides ovatus   2 0 4 0 
Bacteroides uniformis   2 0 3 0 
Bdellovibrio bacteriovorus  2 1 9 21 
Bradyrhizobium sp.   2 1 25 1 
Burkholderia xenovorans   2 1 13 4 
Desulfovibrio magneticus   2 1 8 2 




3.3.3 Salivary protein complexes 
Saliva was run on BN PAGE (discussed in Section 2.7.7) to identify the presence of protein 
complexes in saliva. In total 510 proteins were identified (0.1 % peptide FDR) from 10 GeLC-MSMS 
fractions. For proteins that had a spectral count greater than 5, the protein profile (spectral count) of 
each protein across the 10 fractions of the BN gel was compared with each of the others  and the 
Pearson correlation coefficient was calculated (Figure 3.8 and Figure 3.9).  This correlation analysis 
reveals proteins with similar profiles which may be present in complexes with each other. The largest 
molecular weight complex comprises predominately amylase and immunoglobulins (Figure 3.8d and 
Figure 3.10). The second largest complex comprises many enzymes (Figure 3.11). Lower molecular 































































































































































































































































































































































































































































































Figure 3.10   Putative  salivary protein  complex 1  comprising amylase,  immunoglobulins and  the  kinase RIPK4 
(receptor‐interacting serine/threonine‐protein kinase 4). Saliva was run on a Blue native PAGE gel and ten slices 
were analysed by GeLC‐MSMS. Spectral counts of  the proteins give an estimate of  the protein abundance  in 
each of the fractions.  
Figure 3.11  Putative salivary protein complex 2 comprising various enzymes (LPO, MDH2, GADPH, CAT, ALDOA, 
CA6, PP1B), A2ML1  (alpha‐2‐macroglobulin‐like), CST1  (cystatin 1), CRISP3  (cysteine‐rich  secretory protein 3) 
and LTF (lactotransferrin). Saliva was run on a Blue native PAGE gel and ten slices were analysed by GeLC‐MSMS. 
Spectral counts of the proteins give an estimate of the protein abundance in each of the fractions. 
Figure  3.12    Putative  salivary  protein  complex  3  comprising  various  enzymes  (MMP9,  TGM3,  ASAH1,  PGD), 
SERPINB1  (serpin peptidase  inhibitor), CST3  (cystatin 3), C3  (complement  component), TF  (transferrin), BPIL1 
(bactericidal/permeability‐increasing protein‐like 1) and GSN (gelsolin). Saliva was run on a Blue native PAGE gel 






a Blue native PAGE gel and  ten  slices were analysed by GeLC‐MSMS. Spectral counts of  the proteins give an 
estimate of the protein abundance in each of the fractions. 
 
For confirmation of the presence of the main protein complex in saliva (comprising amylase and 
immunoglobulins), a separate experiment was performed in which a different saliva sample was 
analysed and the gel was profiled. In this case, a complex comprising similar proteins was observed 
(Appendix F.1). The salivary profile from saliva run on an SDS-PAGE gel did not contain such a 
protein complex (Appendix F.2). To determine whether protein complexes could be observed in the 
saliva residue and in tear supernatant these samples were also investigated using BN PAGE protein 
correlation profiling and several complexes were evident (Appendix F.3). 
In-gel BN PAGE kinase activity/kinase abundance correlation profiling (as described in Section 
2.7.7.4) using saliva was performed but poor correlation was obtained on account of poor BN PAGE 
resolution and low spectral counts (Appendix G).  
These experiments using correlation profiling of BN PAGE and LC-MSMS offer great potential as a 
technique to identify protein complexes. Whilst 2D BN/SDS PAGE has been widely used as a method 
to investigate protein-protein interactions, very little work using 1D BN PAGE in combination with 
proteomics has been performed275, 305-306 and only one recent publication reported the use of BN 
PAGE linked with protein correlation profiling to identify protein complexes in mitochondria306. 
Whilst the small precast BN PAGE used in this study may not be suitable for large scale mapping of 
protein complexes, there is potential for greater resolution and loading capacity with larger BN gels. 
Whilst BN PAGE protein correlation profiling was shown to be useful for the identification of protein 
complexes and could be useful for small biomarker studies in the future comparing a few samples, the 
procedure requires sample fractionation and therefore would currently be too time consuming for high 
throughput biomarker discovery with a large number of samples. 
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3.3.4 Comparison of label-free quantitation software packages 
With a view to develop a biomarker platform, three label-free software packages were evaluated: MS-
Xelerator, Progenesis and XCMS. Prior to using these softwares to compare saliva samples, less 
complex mixtures were used. 
3.3.4.1 Experimental design to compare three label-free quantitation software packages 
Three different datasets were used to assess the packages with varying levels of complexity: standard 
peptides (3 different concentrations), BSA digest, and saliva spiked with BSA. Two different saliva 
samples were used to rigorously test the software packages. Significant differences in the saliva 
protein composition can be observed between wake-up (WU) and after-toothbrushing (T). These 
differences were observed on SDS-PAGE (Figure 3.14), where T saliva had a more intense band 
around 75 kDa. The goal was to optimise the assay using samples of different complexity to then 













The aim was to perform analysis of all the samples (peptides, BSA, saliva spiked with BSA, saliva 
WU+T) by four methodological approaches (20 and 150 min gradients on a low and high resolution 
mass spectrometer) using four different quantitation approaches (manual, MSX, Progenesis, XCMS) 
(Table 3.4). By varying the complexity of the datasets, accurate assessment of the dynamic range of 
each software package can be determined. By analysing simple datasets, where the correct fold values 
were known, the parameters were optimised and subsequently applied to the more complex datasets 
where the fold values were not known. Due to time constraints, not all of these combinations were 
obtained before moving from Edinburgh to HMS. Those datasets shown with an ‘X’ were collected 












the datasets  that were  collected and analysed. NA  refers  to datasets  that were  too  complicated  for manual 
analysis. WU refers to saliva that was taken at wake‐up and T refers to saliva taken following tooth brushing. 
MS  HCT  FTICR           





Data analysis  Manual  MSX  Prog  XCMS  Manual  MSX  Prog  XCMS  MSX  Prog  XCMS  MSX  Prog  XCMS 
Peptides  X  X  X  X                     
BSA digest  X  X  X  X  X  X  X  X  X  X  X       
Saliva spiked with peptides  X  X  X  X                     
Saliva spiked with BSA  X  X  X  X  X  X  X  X  X  X  X  X    X 
Saliva (WU vs T)          NA  X  X  X        X  X  X 
 
There are a variety of settings and processing options for the 3 label-free software packages (Table 
3.5). In general, MSX and Progenesis were fairly similar in terms of ease of use and both had a good 
graphical interface. Progenesis had a significant advantage in that many groups could be compared, 
whilst only two groups could be compared in MSX and XCMS. At the time of analysis, linking of 
LCMS quantitation data with LC-MSMS was only possible with the MPeaks module of MSX and 
with Progenesis. Unfortunately, the MPeaks module only allowed the comparison of two LC-MSMS 
runs and not two groups of samples as in the MSCompare module. Integration of the LCMS and LC-
MSMS linking is currently being implemented into the MSCompare module. The earlier version of 
Progenesis, for which only a beta version was available in the laboratory, did not have LC-MSMS 
linking capability. However, the later version allowed this linking capability through importing the 
Mascot results file.  
Table 3.5  Summary of the three label‐free quantitation software packages. The software packages MSX, 
Progenesis and XCMS software packages were evaluated. 
  MSX  Progenesis  XCMS 
File import form  NetCDF/mzXML  NetCDF/mzXML  NetCDF/mzXML 
Operating system  Windows  Windows  Linux, OSX, Windows 



























Group settings  Can only compare 2 groups  Can compare many groups  Can only compare 2 groups 
























3.3.4.2 Standard peptides 
Peptides at three different concentrations (150, 300 and 600 fmol) were analysed on a low resolution 
ion trap mass spectrometer (HCT, Bruker) with a gradient of 20 min. A mixture of 5 peptides 
comprising bradykinin, met-enkephalin, angiotensin II, glu-fibrinopeptide B and melittin was used 













Analysis of the average fold of individual peptide peaks was determined using the three software 
packages as well as manually using the peak area of the extracted ion intensity (Table 3.6). The results 
of the manual analysis and using Progenesis were very similar, with averages very close to the 
theoretical 2.0 and small standard deviations. A much greater number of peaks were identified using 
MSX and XCMS analysis since the software packages do not apply de-isotoping. The melittin peptide 
was not identified using Progenesis, therefore only 4 peaks were identified. The peak-picking 
algorithms of MSX and XCMS were much more sensitive; however a disadvantage of the ability to 
pick up very low abundance peaks is reduced accuracy and analysis of peaks which may not represent 
peptides and may be from noise. If only the peaks for the largest charge stage of each of the 5 peptides 
were chosen, then the accuracy increased (resulting in an average fold value closer to 2) and smaller 
standard deviations were obtained (Table 3.7). Only the peak area values can be obtained using 
Progenesis and XCMS whilst for MSX, both the peak height and peak area can be obtained. One of 
the advantages of Progenesis is that the area of the selected peak can be manually edited, although 
clearly for large numbers of samples this is not practical. A p-value was generated by both Progenesis 
and XCMS. However, MSX at the time of analysis did not provide any statistical measure of error. 
Some of the peaks detected using XCMS were outliers and skewed the results, despite having P values 
of <0.01. If these peaks were excluded (following manual checking of the EIC alignment), the 
accuracy of the average fold value increased. Whilst this manual checking is possible for a small 










































  Peaks Av  SD  Peaks Av SD Peaks Av SD Peaks Av  SD  Peaks Av SD
300/150  5  1.94  0.11  57 2.26 0.45 4 2.02 0.28 29 2.50  1.64  27  2.14 0.54







Manual MSX Progenesis  XCMS
















Bradykinin  379 2+  1.84 2.01 2.01 1.97 1.90  1.95
Enkephalin  574 1+  2.05 1.79 2.11 1.84 1.89  2.00
Angiotensin 2  524 2+  1.85 1.68 2.11 1.98 1.85  1.92
Melittin  712 4+  1.91 1.78 2.21 2.00 NF  1.84
GFP  786 2+  2.07 1.85 3.27 2.14 2.44  NF
           
Average      1.94 1.82 2.34 1.99 2.02  1.93
SD      0.11 0.12 0.52 0.11 0.28  0.07
 
 
3.3.4.3 BSA digest 
As an increase in complexity from a 5 peptide mixture, a BSA digest at 2 different concentrations, 
was analysed using both the HCT and FTICR mass spectrometers. The fold change of individual BSA 
peptide peaks was determined using each of the software packages and the 9 most intense BSA digest 














































Similar to the five standard peptide experiment, very few peaks (only nine) were detected using 
Progenesis. Conversely, 123 and 269 peaks were detected by XCMS and MSX respectively (Table 
3.8). Analysis of the BSA digest using Progenesis was not as successful as the analysis of the five 
peptide sample and the fold value was underestimated, and the standard deviation was large. Many 
more peaks were identified using both MSX and XCMS and both had similar fold values and standard 
deviations. Nine intense BSA peptide peaks were chosen for manual validation and these were 
compared in the three software packages (Table 3.9). In some cases, the software packages did not 
always detect the nine peptides. However, when only these peptides were considered, all the software 
















  Peaks  Av  SD  Peaks Av SD Peaks Av SD Peaks Av  SD  Peaks  Av SD
200/100  9  1.97  0.29  269 2.18 0.41 9 1.35 0.74 123 3.03  9.25  122  2.12 0.45
 
 
Table 3.9   Comparison of  individual peptide  fold values  for BSA digest using  the HCT with a 20 min gradient. 
























8.4  523 2+  1.86 1.72 1.93 1.94 2.09  1.97
9.4  481 2+  2.02 1.89 1.87 1.71 NF  NF
9.4  720 2+  2.33 1.97 2.23 2.10 2.12  2.31
11.0  628 3+  2.21 1.64 NF NF NF  NF
11.7  576 3+  1.98 2.03 2.01 1.95 NF  2.25
11.8  864 2+  2.06 2.02 2.21 2.16 2.03  2.20
13.1  1054 4+  1.96 1.95 1.78 1.87 1.82  1.93
14.1  939 2+  1.29 1.18 2.18 1.56 NF  NF
18.7  968 4+  2.02 2.25 2.12 2.19 NF  NF
Average    1.97 1.85 2.04 1.94 2.02  2.13
SD    0.29 0.31 0.17 0.22 0.14  0.17
 
 
The same BSA digest samples were also analysed on the high resolution FTICR mass spectrometer 
(Table 3.10). Strikingly, the number of peaks identified by MSX and XCMS was far lower whilst a 
greater number of peaks were identified by Progenesis, compared to the analysis with the low 
resolution HCT. For this sample on the high resolution FTICR, the analysis using XCMS was the 
most optimal with an average close to 2 and a small standard deviation. Very large standard deviations 
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were observed for both MSX and Progenesis. When examining individual peptides, the MSX peak 
height measurements were inaccurate on account of poor alignment of the spectra. On examining the 
individual BSA peptides (Table 3.11) many of the peptides were not observed, although the standard 
deviations were smaller than those when considering all the peaks detected.  The lower number of 
peaks identified by MSX and XCMS was likely to be due to the lower sensitivity of the FTICR 
compared to the HCT. Using a higher concentration of BSA, a greater number of peaks were detected 
by all three software packages (Table 3.12). Whilst analysis using MSX and XCMS resulted in similar 
averages, around 2, the analysis using Progenesis resulted in a very large inaccurate fold of 12 and a 











  Peaks  Av  SD Peaks Av SD Peaks  Av  SD

















8.4  523  2+ 2.38 3.02 2.17  1.73
9.4  481  2+ 2.47 4.31 2.97  NF
9.4  720  2+ 1.76 1.79 1.96  1.75
11.0  628  3+ NF NF NF  NF
11.7  576  3+ NF NF 2.32  1.90
11.8  864  2+ 2.50 2.54 NF  NF
13.1  1054  4+ NF NF NF  NF
14.1  939  2+ NF NF NF  NF
18.7  968  4+ NF NF NF  NF
Average    2.28 2.92 2.36  1.79












  Peaks  Av  SD Peaks Av SD Peaks  Av  SD





















8.4  523  2+ 2.24 2.24 1.79  1.91
9.4  481  2+ 2.08 2.08 2.07  1.90
9.4  720  2+ 1.62 1.62 1.88  1.72
11.0  628  3+ NF NF 2.80  1.86
11.7  576  3+ NF NF NF  NF
11.8  864  2+ NF 1.51 1.64  1.43
13.1  1054  4+ NF 1.72 3.63  1.50
14.1  939  2+ NF NF 20.6  1.95
18.7  968  4+ 1.91 1.91 6.26  1.71
Average    1.96 1.85 5.08  1.75
SD    0.27 0.28 6.45  0.20
 
The experiments using high concentrations of BSA were in the pmol range (Table 3.13). However, as 
a result of the relatively high concentrations, the trap in the FTICR mass spectrometer was 
overloaded. For some of the peaks, particularly the most intense ones, the intensity did not increase 
proportionally with the concentration and a plateau was observed (Figure 3.17), accounting for the 




Figure  3.17    Base  peak  chromatograms  of  three  different  concentrations  of  BSA  digest.  Alignment  of  the 
individual LCMS runs was performed using MSX. Different concentrations of BSA digest (1, 2 and 4 pmol) were 
analysed by LCMS using a 20 min gradient on a FTICR MS. Using the high concentrations of BSA, for some of the 
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3.3.4.4 Saliva spiked with peptides and BSA 
For analysis of biological samples, it is important to be able to detect changes in a few proteins 
amongst many unchanging compounds. To model this scenario, digested saliva (a complex mixture) 














Focusing solely on the 5 standard peptides, the averages and standard deviations of the three software 
packages were fairly similar to the analysis ‘by hand’ (Table 3.14). The peptides were spiked in at 150 
and 300 fmol resulting in a theoretical average of two. The fold values observed were slightly less 
than two, presumably on account of ionisation suppression with the presence of saliva peptides. 
Melittin and bradykinin were not identified using Progenesis. The process where peaks are picked 
using Progenesis is based on the observation of a charge state distribution. In the case of the 4+ 
melittin charge state there may have been difficulty in observing this due to the low resolution data 
























Bradykinin  379 2+  1.70 1.32 1.84 1.87 NF  2.02
Enkephalin  574 1+  1.75 1.55 1.71 1.72 1.70  1.66
Angiotensin 2  524 2+  1.85 1.69 1.65 1.67 1.67  1.63
Melittin  712 4+  1.44 1.78 1.62 1.42 NF  1.58
GFP  786 2+  1.65 1.77 1.79 1.68 1.96  1.60
Average    1.68 1.62 1.72 1.67 1.78  1.70



























For saliva spiked with two different concentrations of BSA, for the 9 BSA digest peaks, many peaks 
were not identified by Progenesis (Table 3.15). Smoothing was not used on the peaks and the added 
complexity of the saliva background resulted in lower abundance peaks which were more challenging 
to quantitate. In contrast, analysis using MSX and XCMS, which both use preprocessing smoothing 
algorithms, had smaller standard deviations. However, when the sample was run on a longer gradient, 
150 min rather than 20 min, the accuracy of manual analysis improved considerably (Table 3.16). The 
analysis using Progenesis did not improve with the longer gradient and the quality of quantitation 


























8.4  523 2+  1.95 1.71 2.31 1.95 1.64  1.93
9.4  481 2+  1.78 1.58 1.56 1.76 NF  1.95
9.4  720 2+  1.84 1.62 1.83 2.06 NF  1.73
11.0  628 3+  0.88 0.90 NF NF NF  1.74
11.7  576 3+  0.92 1.12 1.84 1.93 NF  NF
11.8  864 2+  0.75 0.92 1.91 2.10 1.61  1.51
13.1  1054 4+  NF NF 2.24 2.04 NF  1.56
14.1  939 2+  NF NF 1.90 2.03 NF  1.85
18.7  968 4+  1.64 1.5 1.18 1.64 NF  1.75
Average    1.39 1.34 1.85 1.92 1.63  1.75























523  2+ 1.81  1.54 NF NF NF  1.71
481  2+ 1.78  1.41 1.63 1.40 NF  1.59
720  2+ 1.88  1.22 1.44 1.33 NF  1.47
628  3+ NF  NF 1.96 1.80 NF  NF
576  3+ 1.45  1.61 2.09 1.78 NF  NF
864  2+ 2.08  1.83 2.04 1.76 1.96  NF
1054  4+ 1.88  1.54 1.88 1.74 NF  NF
939  2+ NF  NF 1.79 1.68 NF  NF
968  4+ 1.97  1.71 1.82 1.91 NF  NF
Average    1.84  1.55 1.83 1.68 1.96  1.59
SD    0.20  0.20 0.22 0.20   0.12
 
 
Using the FTICR to analyse the 9 BSA peptide peaks, Progenesis analysis identified only three 














8.4  523  2+ NF NF  NF
9.4  481  2+ 2.33 1.95  2.13
9.4  720  2+ 1.84 1.6  1.87
11.0  628  3+ NF NF  NF
11.7  576  3+ NF NF  NF
11.8  864  2+ 2.35 1.90  1.88
13.1  1054  4+ 1.95 NF  2.04
14.1  939  2+ 1.16 NF  1.09
18.7  968  4+ NF NF  NF
Average    1.93 1.82  1.80
SD    0.48 0.19  0.41
 
 
3.3.4.5 Two saliva samples compared: ‘wake-up’ versus ‘after-toothbrushing’ 
As the final level of ‘complexity’, two different saliva samples were compared: ‘wake-up’ (WU) and 
‘after-toothbrushing’ (T). For both the HCT and FTICR, MSX detected the greatest number of peaks 
(Table 3.18 and Table 3.19). For Progenesis, about 16 times as many peaks were detected using the 
FTICR as with the HCT. With the higher resolution, the isotopic distribution was better resolved and 
the charge states were assigned more easily. With the lower resolution HCT, where the isotopic 
distribution could not be resolved, the peak was detected as ‘noise’ since a charge state was not 
defined. For XCMS, the reverse was observed and the number of peaks detected was around 60 times 
more for the HCT than for the FTICR. In all the cases, the number of peaks with a fold change greater 
two between WU and T was high and very close to the number of peaks detected (Figure 3.19). 
Manual inspection of the chromatograms showed poor alignment of the spectra for all the software 





  MSX Progenesis (P<0.01) XCMS (P<0.01)









  MSX Progenesis (P<0.01) XCMS (P<0.01)














with  a 150 min  gradient  and duplicates of each  saliva  sample were performed. Alignment of  the base peak 
chromatograms was performed using MSX.  
 
3.3.4.6 Overall evaluation of software packages 
Initially, analysis using each software package was performed using the default parameters, which 
resulted in poor analytical results, predominately due to poor alignment leading to incorrect ratios. In 
order to improve peak detection and alignment, the parameters for each software package were 
optimised using simple samples for which the absolute ratios were known. A variety of samples of 
different complexities were analysed on low and high resolution mass spectrometers with short and 
long gradients, and processed with the 3 software packages as well as manually (for the simple 
samples). Following optimisation (for more details see Appendix H) a final set of parameters was 
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For comparison of different concentrations of simple standard peptide mixtures and digested BSA 
analysis using all three software packages was fairly good with detected peptide fold changes near the 
theoretical. However, several outlier peaks which were very poorly aligned were often detected with 
XCMS and this adversely affected the results. For simple mixtures, manual validation removed poorly 
aligned peaks. However, for more complex samples, manual validation is not feasible. With peptide 
and BSA spiked saliva, many of the spiked in peptides and BSA peptides were not detected using 
Progenesis for both the short and long gradient. The analysis using MSX and XCMS was better with 
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these set of spiked in samples. Similarly, for the comparison of the two saliva samples, only 25 peaks 
were detected using Progenesis whereas MSX and XCMS detected around 1,000. For simple samples 
on a low resolution instrument, analysis using Progenesis appears to be the most accurate but suffers 
from poor sensitivity. MSX or XCMS would be the better choice for more complex samples where 
peak detection is of greater importance than accuracy.  
3.3.4.6.2 Analysis using high resolution LMS data 
For the comparison of BSA digest samples, at the lower (fmol) concentrations, the best results were 
obtained using XCMS in terms of accuracy, but results were poor in terms of sensitivity (very few 
peaks were detected). For the higher concentration (pmol) of BSA, analysis using XCMS yielded the 
best results of the three software packages and the sensitivity was also improved (364 peaks detected). 
The increase in performance for XCMS with the data obtained from the FTICR data was particularly 
significant. This improvement was not as significant for MSX. For Progenesis it is not strictly correct 
to compare the data analysis from the low and high resolution runs since different Progenesis 
algorithms were used for both the low resolution and high resolution data. Focusing on specific peaks, 
Progenesis can perform well, but the alignment of peaks across multiple datasets is very challenging. 
3.3.4.6.3   General comments 
Analysis using Progenesis relied on detecting an isotopic peak distribution for peak picking. 
Consequently, for low-resolution instruments, it was difficult to determine the isotopic distribution for 
charge states greater than 3+, and hence the number of peaks observed was lower than the number 
identified using MSX and XCMS. For example, for the comparison of WU and T saliva with analysis 
using Progenesis, around 400 peaks were detected on the FTICR, compared to only 25 on the HCT. 
Conversely, neither XCMS nor MSX rely on the isotopic distribution to determine whether a peak is 
‘real’ or ‘noise’. XCMS integration was performed on spectra that have had no background 
subtraction, which accounts for the detection of more peaks compared to Progenesis in which a 
background subtraction was performed. In MSX, there were various options for preprocessing and 
background subtraction. The use of profile, rather than centroided data, was optimal for XCMS and 
Progenesis whilst there was no significant difference between using profile or centroided data for 
analysis using MSX. The analysis using XCMS was more optimised for high resolution FTICR data 
than low resolution ion trap data. For analysis using both Progenesis and MSX, due to the very visual 
nature of the software, it was easy to quickly manually validate the alignment for each of the EIC 
peaks in the biomarker tables generated. For peaks that were misaligned or where noise had 
inadvertently been picked up, it was easy to exclude such peaks. Despite the ability to generate the 
EIC for each peak, XCMS is much less user friendly, and manually validating every peak and 
correcting the table is very time consuming. This manual element of checking is very useful and the 
visual interface of both MSX and MS-Xelerator allow this to be achieved easily. Progenesis takes this 
a step further and allows the user to modify the area over which the peak is integrated whereas manual 
adjustment is not possible with MSX or XCMS. MSX is much more flexible and can therefore be 
easily adapted to different data types and lengths of gradients. Unlike Progenesis and MSX, XCMS 
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currently does not have any normalisation functionality. This was particularly an issue where spray 
reproducibility is poor and the TIC varied significantly. Despite the disadvantages of XCMS, the most 
accurate alignment was obtained using FTICR MS coupled with analysis by XCMS, and this 
combination was ultimately decided to be optimal. 
3.3.4.7 Workflow for biomarker discovery: LCMS and LC-MSMS linking 
Having determined empirically that the FTICR mass spectrometer coupled with data analysis using 
XCMS performed best for label-free quantitation, the question was how to use this combination most 
effectively in biomarker discovery. In order to identify protein differences, it was necessary to 
combine the quantitative LCMS data with the corresponding LC-MSMS. The FTICR had the 
advantages of higher resolution and hence improved chromatogram alignment for label-free 
quantitation. However, the disadvantage of the FTICR is that the duty cycle is long and consequently 
not suited to LC-MSMS runs. To overcome this limitation, the high mass accuracy and resolution of 
the FTICR was combined with the fast MSMS scan rate of the HCT ion trap. The same LC system 
was used to separate the same sample on both the FTICR and the HCT (Figure 3.20). The LC system 























3.3.4.8 Combining LCMS and LC-MSMS data 
Various approaches were assessed in combining LCMS and LC-MSMS data. As previously 
mentioned, there was no LCMS-LC-MSMS linking capability built into XCMS at that time, and the 
linking capability was still not fully developed for MSX and Progenesis. An in-house solution was 
therefore sought. A script, known as ‘AWASH’, written by Dr Holger Husi in the Barran lab, was 
used to match peaks from the aligned LCMS data (Figure 3.21) with the LC-MSMS peaks.  The 
AWASH algorithm (the binary is obtainable from the Proteomic Analysis DataBase PADB307) used 
iterative searches of m/z and retention time pairs and matched the peaks from the Mascot LC-MSMS 
output with the corresponding peaks from the LCMS spectra (output from XCMS). Briefly, a starting 
window of 0.1 Da and 30 s was used and this window was then increased with each round of iteration 
for unmatched datapoints. A maximum of 1 Da for the m/z window and 120s for the retention time 
window was set. For XCMS data pairs that matched to several peptides in the Mascot results file 
within a set window, the best match was returned. However, major challenges with the alignment 
were experienced and a great deal of effort was put into trying to improve the reliability of the 













3.3.4.9 Advion Replay ProtoMate 
Because two chromatographic runs are never exactly the same, accurate alignment of chromatogram 
traces is critical for accurate label-free quantitation. There were major issues with trying to align the 
spectra, hence the original reason for assessing several software packages. To try to address this issue, 
an Advion ProtoMate Replay system was assessed (Figure 3.22). The ProtoMate Replay enabled the 
collection of two identical nanoLC separations from a single injection. This was achieved by means of 
a post-column split and a capture loop. 
   

































Despite the use of a refocusing nanoLC column, the resulting chromatographic peak width increased. 
Another challenge was the technical difficulty in adjusting the chromatographic peak in order to 
optimise timing. Yet another disadvantage with the set-up using the Proxeon’s Easy nanoLC and 
HCT/FT combination was that a series of runs could not be queued due to the direct injection column 
setup (without a precolumn). Since there was no pre-column, successive samples could not be loaded 
onto the column while the replay was in operation, otherwise flow through the capture loop would 
have been disrupted. As a result, the replay could not be permanently kept in the ‘replay’ position. 
Using the replay with a precolumn may have avoided the majority of these problems. A more 
reproducible chromatographic separation was achieved by using two different injections and, since 

















For accurate alignment it was critical to have stable retention times across the replicate LCMS 
analyses. Many of the inaccuracies and challenges experienced were through inaccurate alignment of 
the chromatographic traces. This can partly be blamed on instrumental set up as well as on inadequate 
alignment algorithms. Ultimately, despite a large portion of time dedicated to optimising LC 
conditions and software parameters, the label-free approach using extracted ion chromatograms was 




The aim of the work in this chapter was to develop a platform for salivary biomarker discovery prior 
to the analysis of clinical trial saliva samples. Various fractions of saliva were investigated including 
the supernatant, residue and the phosphoprotein portion of the supernatant for both human and 
bacterial proteins. The presence of protein complexes in saliva was also investigated and several large 
complexes were identified. Three different software packages were evaluated to determine which was 
the most appropriate for the data analysis. 
This is the first global proteomics study performed on the saliva residue and supernatant from the 
same test subject. The large overlap between the proteins observed in the supernatant and the residue 
indicate that many of the proteins in saliva originate from lysed cells from the inside of the mouth, and 
that this proportion is more significant than previously thought. This is also the first report of a human 
salivary phosphoproteome. Whilst this exploratory experiment confirmed the presence of a variety of 
phosphoproteins in saliva, the phosphoprotein enriched fraction of saliva will not be used for the 
clinical trial samples on account of the time consuming sample preparation steps. However, with the 
finding of a large number of bacterial proteins in saliva, both the human and bacterial proteins will be 
investigated further and both the saliva supernatant and the residue will be analysed for the clinical 
trial samples.  
Furthermore, the global analysis of salivary protein complexes using proteomics presented here has 
not previously been performed. This technique provides a good platform which can be applied to other 
systems for the analysis of protein complexes in other body fluids or tissues. In this report, only 
complexes comprising human proteins were considered. Interactions between salivary proteins and 
bacteria are also critical and this system could serve as a useful platform to extend investigation to 
such interactions and complexes. However, one of the problems with such an approach is that only the 
very strong interactions between the salivary proteins and bacteria are retained after sample 
centrifugation, washing and cell lysis. Excluding the wash step of the pellet could help to retain such 
interactions 
After determining that both the saliva supernatant and residue fractions will be used for biomarker 
discovery and that both the human and bacterial proteins will be considered, evaluation of possible 
software packages for quantitation was performed. 
Three label-free software packages were examined: MSX, Progenesis, and XCMS using several 
proteomic datasets with different degrees of complexity (peptides and BSA digest at different 
concentrations, saliva spiked with standard peptides and BSA and two different saliva samples) on 
low and high resolution mass spectrometers. XCMS and Progenesis gave much better results for high 
resolution data acquired on the FTICR versus data from the ion trap (HCT), whilst there was no 
significant difference between low and high resolution data processed using MSX. Whilst all the 
software packages can process simple samples successfully and can achieve correct fold values for 
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specific peaks, the challenge was in the optimisation of the parameters for accurate alignment and to 
achieve a cut-off between significant peaks and noise. For complex samples it was useful to check the 
alignment of the extracted ion chromatograms manually and ensure that the peaks were not noise. The 
visual and user-friendly nature of MSX and Progenesis made this much easier than in XCMS. All the 
software packages were beta versions and were still undergoing development, particularly in the 
algorithms for chromatographic alignment and LCMS and MSMS linking capability. 
For accuracy and best alignment, XCMS combined with data from the high resolution FTICR 
provided the most accurate workflow for label-free quantitation. However, the long duty time of the 
FTICR made LC-MSMS impractical. Attempts were made to try to combine the LCMS spectra of the 
FTICR with the LC-MSMS of the HCT, but due to the difficult nature of this task, no acceptable 
alignment was obtained. In practice and with the state of development of the software at the time, the 
envisioned workflow combining high resolution quantitative FTICR LCMS data with low resolution 
MSMS protein identification was not successful. As a result of the extensive challenges experienced 
with chromatographic alignment, label-free quantitation using the ion intensity was abandoned and a 
spectral counting approach was used instead to compare the saliva samples from the clinical trials. 

















4 Kinase ActivitY Assay for Kinome Profiling 
4.1 Introduction 
A strategy for a multiplexed in vitro kinase activity assay was recently described by the Gygi 
laboratory150-151. This Chapter outlines subsequent development of the original kinase assay and its 
applications to a range of tissue types and organisms. The original Kinase ActivitY Assay for Kinome 
analysis (KAYAK) assay150 used 90 substrate peptides (K90) covering a set of core signalling 
pathways and sites identified from large scale phosphoproteomic studies176, 308-309. One disadvantage 
of the K90 set was peptide redundancy as many of the peptides were phosphorylated by the same 
kinase. Several hundred different peptides were synthesised, purified and evaluated, and from these a 
core set of 60 peptides (K60) was selected. The K60 comprises a subset of the original K90 peptides 
and also includes a number of new peptides that expand the range of pathways covered. The new K60 
set was evaluated in 12 different human cell lines and various tissue types. To determine the general 
applicability of KAYAK in organisms other than humans, KAYAK was performed in Drosophila, 
mouse, and yeast. As an extension of the salivary work presented earlier, KAYAK was performed on 
saliva to ascertain whether kinase activity could be observed in this body fluid.  The application of 
KAYAK to biomarker discovery in saliva will be further discussed in Chapter 5. 
As gene and protein expression are very different between tissues in the same organism, a 
comprehensive proteomic and phosphoproteomic study was performed to characterise protein 
expression in nine mouse tissues310. Large differences in protein expression and phosphorylation were 
observed between the different tissues. To complement this work, kinase activity profiling was 
performed on mouse tissue lysates and compared to the kinase abundance in the different tissues. 
Several kinases may be responsible for the phosphorylation of any one substrate peptide used in the 
KAYAK assay, depending on the sample. A standard biochemical technique to determine the ‘active 
component’ of a mixture is to separate that mixture chromatographically and to analyse each of the 
fractions for activity. Using a similar strategy it is possible to identify the kinase responsible for 
phosphorylation of a particular peptide. The lysate is fractionated by column chromatography and a 
profile of the kinase activities for each fraction is determined using KAYAK. The same fractions are 
also analysed by shotgun proteomics and a profile of protein abundance for each fraction is 
determined. Through correlating the kinase activity profiles with those of the kinase abundance, the 
responsible kinase can be determined. A kinase activity/kinase abundance correlation profiling 
experiment using the K60 substrate set was performed with HeLa nocodazole arrested cell lysate and 
the kinase activity profiles were correlated with the kinase abundance profiles. In addition to profiling 
the K60 kinase activities, selected peptides from a large scale phosphoproteomic study which were 
hyperphosphorylated during mitosis (G2/M) were investigated using kinase activity/kinase abundance 
profiling to determine putative kinases that could be responsible for their phosphorylation. 
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4.2 Experimental procedures 
4.2.1 Kinase activity assay for kinome profiling 
The general protocols for the multiplexed kinase activity assays are described in Experimental 
Procedures Section 2.7.3. Individual experimental conditions and deviations from the general 
KAYAK procedure are given below for each of the experiments discussed in this chapter. 
4.2.1.1 Kinase activity profiling on 12 human cell lysates 
KAYAK was performed in triplicate on 20 µg of lysate from 12 human cell lines. The classical 
eppendorf format KAYAK reaction was used. HeLa cells were grown and lysed as described in 
Section 2.7.2. Three other cell lysates (U-87 MG (glioma), HT-1080 (fibrosarcoma) and DU 145 
(prostate cancer)) were obtained from Dr. Kubota, a post doctoral fellow in the Gygi laboratory, and 
prepared in the same fashion. Other cell lysates were obtained from slightly different growing 
conditions: MCF7 (breast cancer) grown in DMEM media 10% FBS and 0.01mg/ml bovine insulin, 
T-47D (breast cancer) cells from RPMI-1640 medium with 10% FBS and 0.2 µg/ml bovine insulin. 
PC-3 (prostate cancer) cells were maintained in F-12K medium with 10% FBS. Jurkat (human T 
lymphocyte) cells were maintained in RPMI1640 medium with 10% FBS. SUM-159 (breast cancer) 
cells were maintained in Ham’s F-12 medium with 10% FBS, 5 µg/ml bovine insulin and 1 µg/ml 
hydrocortisone.  
4.2.1.2 Kinase activity profiling on HEK 293T cells with overexpression of kinases 
Kinase activity profiling was performed on lysates with overexpressed kinases to determine substrate 
specificity. Of the 22 kinases overexpressed using Gateway cloning (Section 2.6.2.2) only 11 were 
efficiently transfected: AKT1, MAPK14, MAPKAPK3, PAK2, PKN1, PLK1, PRKCB1, PRKCI, 
PRKCZ, PBK and CDC2. Kinase profiling using K60 substrates was performed in triplicate on 20 µg 
of each of the lysates with overexpressed kinases. 
4.2.1.3 Kinase activity profiling on various organisms 
Kinase activity profiling was performed on lysates from various organisms to determine whether 
KAYAK could be used in organisms other than humans, KAYAK was performed on 20 µg of human 
cell lysates (Section 2.7.2), yeast lysate, mouse tissue homogenates and Drosophila embryo lysates 
(Appendix I) . 
4.2.1.4 Kinase activity profiling on saliva 
Kinase activity profiling was performed on saliva to determine whether kinase activity was present in 
saliva and the variability between individuals. KAYAK was carried out on 10 µg of lysate from the 
saliva supernatant and residue from 6 human subjects. The 96 well format KAYAK reaction was used. 
4.2.1.5 Kinase activity profiling on 13 mouse tissues 
Kinase activity profiling was performed on 13 different mouse tissues to determine whether the 
similarities and differences in kinase profiles between the different tissues types. 21-day-old male 
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Swiss Webster mice were sacrificed by CO2 asphyxiation after overnight feeding.  Tissues from three 
male mice were harvested, rinsed with saline solution and flash frozen using liquid nitrogen until 
further use.  Frozen tissues from the three mice were combined, pulverised on dry ice, and 
homogenised in a Dounce homogeniser in the KAYAK buffer as described in Section 2.7.2. 
The kinase activity profiles in 13 different mouse tissues (brain, lung, testis, kidney, brown fat, liver, 
pancreas, white adipose tissue, spleen, heart, tibialis, small intestine and large intestine) were 
determined using 20 µg of lysate and the 96-well-plate KAYAK format. For nine of the mouse tissues 
(brain, lung, testis, kidney, brown fat, liver, pancreas, spleen and heart) the kinase activity profiles 
were compared with the kinase abundance profiles (Figure 4.1) that had previously been determined 











Figure 4.1   Workflow  for kinase activity  ‐ kinase abundance profiling using 9 mouse  tissues.  Individual  tissues 
from  3  mice  were  pooled  and  analysed  for  their  kinase  activities  using  KAYAK  and  their  protein/kinase 
abundance  using  shotgun  proteomics.  Pearson  correlation was  used  to  compare  the  kinase  activity/kinase 
abundance profiles.  
 
4.2.2 Correlation profiling using kinase activity/kinase abundance 
While the previous experiments measured kinase activities, Kinase activity/kinase abundance 
correlation profiling was also performed to determine which kinases were responsible for the 
phosphorylation of particular peptides. Protein separation using anion exchange chromatography was 
performed as described in Section 2.7.6. Kinase activity profiling was performed using the K60 
substrate set and selected peptides from a large scale cell-cycle quantitative phosphorylation study176. 




























asynchronous cell lysate (2.6.1). Only six of the peptides showed significant activity and were 
differentially active between the two cellular states (shown in blue in Table 4.1). To try to identify the 
kinases that are responsible for their hyper-phosphorylation during mitosis, these six peptides and two 
controls were utilised in the KAYAK assay. The two positive controls (B11 and C2) were chosen 
because of their high rate of phosphorylation in the nocodazole arrested state. The group of six 
































4.3 Results and discussion 
4.3.1 Optimisation of a mass spectrometry based kinase assay for kinome 
profiling 
Phosphorylation of a substrate by a kinase is highly dependent on the local amino acid sequence 
flanking the phospho-acceptor site, known as the ‘phospho motif’. For example, AKT is known to 
phosphorylate peptides containing the motif: RXRXX[pS/pT]311. Various factors are also important, 
including the activity state of the kinase, substrate availability and configuration312. With the use of 
peptide library approaches, the preferred motifs for many kinases have been identified in literature 
studies.  
Designing a substrate peptide that is specific for a single kinase is a challenging task. The K90 set was 
developed by the Gygi laboratory to include substrates for kinases in various signalling pathways, as 
well as peptides that had been identified from large scale phosphoproteomic studies for which the 
kinase was not known. In the K90 set, there is a large amount of redundancy of the peptides. To 
reduce the redundancy and increase the number of pathways covered, many peptides with diverse 
sequences were synthesised, purified, and analysed with various cell lysates to identify peptides which 
show high phosphorylation rates with high specificity. From a library of approximately 300 peptides, 
60 were selected, 28 of which were from the previous K90 selection. To assess these 60 peptides, the 
basal kinase activity in 12 different human cell lines was profiled with K60 using a substrate 
concentration of 5 µM and 1 µM. Kinase activity in a human cell line (HEK 293 T) in which certain 
kinases were overexpressed was also performed. 
4.3.1.1 Kinase profiling of 12 human cell lines 
Kinase profiling of the basal activities in the different cell lines can elucidate the activation state of 
signalling pathways and even identify hyperactivated kinases. KAYAK using the K60 substrate set 
was performed to detect signature kinase profiles for the 12 human cell lines, (Figure 4.2). 
Hierarchical cluster analysis was performed on both the peptide substrates and the cell lines to group 































lines  comprise:  MCF7  (breast),  U‐87  MG  (glioblastoma),  PC‐3  (prostate),  DU  145  (prostate),  U‐2  OS 
(osteosarcoma),   HEK‐293, T‐47D (breast), BJ (foreskin fibroblast), HeLa (cervical), SUM‐159 (breast),   HT‐1080 
(fibrosarcoma),  Jurkat  (T  lymphocyte).  (a)  Heat  map  of  kinase  activities  using  5  µM  peptide  substrate 
concentration where  the  activity was normalised  to  the median  value  in  each  row,  followed by hierarchical 
cluster analysis. b) Examples of  individual peptide profiles  from  (a). Kinase activity values are  the mean value 













































































































































































































The two prostate cancer cell lines (PC-3 and DU 145) cluster together and show decreased MAPK 
substrate peptide (MM*) activities. Whilst the three breast cancer cell lines (MCF7, T-47D and SUM-
159) do not cluster together and appear to have different profiles, the PKC activity (CC peptides) 
appears downregulated in all three samples. Interestingly, peptides designed for similar kinase targets 
are also observed to cluster together. For example, the PKC peptides are largely grouped and KK1 and 
KK2, which are known targets of AKT, are also clustered together. There is a further cluster of proline 
directed (PP) and MAPK (MM) substrates which have high phosphorylation in HeLa, SUM-159 and 
Jurkat lysates. Jurkat cells show significantly higher phosphorylation than the other cell types for at 
least half of the peptides, particularly the tyrosine kinases (WW, XX, YY, ZZ peptides) and the PKCs. 
MCF7 cells showed higher phosphorylation for PKA substrate peptides (AA peptides) and many basic 
peptides (BB). U-87 MG displays extremely high AKT activity (KK1 and KK2). This is consistent 
with the fact that the U-87MG cell line has a PTEN mutation, resulting in upregulation of PI3K and 
subsequent AKT activation. The same pathways that were shown to be upregulated in the K90 
substrate set are also observed in the K60 substrate set, illustrating that the K60 set behaves similarly 
to the K90 and no major loss of pathway coverage is observed. 
The K60 substrate set also covers more pathways than the K90 substrate set as it includes peptides 
that are substrates of checkpoint kinases. Two such substrate peptides which are included in K60 but 
not K90 are the peptide CH1, which is a substrate of CHEK1, and CH2, a putative substrate of 
CHEK2. Both of these peptides demonstrate high activity in BJ sells. BJ foreskin fibroblasts display 
high antioxidant capacity and slow telomere shortening313. BJ cells and HEK293 cells are the only 
non-cancer cell lines included in the study. It is possible that the BJ cells minimise the accumulation 
of genomic damage by a hyperactivated DNA damage response. It is known that stress induced 
senescence and telomere-dependent replicative senescence processes result in the activation of the 
DNA damage response kinases (ATM, ATR) and the downstream effector kinases CHEK1 and 
CHEK2314-316. The kinase activities of the checkpoint kinases are fairly low in the cancer cell lines, 
indicating that the DNA damage repair pathway might be suppressed. It would be interesting to 
compare the kinase activity of the checkpoint kinases in other human fibroblast cell lines to determine 
whether high CHEK1 and CHEK2 activity is also observed. Other kinases included in the K60 set and 
not in the K90 include GSK3 and FAK. The peptides GG1 and GG2, proposed GSK3 substrates, 
appear to be fairly uniformly phosphorylated across the 12 cell lines except with lower 
phosphorylation observed in U-87 MG and BJ cells. WW3 is thought to be a substrate of FAK and is 
highly phosphorylated in Jurkat and MCF7 cells. These examples demonstrate the broader coverage 
the K60 set provides and its potential implications for understanding of intracellular protein activity 
dynamics. 
KAYAK assays were performed with three replicates. Very little variation is seen between the 
different replicates as can be observed by the small standard deviations (shown as the error bars in 
Figure 4.2b) and the clustering of each of the three replicates (Figure 4.2c).  This suggests that the 
KAYAK technique is highly reproducible and generates very robust results. 
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While profiling was performed at 5 µM for the K90 substrate set150, lower substrate peptide 
concentrations may have been feasible. Therefore, upon conducting profiling experiments utilising the 
K60 set, concentrations of both 5 µM and 1 µM were tested. The kinase activity profiles at the two 
concentrations were very similar (Figure 4.3). However, when comparing the columns for each cell 
line at 5 µM and 1 µM, a few differences can be observed. For example, for BJ at 5 µM peptides BB2, 
BB1, AA10 and AA9 all show significant phosphorylation, but at the 1 µM concentration the 
phosphorylation of AA10 becomes much more significant. Also, at 1 µM the lower GSK3 activity 
(GG1 and GG2) is much more significant than at the 5 µM concentration. In the PC-3 cell line, WW3 
has significant phosphorylation which was not observed at the 5 µM concentration. The cluster of 
PKA/basophilic kinase activity (AA2 to BB8) appears very similar, with the activity in the MCF7 cell 
line dominating the others. However, with the lower substrate concentration, more differences were 
observed between the different peptide profiles. It might have been expected that at the lower 
substrate concentration (1 µM) the activity of many of the peptides could be below detection levels, 
but this was not the case, and suggests that a lower concentration could be used routinely. Lowering 
the substrate concentration would be expected to lead to increased substrate specificity and reduced 
kinase promiscuity, and there is some evidence of this for a few peptides where the profile changes 
between the two concentrations, but in general the profiles were very similar. 
All the kinase activities detected by the K60 substrate set were still detectable at 1 µM and the general 
similarity of the protein profiles at both concentrations indicates that the next generation KAYAK 
assay could be based on a lower substrate concentration of 1 µM. Advantages of using lower substrate 
concentrations include the reduced peptide consumption (lower cost) leading to significant time 
saving in peptide purification, reduced sample clean-up procedures prior to mass spectrometric 
analysis as well as the potential to expand the number of peptides included to perhaps 500.  
It is important to consider that although protease inhibitors are present in the cell lysate, degradation 
or modification of the kinase substrate peptides or the phosphorylated form may occur by proteases or 
other enzymes that are not inhibited. This may result in an underestimation of the degree of 
phosphorylation observed. The extent of possible degradation and modification of the substrate 
peptide will be investigated in future work. 
In the future, kinase activity profiles may be useful in the investigation of drug effects (e.g. kinase 
inhibitors) in different cell types. There is much less redundancy in the K60 substrate set than in the 
previous K90. Whilst some redundancy can still be observed (for example with peptides CC8 and 
CC3, XX1 and XX2), the peptides may react differently under different circumstances and a core 
number of peptides against certain kinases is needed. For example different CC peptides have 
preference for the different PKC isoforms. To test a substrate set thoroughly it is necessary to profile a 



































4.3.1.2 Kinase profiling of a human cell line with overexpressed kinases 
One possible method for associating peptide substrates and the kinases responsible for their 
phosphorylation is the use of recombinant kinases. Disadvantages of such an approach include kinase 
promiscuity and the fact that kinases may not be in an active configuration (may need cofactors, 
binding partners). Using a kinase overexpressed in a cell lysate avoids many of these problems and 
may give a more accurate representation of phosphorylation activities in vivo as protein-protein 
interactions are maintained. Purified kinases lack cellular context and results obtained in this way may 
be misleading. 
These initial studies involving the overexpression of 11 kinases (Figure 4.4a and b) are part of a larger 
project goal to overexpress and knock down a large library of kinases. This project aims to help 
elucidate the kinase substrate specificities, as well as investigate the effect on kinase activity by 
perturbing kinase signalling pathways.  
Notably, overexpression of particular kinases in the HEK 293 T-cell line lead to greater 
phosphorylation of expected substrates in the majority of cases. AKT1 overexpression lead to 
increased phosphorylation of KK1 and KK2 (known AKT substrates) by over 5 fold (Figure 4.4c and 
d). Overexpression of PRKCB1 (PKC beta) leads to overexpression of a cluster of PKC target 
peptides (CC8, CC1, CC3, CC9). Interestingly, overexpression of PRKCZ (PKC zeta) only displays 
significant phosphorylation of CC9 and not the other PKC peptides, indicating that the peptides are 
specific to different PKC isoforms. MAPK14 leads to increased phosphorylation of many proline 
directed and MAPK target peptides (MM1, PP3, PP7, PP6, MM2, PP9) as would be expected. PAK2, 
TOPK and the control have very similar profiles, indicating either that these kinases were not active or 
there are no peptides in the K60 which are able to report on their activity. This proof-of-concept work 













































4.3.2 Applications of mass spectrometry based kinase assay for kinome 
profiling 
This section presents the results obtained from kinase activity profiling performed on a range of 
samples. Activity profiles were obtained for several organisms (human cell culture, mouse, 
Drosophila, yeast), human saliva and 13 mouse tissues.  
4.3.2.1 Kinase activity profiles in different organisms and tissue types 
To determine whether kinase profiling using KAYAK would be useful in organisms apart from 
humans, the method was assessed on lysates from yeast (Appendix K) as well as homogenates from 
different mouse tissues (Appendix J) and Drosophila embryos (Appendix I). Although the peptide 
substrates had been designed for human kinases, significant kinase activity was detected in the various 
organisms against many of the peptides in the K60 substrate set (Figure 4.5). Furthermore, for various 
peptides, activity was greater in organism extracts than some human cell lysates. The results from the 
samples cluster together based on the organism from which they are derived. There are two very 
distinct branches: one for mouse and human and the other for Drosophila and yeast. This is expected 
because human and mouse are more closely related to each other than to Drosophila and yeast.  
PKC substrate peptides were highly phosphorylated by mouse liver extract and many proline directed 
substrate peptides were significantly phosphorylated by yeast extract. Proline directed kinases are 
involved in cell cycle control, and for this reason it might be expected that they are conserved from 
yeast to humans since cell cycle control is such a fundamental process.  Drosophila embryo extracts 
displayed significant phosphorylation of a range of substrates, but very few tyrosine substrate peptides 
were phosphorylated. Whilst some tyrosine phosphorylation was observed in mouse, the majority of 
the tyrosine kinase substrates were most highly phosphorylated in human HEK cells. This type of 
comparison could indicate which kinase motifs are conserved through evolution. Phosphorylation of 
peptide substrates for PKAs, PKCs and MAPKs are observed for the four organisms. However, 
significant phosphorylation of the tyrosine kinase substrates was only observed in humans and to a 
lesser extent in mouse.  
Due to the many gains and losses of kinase groups during evolution, the distribution of kinase families 
is very different across the major phyla. The emergence of the metazoa from opisthokonts resulted in 
76 new classes of kinases including, most importantly, the tyrosine kinase group317. Yeast, a fungus 
and earlier branch on the opisthokont line, does not have any conventional tyrosine kinases, 
explaining the complete absence of the phosphorylation of any tyrosine kinase substrates in yeast 
(Appendix K). 
The presence of kinase activities in the different organisms confirms that KAYAK can be used 
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4.3.2.2 Kinase activity profiles in saliva 
Kinase activity profiling using the K60 substrate set was performed on the saliva supernatant and 
saliva residue from 6 subjects (Figure 4.6a), and significant kinase activity was observed in both the 
saliva supernatant and residue. 
Saliva supernatant shows significant phosphorylation of peptides AA1, AA9, AA10, very similar to 
the activities observed for the saliva residue, indicating high PKA activity. Significant 
phosphorylation of RR1 and RR2, which are known RSK substrates, as well as for GG, a substrate for 
GSK3, and AM1 a substrate from AMPK was observed. High activity in the residue was also 
observed for PKC substrate peptides CC1, CC8, CC3, CC9, and CC2, with slightly lower levels 
observed in the supernatant. Significant basophilic kinase activity was also present in the residue with 
BB2, BB1, BB9, BB3, and BB4 being highly phosphorylated. MAPK activity was detected in the 
residue but very little was observed in the supernatant. In general, very low tyrosine activities were 
observed in both the residue and the supernatant. Whilst greater kinase activity was observed on 
average in the residue compared to the supernatant, there were several peptides that had similar or 
even sometimes greater activities in the residue. 
Large inter-subject variation in kinase activities was clearly seen in Figure 4.6b. One may expect that 
if, for each subject, supernatant and residue kinase activity profiles are similar, this result may be an 
artefact of dead epithelial cells. However, the kinase profiles of the lysed cells may be different due to 
protein/kinase degradation or due to the different signalling pathways involved in apoptosis and 
necrosis. In general, for the same amount of total protein measured in each (10 µg), greater KAYAK 
activity was observed in the saliva residue when compared to the supernatant. 
To try to determine the source of the kinase activity in saliva, the kinase activities obtained in the 
saliva supernatant were compared with those in the residue. The bulk of the kinase activity in the 
supernatant was expected to originate from lysed cells. To determine whether glandular secretions 
contribute to kinase activity KAYAK will be performed on gingival crevicular fluid and pure 
glandular secretions in the future. 
The role of the observed kinase activity in saliva has not been studied previously, and could be of 
potential biological interest. ATP (source of phosphate for kinase reactions) is known to be present in 
saliva at concentrations ranging from 8 to 1515 nM, and has been shown to be directly correlated with 
the bacterial count and epithelial cell numbers318. Of the total ATP concentration in whole saliva, it 
was shown that approximately 14% of the ATP was in the soluble fraction and not in the human 
cellular or bacterial residual portion318. The source of this ATP in the soluble saliva fraction is not 
known, but is likely to be the release of ATP from dead mouth epithelial cells and bacteria. It is not 












































































































4.3.2.3 Kinase activity profiling in 13 mouse tissues 
Whilst generalised cell signalling models and phosphorylation networks have been determined, these 
have been generated using model systems, but the signalling pathways and networks are likely to be 
different in various tissues and diseased states. Global characterisation of kinase activities in different 
tissues can ultimately aid in generating a picture of which pathways may be significant in particular 
tissue types. Kinase activity profiling was performed on 13 different tissues from a mouse: brain, lung, 
testis, kidney, brown fat, liver, pancreas, white adipose tissue, spleen, heart, tibialis (muscle), small 
intestine and large intestine (Figure 4.7).  
The kinase profiles of the small and large intestines cluster together and are very different from the 
profiles of the other mouse tissues. For the small and large intestine extracts, several basophilic kinase 
substrates are highly phosphorylated (BB1, BB2, BB3 and BB9) as well as several PKC substrate 
peptides (CC1, CC2 and CC4) and CHEK kinase substrates (CH1, CH2). However, the activity of the 
tyrosine kinases are much lower than those in the other tissues. It is possible that natural bacterial flora 
present in the small and large intestine could be contributing to the kinase activity profile and could 
explain the very different kinase activity profiles observed in the intestinal tissues. Much less is 
known about bacterial kinases compared to those in eukaryotes, and whilst most prokaryotic 
signalling and protein phosphorylation is proposed to occur through histidine-aspartate kinases, there 
are various eukaryotic Protein Kinase-Like kinases (PKLs) known to be present in bacteria319. Whilst 
there are known to be tyrosine specific kinases present in bacteria, it might be expected that their 
motifs are less well conserved than for serine/threonine specific kinases since in eukaryotic evolution 
the tyrosine kinase class was only added with the emergence of metazoans317. Therefore, very little 
tyrosine phosphorylation by bacteria of the human tyrosine kinase substrates would be expected. 
Another reason why the kinase activity profiles for the small and large intestine are so different from 
the other tissues could be on account of degradation or modification of the kinase substrate peptides 
(or phosphorylated product peptides) through the large number of proteases present in the small and 
large intestines. Although protease inhibitors are added to reduce proteases, the wide variety of 
proteases inevitably leads to some still remaining active. The small and large intestines are have a 
much larger proportion of proteases compared to the other tissues and this could explain and the lower 
kinase activities observed. 
The results for the heart and the tibialis extracts cluster together, as would be expected for these two 
muscle tissues. PKA activity is high in both these tissues. This is consistent with mRNA profiling data 
where PKA abundance (PRKACA) is high in heart and muscle320. PKA is involved in the regulation 
of glycogen metabolism and occurs predominately in muscle tissue. With regard to the other profiled 
tissues, the greatest kinase activity is observed in the brain, including the phosphorylation of many 
tyrosine kinase substrates, followed by the lung, testis and spleen.  
A comprehensive protein quantitation and phosphorylation study was performed using nine different 
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mouse tissue samples by post doctoral fellows in the Gygi laboratory310. Kinase activity profiling was 
performed using the same tissue samples that were used for protein quantitation (and four extra tissue 
types). This was done to complement the phosphomouse catalogue and determine whether changes in 
the kinase activity as assessed by KAYAK could be correlated with the abundance of kinases in the 
different tissues. 
However, increased kinase abundance does not necessarily equate to increased kinase activity as the 
kinase may not be in its active state. The activation of many kinases involves the phosphorylation of 
specific activation loop residues which induces a conformational change. Taking this factor into 
consideration, post doctoral fellows in the Gygi laboratory mapped the spectral count of the activation 
loop phosphorylation sites on kinases as an indirect measure of kinase activity310. 
The kinase activity profiles of the nine mouse tissues, obtained using KAYAK (Figure 4.8a), were 
compared to the kinase spectral count abundance profiles (Figure 4.8b) and the spectral count of the 
kinase activation loop phosphorylation sites (Figure 4.8c). The kinase abundance profile is dominated 
predominately by the brain, with high kinase abundance also present in the lung, spleen and testis. For 
the kinase activity profiles, the brain also has the highest kinase activities. Since neural tissue, the 
primary constituent of the brain, contains a wide variety of different cell types and complicated 
signalling networks between the different cell types, high kinase activity would be expected and is 
consistent with the finding that the brain contains the greatest number of phosphopeptides310. 
The kinase activity profiles and the kinase abundance profiles were compared using Pearson 
correlation (Figure 4.9). Many of the PKC substrate peptides cluster together (CC1, CC3, CC4 and 
CC9) and have good correlation coefficients with PRKCD abundance (Figure 4.9b). RR1 and RR2 
(RSK substrate peptides) have high correlation coefficients with RSK abundance, RPS6KA1 (Figure 
Figure 4.9c). Looking at specific kinase-substrate pairs, the correlation coefficient between AKT1 and 
KK1 is 0.71 with the lung displaying highest AKT1 abundance and greatest KK1 phosphorylation 
(Figure 4.10). Other examples include CDK5 and PP5 with a correlation coefficient of 0.93, with the 
abundance and activitiy most prominent in the brain. The abundance of casein kinase and 
phosphorylation of DD9, a substrate of casein kinase are highly correlated (Pearson correlation 
coefficient 0.98) with the maximum activity observed in the testes followed by the brain and then the 
spleen.   
The kinase activity profiles were also compared with the spectral count of the phosphorylation sites on 
kinase activation loops (Appendix L). In general, the correlation was poorer than using the kinase 
abundance spectral count. This is likely to be on account of the use of different samples for the 
phosophoprotein identification and for the kinase activity assay. Whilst the same type of mouse was 
used for both, replicates from the same extracts were used for kinase activity and kinase abundance, 





















tissues  from  the  brain,  lung,  testes,  kidney,  brown  fat,  liver,  pancreas, white  adipose  tissue,  spleen,  heart, 
tibialis, small  intestine and  large  intestine. Analysis by Pearson correlation hierarchical clustering was used  to 
group  similar  responders  together.  Each  row  represents  the  phosphorylation  rate  of  a  particular  peptide 
normalised  to  the median  of  kinase  activities  for  each  tissue.  A maximum  fold  cut  off  of  3 was  used.  (b) 











































































Figure  4.8    Profiling  experiment with  9 mouse  tissues.  (a)  Kinase  activity  profiles  of  9 mouse  tissues:  brain, 
brown  fat,  heart,  kidney,  liver,  lung,  pancreas,  spleen  and  testes  using  KAYAK.  The  kinase  activities  are 
normalised  to  the  sum  of  all  the  kinase  activities  for  a  specific  peptide  across  the  9  tissues  and  similar 
responding peptide substrates are clustered together by hierarchical clustering.   (b) Kinase abundance profile in 
9  tissues  obtained  using  shotgun  proteomics with  spectral  count  as  a measure  of  protein  abundance.  The 
abundance of the kinase  is normalised to the sum of spectral counts for a specific protein across the 9 tissues 
and  similar  kinase  abundance  profiles  are  clustered  together  by  hierarchical  clustering.          (c)  Profiles  of 
phosphorylation site spectral counts on the kinase activation loop across 9 mouse tissues. The abundance of the 


















































































Figure  4.9    Correlation  profiling  for  kinase  activity‐kinase  spectral  count.  Heat map  of  Pearson  correlation 
coefficients between the Kinase activity profile (KAYAK) and kinase abundance profile (spectral count) for the 9 



























Figure 4.10   Correlation profile bar  charts of  several  kinase‐substrate pairs.  The  kinase  acitivity  and  spectral 
count are each normalised to the maximum value observed across all tissues. The normalised spectral count and 




4.3.3 Correlation of kinase activity with kinase abundance to identify kinase-
substrate pairs 
Arguably the most important issue in phosphorylation studies is to determine kinase-substrate 
relationships. Kinase activity correlation profiling is a technique that can be used to identify the kinase 
responsible for a particular phosphorylation event and involves the fractionation of a lysate at the 
protein level. After the fractionation, each of the fractions is analysed for activity and an activity 
profile for a particular substrate peptide is obtained. This activity profile is compared with the kinase 
abundance profiles (obtained using shotgun proteomics) using Pearson correlation to obtain candidate 
kinases that could be responsible for the phosphorylation of the substrate peptide. Correlation 
profiling using kinase activity/kinase abundance, developed by Dr. Kubota in the Gygi laboratory, has 
previously been shown to be successful using anion exchange chromatographic separation, however, 
this technique may be applied to many other separation techniques. The use of gels as a means of 
chromatographic separation has many advantages on account of their ease of use and the feasibility of 
using a blue native gel separation in conjunction with an in-gel kinase activity/kinase abundance 
correlation profiling was tested. In-gel kinase activity/kinase abundance correlation profiling was 
previously described in Section 2.7.7. This was the first time that KAYAK had been performed in-gel 
and the proof of concept demonstrated significant kinase activity was observed in the gel. Whilst 
KAYAK in-gel correlation profiling was successful to a degree, and the principle works, the 
procedure suffers from the low resolution on the BN PAGE and is more suited to the analysis of 
simple samples. For more reliable kinase-substrate identification with complex samples, protein 
separation using anion exchange chromatography (AEX) is the preferred technique. 
Kinase activity/kinase abundance correlation profiling using AEX was performed on HeLa cell 
nocodazole arrested cell lysate to identify kinase-substrate pairs. HeLa cell nocodazole arrested cell 
lysate was subdivided into 40 fractions using anion exchange chromatography. Each fraction was 
analysed by KAYAK using K60 substrate peptides to generate kinase activity profiles as well as by 
LC-MSMS shotgun proteomics to identify and quantitate the proteins and kinases present in the 
lysate. In total 5,626 proteins, including 172 kinases, were identified by shotgun proteomics. 
Hierarchical clustering was used to group peptide substrates with similar activity profiles together 
across the various fractions (Figure 4.11a). The majority of kinase activities for the different peptide 
substrates peaked between fractions 8 and 30, with low activity being observed in the early and late 
fractions. Similarly, the majority of the kinase abundance profiles had their maximum between 
fractions 8 and 30 (Figure 4.11b). 
The kinase activity-protein abundance profiles were compared using Pearson correlation (Figure 
4.12). Hierarchical clustering of the Pearson correlation coefficients indicates which peptide substrates 
may be phosphorylated by similar kinases or by kinases that are present in the same protein complex. 
Many of the substrate peptides for MAPK and proline directed kinases are clustered together (PP4, 
MM3, PP6, PP7, PP5, PP1, MM1, MM2, PP9, PP10, PP3). A cluster of PKC substrate peptides are 
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also present (CC1, CC3, CC8) as well as a large cluster of substrates for PKA and basophilic kinases 
(BB2, AA2, AA1, BB3, BB8, BB9, BB1, AA10, AA9). Various clusters of tyrosine kinases are also 
observed (XX2, XX1, WW3 and YY2, YY9, WW1, WW9, WW8). Focusing on likely kinase-
substrate pairs, the Pearson correlation coefficient between KK2 and AKT2 was 0.88 whilst acidic 
substrate DD9 showed very good correlation with casein kinase 2 (CSNK2A2) with a Pearson 
correlation coefficient of 0.97(Figure 4.13). 
In general, broader profiles, spanning more fractions, are often observed for the kinase activity 
profiles compared to the protein abundance profile. This is likely to be on account of the greater 
sensitivity of the kinase activity compared to the spectral counting method used for quantitation of the 
protein abundance. This unfortunately reduces the accuracy of the correlation for proteins with low 
spectral counts. For example, the kinase CDK7 shows good correlation with the peptide substrate PP9 
in fractions 14-19 (Figure 4.13). However, in the neighbouring fractions, whilst kinase activity is still 
detected (fractions 11-14 and 19 to 32), very bad correlation is observed with the kinase spectral count 





















lysate  AEX  fractions.  Kinase  activities  determined  by  K60  substrate  set  on  each  AEX  fraction  for  (a).  Kinase 
abundance determined by shotgun proteomics and LC‐MSMS analysis for (b). List of proteins labelled 1‐175 (b) 
is  detailed  in Appendix M. Analysis  by  Pearson  correlation  hierarchical  clustering was  used  to  group  similar 

















































































































































































































































































































































































4.3.4 Correlation profiling to identify kinases responsible for the 
phosphorylation of proteins during mitosis 
In the previous analysis it was shown that AEX KAYAK correlation profiling was able to identify 
known kinase-substrate pairs. The following analysis describes the application of KAYAK correlation 
profiling to determine the identity of the kinases responsible for the phosphorylation of substrates 
where the responsible kinase is not known. 
It is of interest to characterise the cellular machinery which can lead to genomic instabilities as a way 
to better understand malignant disease mechanisms. The genes involved are not only of prognostic 
value, but also serve as cancer therapeutic targets. Many cancers involve altered regulation of the cell 
cycle and therefore greater understanding of cell cycle regulation and progression is of great value.  
4.3.4.1 Kinase activity assay on peptides from mitotic phosphorylation study 
From a study of mitotic phosphorylation by Dr. Noah Dephoure in the Gygi laboratory176, 10 peptides 
with interesting motifs and mitotic phosphorylation activity were selected (Table 4.1). It should be 
noted that the cognate kinase for each selected peptide was unknown. To determine whether 
differences in phosphorylation of these peptides occur, KAYAK was performed on asynchronous 
(AS) and nocodazole arrested (G2/M) HeLa cell lysate using the selected 10 peptides at 5 µM 
substrate concentration. Significant differences in kinase activities were detected between AS and 
G2/M HeLa lysate against 3 peptides: 5B6, 5B7 and 5B8. Very little kinase activity was detected for 
the other 7 peptides. The assay was repeated using a higher concentration (50 µM) of the seven 
peptides and resulted in significant differences in activity being detected between G2/M versus AS for 









































4.3.4.2 Kinase activity-abundance correlation profiling on mitotic peptides 
To identify the kinases responsible for the mitotic peptides of interest (5B6, 5B7, 5B8, 5B4, 5B10 and 
5B11), a kinase activity assay correlation profiling experiment was performed. Separation was 
performed using AEX, and HeLa cell nocodazole arrested lysate was divided into 40 fractions, each 
then being analysed using KAYAK (to determine the kinase activity) and shotgun proteomics (to 
determine the kinases present in that fraction). By correlating the kinase activity with the kinase 
abundance profile, putative kinases responsible for the phosphorylation of each particular peptide 
were obtained.  
For each of the 40 fractions, KAYAK was performed using a K8 substrate set which comprised the six 
mitotic peptides which were differentially phosphorylated in asynchronous versus nocodazole arrested 
HeLa cells (Table 4.1) and two peptide controls (B11 and C2) whose extent of phosphorylation is 
known to increase at G2/M . The mitotic peptides 5B6, 5B7 and 5B8 were at 5 µM whilst 5B4, 5B10 
and 5B11 were at 50 µM substrate concentration, and the K8 kinase activities were measured across 
the 40 fractions to obtain kinase activity profiles (Figure 4.15). Of the K8 peptides: 5B6, 5B7 and 5B8 
had similar normalised profiles (labelled peak 3 in Figure 4.15), 5B4, 5B10, B11 and C2 (labelled 
peak 2 in Figure 4.15) also had similar normalised profiles, whilst 5B11 overlapped slightly with peak 
2 but was slightly offset (labelled peak 1 in Figure 4.15). This suggests that a single kinase might be 
responsible for the phosphorylation of 5B6, 5B7 and 5B8 (peak 3), another kinase for peak 2 (5B4, 




















Shotgun sequencing by LC-MS/MS of each of the 40 fractions resulted in the identification of 7150 
proteins (peptide FDR 0.41%, protein FDR 10.2%). Spectral counting of proteins annotated with gene 
symbols resulted in the quantification of 5626, 177 of which were kinases. To correlate the protein 
profile with the kinase activity, the Pearson correlation coefficient was calculated for each protein for 
each kinase activity profile. For the peptides 5B6, 5B7 and 5B8, the Pearson correlation coefficients 
of the top four proteins ranged from 0.75-0.90 and included the proteins PBK, SCYL1, MAPK14 and 














Figure 4.16   Correlation profiles of kinase activity  for 5B6, 5B7 and 5B8 and  top 4 protein kinase profile hits. 








  5B6 5B7 5B8 
PBK  0.90 0.87 0.81 
SCYL1 0.85 0.84 0.80 
MAPK14 0.80 0.79 0.78 






The top ranked putative kinase for peptide 5B11 was PAK3 with a Pearson correlation coefficient of 
0.97 (Figure 4.17). The coefficients for the next top possible hits (PAK2, PRKACA, EIF2AK2, 
PRKCD and TP53RK) were much lower. PAK3 was the first ranked kinase for 5B11 and was the 
third ranked protein out of the 5626 proteins. For peak 2 (Figure 4.15), which comprises the peptides 
5B4 and 5B10 as well as the two peptides which were added as standards (B11 and C2), the top hit 









One potential source of error with the current correlation-based approach is that the quantitation using 
spectral counting may have some level of inaccuracy, especially for low abundance kinases with only 
one or two spectral counts. Improved protein profiles might be obtained by using raw ion currents 
(label-free), aqua peptides to quantitate each of the kinases, or stable isotope labelling of consecutive 
fractions. Another approach to remedy this situation would be an enrichment of kinases using 
kinobeads321 or Proteominer beads (Biorad) to be able to identify more kinases. Alternatively, a two 
dimensional approach could be used whereby the proteins are fractioned twice, for example the first 
dimension on a gel filtration column and the second dimension using AEX. All these approaches will 
be investigated in the future. Regardless of the possible inaccuracies in the quantification of the 
substrate pairs, interesting biological insights have been obtained.  
To improve the accuracy of the protein profiles (kinase abundance) and to determine how variable the 
spectral counting profiles were, fractions 10-20 were shot on the mass spectrometer 3 times. Although 
there were some differences in the ranking order and correlation coefficients, illustrating the 
variability in the spectral counting protein quantitation, the top ranked proteins were similar to those 
found previously.   
Since there were several high ranking kinases for the putative kinase-substrate pairs, it was necessary 





4.3.4.3 Validation experiments - Kinase assays using recombinant kinases 
The standard peptides B11 and C2 are known to be phosphorylated by Cdc2/cyclin B150. Since the 
KAYAK profiles of 5B4 and 5B10 co-elute with the B11 and C2, 5B4 and 5B10 may also be 
phosphorylated by Cdc2/cyclin B. To validate this hypothesis, KAYAK was performed on the K8 
peptides using purified Cdc2/cyclin B kinase (Table 4.2). The standard peptides B11 and C2 were 
significantly phosphorylated. However, the remaining peptides, including 5B4 and 5B10, fell below 
























Subsequent investigation involved the elucidation of the responsible kinase activity and validation of 
the results from the correlation profiling experiments. For each putative kinase that was commercially 
available, KAYAK was performed on the K8 substrate mix (Figure 4.19). Phosphorylation of 5B11 by 
purified PAK3 was clear, validating the results from the correlation profiling experiment. Apart from 
the standard peptides (C2 and B11) which were phosphorylated by CDC2/cyclinB, none of the other 
purified kinases phosphorylated the peptides of interest. There are several possible explanations for 
this result. Firstly, the purified kinase may not be active, a common problem with commercial kinases. 
Secondly, kinase activity may require the presence of a cofactor, or only be active when it is present in 






















To address the first point (active kinase): PLK1 and PBK were obtained from various manufacturers 
(CST, Millipore, SignalChem) and no significant phosphorylation of the peptides of interest (5B6, 
5B7, 5B8) was observed using any of these kinases. To address the second point (presence of 
cofactors), KAYAK assays were performed on the purified kinases in the presence and absence of cell 
lysate. The presence of cell lysate did not appear to increase the activity of the kinases PLK1 and PBK 
for the peptides 5B6, 5B7 or 5B8. However, there was evidence that EIF2AK2 in the presence of 
nocodazole arrested lysate led to some increased phosphorylation of 5B4 and 5B10 compared to 
EIF2AK2 or lysate alone. This may indicate that a cofactor needs to be present for EIF2AK2 to be 
active, and that EIF2AK2 could be the responsible kinase for the phosphorylation of 5B4 and 5B10. 
This is discussed in further detail in Appendix N. Finally, to address both issues simultaneously (to 
ensure that the kinase was active and that its binding partners were present) the kinases were 
overexpressed (using Gateway cloning) and knocked down (using siRNA) in human cells.  
4.3.4.4 Validation experiments - kinase assays using overexpressed kinases 
To overcome the problems associated with using purified commercial kinases, and to ensure the 
kinases were active and present with the relevant cofactors and binding partners, various kinases were 
overexpressed. Overexpression was performed in HEK 293 T cells using Gateway cloning. KAYAK 
was performed on each of the overexpressed kinase lysates for both K9 and K60 substrates. The 
kinase activities for 5B6, 5B7, 5B8 were significantly upregulated by 2- to 3-fold in the lysate with 
overexpressed PLK1 (Figure 4.20a and b).  Along with PLK1, TOPK and MAPK14 were the the other 
two top putative kinases. However, upregulation of kinase actvity was not detected for either 
overexpressed TOPK (PBK) or MAPK14. Whilst the overexpression of PLK1 leads to increased 
phosphorylation of the the substrates 5B6, 5B7 and 5B8, it does not confirm whether PLK1 is a direct 
or indirect agent of phosphorylation. Overexpression of PLK1 may be responsible for the activation of 
another kinase which is then responsible for the increased phosphorylation of 5B6, 5B7 and 5B8. 
Unfortunately, constructs for all the kinases of interest were not available or their transfection was not 
successful, and siRNA knockdown of several kinases was investigated including TP53RK, CDC2, 
PAK3, MAPK14 and TOPK (PBK). Unfortunately, siRNA PLK1 is lethal to the cell and therefore 
this kinase cannot be knocked down. An alternative would be to immunodeplete PLK1, and this will 
be performed in the future. The results of the knock down experiments were inconclusive and are 

























From the correlation profiling data of the mitotic peptides, PAK3 is responsible for the in vitro 
phosphorylation of 5B11 and PLK1 appears to be responsible for the phosphorylation of 5B6, 5B7 
and 5B8. Further validation experiments need to be carried out to determine which is the responsible 
kinase phosphorylating 5B4 and 5B10. TP53RK would appear to be the top hit. However, the 
recombinant kinase is not available commercially and the overexpression of TP53RK was not 
successful. 
For the putative kinase-substrate pairs (PAK3-5B11), (PLK1-5B6, PLK1-5B7, PLK1-5B8), the 
correlation profiles of proteins that are known to interact with the kinases of interest were considered. 
Since the presence of particular binding partners is sometimes required for the kinase activation, the 
presence of such partners could help indicate whether the kinase is active or not. For example, it is 
known that Cdc2/cyclinB phosphorylates peptides B11 and C2, but Cdc2 alone is not able to 













































































































































































































































































































4.3.4.5 Biological importance 
The KAYAK correlation profiling platform allowed for the identification of four potential kinase-
substrate pairs (Table 4.3). These findings are novel associations of the kinase PAK 3 to substrate 
5B11 (derived from protein ADNP) and the kinase PLK1 to substrates 5B6, 5B7 and 5B8 which are 
derived from the proteins NFKB2, CAMSAP1L1 and PB1 respectively.  
Table 4.3   Putative kinases  for peptide substrates 5B10, 5B11, 5B4, 5B6, 5B7 and 5B8 and a summary of  the 
experiments providing the evidence. 
Peptide  Sequence   From protein   Top Putative 
kinase   
Evidence      















5B11  HFRNVHsEDFENRfK   ADNP  PAK3   yes   yes  N/A  no 





5B6  DDFKLNSsIVEPKfK   NFKB2   PLK1    no    no   yes   N/A 
5B7  IEKLNSsLHFLQQfK   CAMSAP1L1   PLK1   no    no   yes   N/A 
5B8  AQHPDYsFGELSRfK   PB1  PLK1   no   no   yes   N/A 
4.3.4.5.1 PAK3 
The sequence of the 5B11 substrate peptide found in ADNP (Activity-dependent neuroprotector 
homeobox) has an arginine at the -4 position and a phenylalanine (a hydrophobic residue) at the +3 
position. This is consistent with the reported residue preferences reported by Rennefahrt et al.322 and 
Zhu et al.323, and thus it is likely that PAK 3 is responsible for phosphorylation of 5B11. ADNP is a 
chromatin binding protein that plays a role in cell-cell adhesion and the regulation of gene expression 
during embryogenesis. ADNP is a neuroprotective factor and can either stimulate or inhibit the growth 
of particular tumour cells. ADNP contains 9 zinc finger domains and one homeobox and it is a 
putative transcription factor. ADNP is known to be critical for brain development. 
PAK3 is a member of the p21 activated kinase (PAK) family and a member of the MAPKKK 
orthofamily. There are 6 known PAK isoforms that are split into 2 groups: Group I PAKs (PAK 1-3) 
and Group II PAKs (PAK 4-6)324. The 2 groups are split based on their sequence and regulatory 
mechanism similarities. PAKs are targets of the Rho family GTPases RAC and CDC42, and Group I 
PAKs are significantly upregulated on binding to GTP-bound RAC or CDC42. Group II PAKs are 
known to bind RAC and CDC42 but do not appear to be activated by the binding322. The roles of 
PAKs are not known exactly. PAKs appear to be involved in multiple signalling pathways in a 
subcellular location-dependent manner involving ERK2 and JNK325. As well as having general roles 
in cellular processes including actin cytoskeletal reorganisation, it is likely that PAKs also play a role 
in specialised activities such as neuronal cell differentiation and motility325. The proposed 
phosphorylation of ADNP by PAK3 is interesting since ADNP is known to be critical for brain and 
neuron development and PAKs are thought to play a role in neuronal cells and this work offers a link 
between the two which has previously not been reported. The role of PAK3 could be important for the 




PLK1, polo-like kinase, is a serine-threonine kinase and is involved in the G2/M transition in the 
mitotic cell cycle. PLK1 is highly upregulated in G2/M, along with Aurora and cyclin-dependent 
kinases176. There are 4 known polo-like kinases in mammalian cells: PLK1, PLK2, PLK3 and 
PLK4326. All the PLKs have a similar structure comprising an N-terminal S/T kinase domain and a C-
terminal polo-box domain (PBD) that comprises polo box 1 and polo box 2 with a linker in between. 
PLK1 is known to be involved in many events in mitosis, particularly during M phase. PLK1 
phosphorylates Cdc25C and cyclin B1, resulting in their translocation to the nucleus. PLK1 is known 
to phosphorylate the cohesion subunit SCC1 which allows cohesion to be displaced from the 
chromosomes to centromeres. PLK1 phosphorylates various APC (anaphase promoting complex) 
subunits, where APC activation is required for mitotic exit327.  
The PLK1 motif, according to the PhosphoMotif Finder Human Protein Reference Database 
(HPRD)311, is [D/E]X[pS/pT][I/L/V/M]X[D/E]. This is very similar to the sequence for 5B8 
(AQHPDYsFGELSRfK) which has a phenylalanine (F) residue instead of an I/L/V/M residue. 
Phenylalanine is hydrophobic, as are isoleucine (I), leucine (L), valine (V) and methionine (M), and 
therefore it is likely that PLK1 would phosphorylate this peptide. The peptide sequences for 5B6 
(DDFKLNSsIVEPKfK) and for 5B7 (IEKLNSsLHFLQQfK) have very similar motifs, both with 
KLNSs. However, they are not at all similar to that reported for PLK1, and this data suggests that this 
could be a new motif for PLK1. In general, PLK1 substrates do contain consensus phosphorylation 
motifs328-329, which is consistent with the identification of two motif types in this study. 
Peptide 5B6 is derived from NFKB2 (NF–κB:  nuclear factor kappa-light-chain-enhancer of activated 
B cells) which is a very important protein involved in DNA transcription. PLK1 has not been 
associated with the phosphorylation of NF–κB, therefore the identified link between kinase and 
transcription factor is a novel and extremely important finding in the control and regulation of mitotic 
progression.  
Protein kinases are predominately responsible for the regulation of cell cycle progression. However, 
the transcriptional control of cell cycle regulators during mitosis is not well understood. It is therefore 
important to determine the links between kinases and transcription factors to understand regulation of 
the cell cycle fully, and also its misregulation which occurs in many cancers330-331. In cancers, many 
cell cycle kinases are often erroneously upregulated and investigation of the interplay between kinases 
and transcription factors could provide insight into the link between kinase upregulation and cell 
proliferation through alterations in transcriptional programmes. 
Whilst many PLK1 mitotic substrates are known332-337, to date there has been only one report of a 
direct link between PLK1 and transcription factors involved in gene expression. It was found that 
PLK1 directly binds and phosphorylates the mammalian transcription factor Forkhead Box M1 
(FOXM1)338-340 and that this phosphorylation regulates a transcription programme that is essential for 
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mitotic progression341. PLK1 comprises a polo-box domain (PBD) that is responsible for the 
subcellular localization of PLK1 during mitosis and has been proposed to target the kinase to its 
substrates342. The optimal motif for the PLK1 PBD binding was found to be S-[pT/pS]-(P/X)343. 
Proline (P) in the (pT/pS) +1 position is helpful but not critical for binding. Proline directed mitotic 
kinases which phosphorylate SP and TP sites can generate PBD binding sites where there is a serine in 
the -1 position. The PBD in PLK1 is similar to the SH2 domain in the Src family of kinases in that the 
PBD binds to the kinase domain and inhibits the kinase activity in the basal state. The binding of 
phosphorylated substrates to the PBD of PLK1 results in it becoming active. Many of the PBD sites 
for PLK binding are initially phosphorylated by the Cdc2/Cyclin B complex341. 
Examining the sequences of CAMSAP1L1, PB1 and NFKB2 (the proteins from which 5B6, 5B7 and 
5B8 are derived), all three proteins have several S-[T/S]-(P/X) motifs (Table 4.4 and Appendix Q). To 
determine whether there are S-[pT/pS]-(P/X) motifs where the threonine or serine is phosphorylated, 
data from a phosphoproteomic study of HeLa cells in G2/M was searched176. From this data, 3 
different S-pS-X sites were found in CAMSAP1L1, one of which is the sequence where the PLK1 
kinase is thought to phosphorylate. Two different sites in PB1 were found with S-pS/pT-P. Apart from 
the site on PLK1 LNSpS, which is the peptide PLK1 is thought to phosphorylate, no other PBD 
binding motifs were observed in this dataset. The sequences for both 5B6 and 5B7 include a leucine at 
the -3 position. Similarly, the site on FOXM1 (a transcription factor) which is phosphorylated by 
PLK1 also has a leucine at the -3 position at the Ser 724 phosphorylation site (ILLDIpSFPGL).  
Table 4.4   Peptide sequences containing possible PBD binding motifs  in CAMSAP1L1, PB1 and NFKB2. Possible 
PBD binding sites are shown in red. # indicates phosphorylated residue. Data obtained by Dr. Dephoure176. 
Protein Name site Ascore  Peptide 
CAMSAP1L1 415 5 RSS#SMSYVDGFIGTWPK 
CAMSAP1L1 901 17 LNSS#LHFLQQEMQR 
CAMSAP1L1 974 7 QAGLSS#AIAPFSSDSPRPTHPSPQSS#NR 
PB1 28 6 AT#SPSSSVSGDFDDGHHS#VST#PGPSR 
PB1 178 6 GEADDEDDDEDGQDNQGTVTEGSS#PAYLK 
NFKB2 23 18 LNSS#IVEPK 
 
The PBD inhibits the kinase activity of PLK1 and therefore if the PBD is not bound to a substrate, 
such as is the case with purified recombinant PLK1, no activity would be expected. This explains why 
the purified PLK1 from the commercial sources (Millipore, CST, SignalChem) did not phosphorylate 
the substrate peptides 5B6, 5B7 and 5B8. However, a peptide known as PoloBoxtide 8T with the core 
sequence MGSpTPL binds to the PBD and activates the kinase343. Adding this into the KAYAK 
reaction should activate PLK1 and allow the substrate peptides to be phosphorylated by recombinant 
PLK1. This experiment will be performed in the future. There is also a chemical inhibitor of PLK1 




The PBK (PDZ-binding kinase) gene/protein was discovered following a two-hybrid screen345. PBK is 
phosphorylated at mitosis in HeLa cells and this phosphorylation event is critical for its kinase 
activity. CDC2/cyclin B phosphorylates PBK in vitro. However, in vitro phosphorylation of PBK by 
CDC2/Cyclin B does not appear to activate PBK345. Presumably, other posttranslational modifications 
or the presence of a cofactor are required for PBK activation. PBK binds to the PDZ2 domain in the 
human homologue of the Drosophila Discs-large tumour suppressor protein (hDLG). PBK is 
hypothesised to have some role in DNA damage sensing and repair346-347.  PBK also binds to TP53 
and is involved in histone phosphorylation348. PBK is found to be most abundant in the placenta and is 
upregulated in various malignancies, particularly haematological ones. There is no published PBK 
motif for substrate phosphorylation and little is known about its role during mitosis, or signalling 
pathways in which it has a role.  
4.3.4.6 Future validation studies 
These initial studies predicting kinase-substrate pairs are a proof-of-concept that, by starting with a 
‘hit’ from a phosphoproteomic experiment176, KAYAK correlation profiling can identify putative 
kinases responsible for phosphorylation of a particular substrate peptide. 
Given the outcome of these profiling experiments discussed above, further validation studies will be 
performed using immunodepletion and chemical inhibition of the kinases of interest. Future studies 
will focus on determining whether the proposed substrate-kinase pairs are direct or indirect substrates. 
Shokat and co-workers have developed various mutant kinases which can be specifically and rapidly 
inhibited by the pyrimidine-based inhibitor 1-NM-PP1349. The Shokat team has also developed mutant 
kinases that can only bind bulky ATP. Bulky ATP is an analogue of ATP with bulky substituents 
synthesised in the N-6 position and the mutant kinases are created by introducing a space-creating 
gatekeeper mutation into the kinase ATP binding pocket. This allows the mutant kinase to bind bulky 
ATP which cannot be utilised by wild type kinases. By comparing the mutant PLK1 cell lines, both 
with the inhibitor and with a bulky ATP and controls, it will be possible to determine whether the 
substrates are direct or indirect. 
Further studies will also involve investigating binding partners of PLK1 and PAK3 using 
immunoprecipitate mass spectrometric analysis to determine whether the proteins that are pulled down 








The multiplexed kinase assay with a 60 peptide substrate set (K60) was used to analyse a wide variety 
of tissues from different organisms; including human saliva, human cell lines, tissues from mouse, 
Drosophila embryos and yeast. Significant kinase activity was observed in human saliva. The source 
of kinase activity in saliva is not known but proposed to be lysed cells from the lining of the mouth. 
Although the kinase substrates were designed for human kinases, many of the substrates are also 
phosphorylated by kinases in other organisms. This illustrates that the kinase substrate motifs are 
conserved between species and demonstrates the wide applicability of KAYAK as a cross species 
kinase assay. 
Large differences in kinase activity were observed in the different mouse tissues, and in general there 
was good correlation between the kinase abundance (spectral count) profile in the different tissues and 
the corresponding kinase activity of the putative kinase-substrate pairs. This is the first report of a 
kinase activity/kinase abundance correlation profiling comparison between different tissues. 
Proof-of-concept work was performed for an in-gel kinase activity assay and kinase activity/kinase 
abundance correlation profiling using blue native polyacrylamide gel electrophoresis. However, low 
resolution of the gels limits the applicability of this technique for identification of kinase-substrate 
pairs. Kinase activity/kinase abundance correlation profiling was performed using anion exchange 
chromatography to identify the kinase responsible for the phosphorylation of substrates during mitosis 
and, as a result, novel kinase-substrate pairs have been proposed. This illustrates the power of the 
technique to identify kinases responsible for unknown substrate phosphorylation events. 
Correlation profile identification of the kinase responsible for a specific phosphorylation event was 
also performed. This study showed that the sample complexity was a challenge and several candidate 
kinases were selected for validation experiments. To narrow down the number of candidate peptides, 
two dimensional chromatographic separation could be carried out; for example, gel filtration 
chromatography followed by anion exchange chromatography could be performed. 
KAYAK has huge potential in diagnostics, drug development and testing, and research into cause of 
disease and signalling pathway disruption. There are several different ways the KAYAK assay could 
be further developed. This includes optimisation for the testing of drugs such as kinase inhibitors, or 
alternatively, it could be envisaged as having a role in hospitals for disease diagnosis. Furthermore, 
various KAYAK kits with peptides specific for particular diseases could be developed. A general 
peptide kit, along the lines of the K60, could be used for ‘broad diagnosis’ (e.g. healthy/diseased). 
More specialised peptide kits could aid in diagnosis of specific pathway dysfunctions, including 
peptides whose phosphorylation state can differentiate subtle changes in signalling cascades.  
KAYAK may also be used to process biopsy samples, such as tumours. This technique would be 
particularly useful in cases where both healthy and cancerous tissue can be obtained from the same 
patient, renal cell carcinoma or skin cancers for example, allowing for a patient to act as their own 
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control. Beyond cancers, there are many other diseases that could benefit from analysis by KAYAK. 
For many diseases KAYAK could help characterise the signalling pathways which are altered and 
possibly lead to the development of kinase-related diagnostic tools. The detection of kinase activity in 
saliva and also in other body fluids (e.g. tear and serum) opens up another large diagnostic field. 
Another possible enhancement to KAYAK would be to extend the K60 kit to include a very large 
number of peptides, perhaps to the order of thousands, for research purposes. Although many kinases 
across different species recognise similar motifs, it would be of value to provide KAYAK peptide kits 
specially tailored for individual species.  In terms of kinase-motif evolution it would be interesting to 
compare the KAYAK peptides of a much greater range of organisms from different phyla. It would be 
particularly interesting to study the KAYAK activity present in tissues of the nematode C. elegans, 
due to the relatively conserved nature of the kinase families between humans and C. elegans. Whilst 
kinase evolution can be investigated using genomics, this does not determine whether the kinase is 
active or not. KAYAK, on the other hand, can assess the kinase activity and also assess the 
conservation of the motifs that the kinases recognise. 
The kinase activity/kinase abundance correlation profiling method offers a unique way of identifying 
kinase-substrate pairs. Profiling different tissues allows for determination of the particular location in 
which a kinase is active. The location of kinases in different tissues and different parts of the cell 
affects their activation. By performing kinase activity assays and kinase abundance profiling on 
different cellular preparations (e.g. membrane, endoplasmic reticulum, nucleus, mitochrondria), 
information and insight about the localisation of kinase-substrate pairs in different portions of the cell 
can be obtained. By performing kinase activity/kinase abundance profiling in this way kinase-
substrate pairs should be easier to identify. 
As well as investigating kinase activity, the KAYAK strategy and the kinase activity/kinase 
abundance correlation profiling approach has the potential to be applied to numerous other enzyme 
classes.  The results presented here, taken together, demonstrate the wide applicability of the KAYAK 
method for understanding protein function, and highlight it as a tool with great potential for research 









5 Saliva biomarkers for gingivitis 
5.1 Introduction 
This chapter integrates the work on salivary proteomics as discussed in Chapter 3 with the work on 
saliva kinase activity profiling as discussed in Chapter 4 in the context of two clinical trials. The first 
trial comprised a small study where saliva samples were obtained from 10 gingivitis patients and 10 
healthy subjects. This study was performed ‘in-house’ at the Proctor & Gamble site in Rusham Park, 
Egham. The second trial, carried out at the Eastman Dental Institute (London, UK), involved 
induction of gingivitis in healthy subjects via abstention of teeth brushing.  
Chapter 3 detailed the work investigating the salivary proteome and analysing the data using three 
different label-free software packages, with the goal of developing a workflow for comparison of the 
clinical trial saliva samples. However, because none of the label-free software packages for use with 
the ion intensity data were suitable for analysis of the saliva clinical trial samples, a more simple 
method, spectral counting, was used. In this case, the number of spectral counts per protein was used 
as an estimate of protein abundance.  
The saliva samples from the clinical trials were analysed by proteomics. The saliva samples from the 
induced gingivitis clinical trial were also analysed by KAYAK to determine the kinase activity of both 
the supernatant and the residue. In the second clinical trial (induced gingivitis), both the saliva 
supernatant and the residue were investigated and searched against both human and bacterial protein 
databases. It is hypothesised that gingivitis is caused by, or is a result of, large-scale changes in 
bacterial populations and activity. If true, this suggests that investigating quantitative changes in 
bacteria protein abundance and activity may provide a useful method for gingivitis biomarker 
discovery. Despite the potential wealth of clinically-relevant information which may be present in 
proteomic analysis of saliva residue, very few past studies have investigated either the bacterial or 
human cellular protein profiles in saliva residue211. 
 
5.1.1 Gingivitis and periodontitis 
Gingivitis and periodontitis are gum diseases with symptoms including bleeding, swollen, and 
receding gums (Figure 5.1). Gingivitis is a mild form of periodontitis and is reversible, whilst 
periodontitis is not.292 Gingivitis lesions can spread to deeper, supporting tissues and lead to 
destructive periodontitis lesions. However, this progression does not always occur and the factors that 
affect this progression are not fully understood. The primary cause of periodontitis is the build up of 
bacterial plaque that is often a result of inadequate oral hygiene. This build up of plaque results in 
inflammation leading to the degeneration of epithelial cells at the junction of the tooth and gingiva. 
This inflammatory lesion may become more extensive, leading to the destruction of dentogingival 
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alveolar crest fibres and connective tissue down the root surface101. With the destruction of connective 
tissue, an irreversible periodontal pocket forms and can eventually lead to tooth loss. 
 
Figure 5.1  Schematic illustrating gingivitis and periodontitis. Gingivitis is considered a milder form of 
periodontitis and the symptoms can be reversed, unlike periodontitis. Depth of probing (shown in figure as a 
white and black rod) is used as a clinical indication of the severity of gingivitis/periodontitis. Schematic adapted 
from Bostrom et al.350 
While the build-up of plaque is the primary cause of gingivitis, various factors, including the 
composition of the local bacterial flora, affect the overall progression of the disease. Inflammation of 
the gingiva is thought to start when endotoxin or bacterial lipopolysaccharides induce the release of 
proinflammatory cytokines by gingival cells351. It has been suggested that there are between 6-12 
bacterial species which are particularly prevalent in progressive periodontitis352,353. Although oral 
hygiene plays a large role in periodontal disease, other factors play a role. It has been reported that, 
independent of oral hygiene, around 10% of patients with gingivitis have a high risk of developing 
destructive, rapid progressing periodontitis and tooth loss; around 80% have susceptibility to 
periodontitis but progression is slow and normally doesn’t result in tooth loss; and around 10% are 
relatively resistant to destructive periodontitis354. These differences are likely a result of the genetic 
constitution of the patient. The progression of gingivitis to periodontitis is dependent on the 
interactions between periodontopathic bacteria and the cells of the host immune system. These 
interactions are mediated by the various cytokines and chemokines secreted by leukocytes and 
gingival tissues.355 These molecules are produced at the site of inflammation and the main sources 
include monocytes/macrophages and polymorphonuclear (PMN) leukocytes. 
Several studies have found various proteins to be present in different amounts in healthy/gingivitis 
saliva/gingival tissue (Table 5.1). The majority of literature reports which have attempted to identify 
biomarkers for gingivitis/periodontitis trials have compared saliva, gingival tissue or gingival 
crevicular fluid, between groups of pooled ‘healthy’ versus ‘gingivitis’ individuals. These studies have 
often focused on a small subset of enzymes and used antibody detection techniques (e.g. ELISA) 138,
356-358 on account of their ease of use. Many of the procedures used to date estimate the concentration 
of proteins using a saliva-volume-based normalisation and do not take individual protein 
concentrations into account. Because the salivary flow rate and protein concentration are known to 
vary significantly from patient to patient, day to day, as well as the time of day182, 289, these past 
studies often suffer from poor resolution and incorrect conclusions may be drawn. There have been 
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several recent publications within the last year that have used proteomic profiling comparison of 
saliva from patients with periodontitis and controls using 2D SDS PAGE359-361. In these studies, 
quantitation was based on spot intensity and very few proteins (spots) were found to be upregulated. 
Only the most abundant proteins were detected using this methodology. For example, one report using 
2DGE proteomics, comparing protein abundance changes before and after periodontitis treatment, 
identified 15 out of 128 protein spots that were differentially changed. Only 10 of these were possible 
to characterise.361 These previous reports are often conflicting with regard to the reported changes in 
protein expression during gingivitis or periodontitis. This is likely a result of the small numbers of 
patients tested, a pooling of samples, and the utilization of only two time points (before and after 
periodontitis treatment). Currently, only one large non-gel proteomic comparison of 
gingivitis/periodontitis has been performed to date362. This study analysed proteins in human gingival 
crevicular fluid in ten people (5 healthy, 5 with gingivitis) and quantitated the protein abundance using 
label-free  technology362. A total of 154 proteins were identified, but many of the lower abundance 
pro-inflammatory cytokines were not detected.  In this case, depletion of high abundance proteins 
could have been performed to identify more protein species. However, recent studies suggest that such 
depletion methods may unintentionally remove proteins of interest that are complexed to proteins that 
are being depleted. For example, albumin is known to bind to hormones, cytokines and lipoproteins, 
and such proteins are inadvertently removed during albumin depletion363. Concerns regarding the 
reproducibility of protein depletion also exist in current literature362. 
Induced gingivitis trials, which potentially allow for the collection of controlled, high quality, 
longitudinal data, have been very rarely performed in conjunction with biomarker searching. A 
longitudinal study involves the sampling the same patients over a period of time (during the induction 
of gingivitis) whilst a cross-sectional study only investigates the subjects at a defined timepoint. The 
main reported longitudinal trial monitored the transcriptome profile of gingival biopsy tissue from an 
induced gingivitis trial364. However, only 3 samples were taken from each patient (prior to induction, 
following 28 days of induced gingivitis, and following treatment). Taking samples during the 
induction of gingivitis would have allowed a time course profile to be generated, which may have 
substantially improved this study. In addition to gingival tissue sampling, cell culture models of 
gingival fibroblasts have been investigated and the effect of induction by Interleukin-1β has been used 
to model the effect of inflammation, effectively modelling gingivitis365. 
The aims of this chapter are to identify putative biomarkers for gingivitis using saliva samples from 
two clinical trials and to determine whether specific proteomic platforms can provide enough 
sensitivity to identify previously reported biomarkers that were identified using antibody-based 
techniques (Table 5.1). In one of these clinical trials, multiple samples were obtained during gingivitis 
induction to allow for time-course profiling of protein levels. Proteins of both human and bacterial 
origins are considered for biomarker discovery in the saliva supernatant and residue. Furthermore, to 
determine whether kinase activity profiling has potential for biomarker discovery in saliva, the 
application of KAYAK on saliva samples from an induced gingivitis clinical trial are evaluated. 
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saliva  PIP  Prolactin  ‐1.36  Haigh, 2010361 
  S100A6  Calcium binding  1.64 
  S100A8  Calcium binding  2.31 
  S100A9  Calcium binding  1.45 
  SPLUNC2  Parotid secretory protein  ‐1.50 







  TKT  Transletolase  5.37 
Saliva  GOT  Aminotransferase  Ca. 3.7‐8.7  Todorovic, 2006357 




  GGT1  Gama glutamyl transferase  1.5‐2.6 
Saliva  MMP8  Matrix metalloproteinase 8  4.3  Miller, 2006358 
  IL1B  interleukin‐1 beta  3.5 
Saliva  LDH  Lactate dehydrogenase  1.3‐3.2  Zappacosta, 
2007366   AST  Aspartate aminotransferase  1.2‐2.5 
Saliva  MMP8  Matrix metalloproteinase 8  3.3‐4.5  Rai, 2008356 
Gingival tissue, 
biospsy 
PROK2  Prokineticin 2  4.55  Offenbacher, 
2009364 




  ANGPTL1  Angiopoietin‐like  2.07 
  ITGB2  Beta integrin 2  1.84 
  CMTM2  CKLF‐like MARVEL TD  1.81 
  IL8  Interleukin 8  1.81 
  IL1A  Interleukin 1 alpha  1.79 
  CCL5  RANTES  1.76 




  SOD2  Superoxide dismutase 2  1.68 




























5.2 Experimental procedures 
5.2.1 Procter & Gamble gingivitis trial 
On wake-up (WU), saliva samples (1 ml) were self-collected by the subject. The saliva was 
expectorated into a sterile vial and brought by the subject into the P&G site where it was frozen at –
80°C. An informed consent form was signed by all participants. In total 20 subjects were selected by 
the dentist at P&G oral care: 10 displaying some level of gingivitis and 10 showing no symptoms. 
Subjects were excluded if any of the following criteria applied to them: 
• Use of antibiotics, antimicrobial mouthwash, medicated lozenges or chlorhexidine 2 weeks 
prior to the study or during the study period. 
• Sufferers of caries, advanced periodontitis, oral candidiasis or other diseases that could 
interfere with the study (e.g. diabetes, bacterial infection, malaria, tonsillitis, sinusitis, 
bronchitis, etc.) 
• Have undergone significant oral surgery in the last 12 months or had dental conditions that 
could interfere with the study. 
• Pregnancy or nursing. 
Around 2 ml of whole saliva was collected at wake-up from 10 people with gingivitis and 10 healthy 
people on 6 different days over a 2 week period. The samples were frozen at -80°C prior to 
processing. 
 
5.2.1.1 Sample preparation and mass spectrometric analysis 
Saliva samples from 10 subjects with gingivitis and 10 controls were pooled respectively and the 
supernatant was analysed by GeLC-MSMS as described in Section 2.3.1 and 2.3.3. In brief, the 
pooled saliva samples were reduced, alkylated, separated on SDS-PAGE, before being digested in-gel 
and analysed on an LTQ Orbitrap mass spectrometer at HMS (Section 2.5.1-2.5.3). Proteins were 
quantitated using spectral counting and the protein abundance was compared between the pooled 
gingivitis and control set. 
In addition to the pooled analysis using GeLC-MSMS, individual saliva samples were analysed 
individually by in-solution digestion as described in Section 2.2.1 In brief, 20 saliva samples (10 
healthy, 10 gingivitis subjects) were reduced, alkylated, digested with trypsin in-solution and analysed 
by LC-MSMS on the HCT mass spectrometer at Edinburgh (Section 2.4.1.1). Proteins were 
quantitated using spectral counting and the protein levels compared between subjects with gingivitis 
and the control subjects.   
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5.2.2 Eastman Dental Institute induced gingivitis clinical trial 
A single centre, randomised, double-blind, and parallel-group (3 groups) clinical trial was performed 
on 45 subjects (15 per group) who met the all the necessary inclusion and exclusion requirements 
(Appendix R). Subjects presented to the clinical site for initial screening and enrolment (day -7), 
having refrained from brushing and inter-dental cleaning for at least 12 hours prior to the baseline 
visit. Following the screening examinations, the subjects received a complete dental prophylaxis to 
remove plaque, stains and calculus. Subjects began a regime of twice a day brushing (morning and 
evening) and daily flossing (evening) for 7 days. On the eighth day, subjects presented to the clinical 
site for baseline clinical measurements and sample collection (saliva and plaque) and were 
randomised to their assigned rinse material (day 0).  They then began their regimen of rinsing with 10 
ml of mouthrinse for 30 seconds twice daily (morning and evening after meals) for 14 days and this 
was the sole oral hygiene routine (no brushing or flossing).  Rinsing was unsupervised and took place 
at home. Saliva and plaque samples were taken on days 7, 9, 12 and 14. Subjects were randomly 
assigned to one of three groups with a mouthwash containing ‘flavoured water’ (negative control), 
‘chlorhexidine’ (positive control) or ‘test compound’. 
An oral examination was conducted at each visit to monitor the effect of the mouthrinse formulations 
on the soft and hard tissues. Buccal and sublingual mucosae, lips/labial mucosa, mucobuccal fold, 
gingiva, tongue, hard and soft palate, uvula, oropharynx, teeth and dental restorations were examined 
and clinical measurements made.   Changes from the baseline and previous visits were recorded at 
each subsequent clinic visit.  Saliva was collected on day 1, 7, 9, 12 and 14 of the trial before any 
clinical sampling or measurement took place.  Study participants refrained from eating, smoking, or 
drinking for 60 minutes prior to saliva collection.  The patient was seated in a quiet environment with 
their head tilted forward.  Whole saliva samples were collected using plastic tubes (approximately 1 
ml) to which protease inhibitors were added (Complete protease inhibitor 1x, Roche) prior to freezing 
at -80°C. 
5.2.2.1 Sample preparation 
After defrosting the saliva at 4°C, it was centrifuged at 1,500 rpm for 5 min and the residue and 
supernatant were separated. The supernatant was further clarified by centrifugation at 16,000 rpm and 
the residue from this second centrifugation step was discarded and the supernatant was used for the 
KAYAK assay and shotgun proteomic analysis. All centrifugation and preparation was carried out at 
4°C to minimise protein degradation. The residue from the first centrifugation step was washed with 1 
ml of PBS and lysed using 750 µl of KAYAK lysis buffer (Section 2.7.2). Proteins (20 µg) in the 
saliva supernatant and residue following lysis were precipitated with methanol/chloroform (Section 
2.3.1) after addition of 500 fmol CKM (creatine phosphokinase, rabbit) as an internal standard. The 




5.2.2.2 Mass spectrometric analysis and data processing 
LC-MSMS analysis was performed on an LTQ-Orbitrap Velos mass spectrometer (Thermo 
Scientific). The LTQ-Orbitrap Velos was operated in data-dependent mode with dynamic exclusion 
(20 s), where the high resolution survey scan was followed by 20 MS/MS scans in the LTQ on the 20 
most abundant ions (TOP 20 method). Apart from the TOP20 acquisition, all other parameters were 
the same as described in the Experimental Procedures Section 2.5.1 The MSMS data was searched 
using the SEQUEST algorithm against a combined database of eubacteria, archaea and human (IPI) 
proteins. Peptides were filtered to a false discovery rate < 1% at the protein level. The protein 
abundance was estimated by spectral counting normalised to the count of internal standard (CKM, 
rabbit) peptides. Hierarchical clustering was performed using Clustal 3.0 to group similar responding 
proteins together. 
 
5.2.3 Kinase activity profiling of saliva 
Kinase activity profiling using KAYAK was performed on the saliva supernatant (10 µg) and residue 
(10 µg) for all samples from the Eastman Dental Institute induced gingivitis trial (60 samples in total). 
The kinase reactions were performed using the 96 well KAYAK assay format with the K60 peptide 














5.3 Results and discussion 
5.3.1 Comparison of healthy and gingivitis saliva samples from Procter & 
Gamble trial 
Wake-up saliva samples were obtained from a P&G trial using 10 healthy and 10 gingivitis sufferers. 
Over a period of 2 weeks, 6 samples from each patient were obtained. The 6 samples from each 
patient were pooled to minimise day-to-day variation. Subsequently, the healthy and gingivitis saliva 
samples from the 10 people in each group were pooled. These 2 supernatant saliva samples were 
analysed using GeLC-MSMS (10 fractions for each sample) and spectral counting was used for 
quantitation. In total, 671 proteins (peptide FDR < 0.1%) were identified in the two samples. The 
spectral counts for the proteins across the 10 fractions for each sample were summed and the fold 
value (gingivitis/healthy) was determined (Figure 5.2). The results were filtered to consider only those 
proteins with a total spectral count of greater than 5 and a fold value greater than 2 for gingivitis 
compared to healthy samples or vice versa. The majority of the proteins fall within a fold value of less 
than two, however, 45 proteins have a spectral count (SC) and fold value which lie beyond this cut-off 
(Table 5.2). One of the proteins, IL1F6 (interleukin family member 6), is an inflammatory cytokine 
and would be expected to be unregulated in gingivitis. However, no other cytokines or putative 
periodontitis biomarkers such as MM8 were significantly upregulated. 
 






Table 5.2    List of proteins  that  increase/decrease  in gingivitis  (G) and healthy  (H) pooled  saliva  samples. The 





















This result may be expected due to the intrinsic limitations of such a pooled analysis. Whilst the 
comparison of the pooled healthy and gingivitis samples can give an indication of proteins present in 
different quantities in saliva from healthy people and those suffering from gingivitis, it takes no 
account of the variation of protein abundance within each group of healthy and gingivitis people. 
Taking this into consideration, the individual saliva samples from the healthy and gingivitis people 
were analysed by LC-MSMS and spectral counting. Due to the large number of samples, it was not 















































sample was subjected to in-solution trypsin digestion prior to analysis by LC-MSMS. A very large 
amount of variation within the healthy and gingivitis groups was observed and no proteins were 
significantly different between the healthy and gingivitis group (Figure 5.3). A t-test was performed 
between the individual samples in the healthy and gingivitis groups but no proteins were found to be 





Compared with the experiment where the pooled healthy and gingivitis samples were fractionated by 
SDS-PAGE, far fewer proteins were identified when the individual healthy and gingivitis samples 
were analysed by LC-MSMS with no fractionation as a result of increased depth of sampling. Also, 
the individual healthy and gingivitis samples were analysed on a different LC-mass spectrometer 
setup (HCT, Bruker) compared to the pooled samples (LTQ, Thermo) and therefore there were two 
variables. 
It was later understood that the saliva samples from the gingivitis and control subjects had not been 
obtained in the same timeframe, but approximately a year apart. This implies that the trial may have 
been confounded and that observed differences may be a result of gingivitis or length of storage. As a 
consequence of this, no in-depth analysis was performed on these samples. However, this cross-
sectional study was useful in that it clearly demonstrated that the large inter-person variability must be 
taken into account to obtain accurate results. Therefore, an effort was directed towards obtaining 




5.3.2 Induced gingivitis clinical trial at the Eastman Dental Institute 
Saliva samples were obtained from a longitudinal induced clinical trial performed at the Eastman 
Dental Institute (London, UK). This was a randomised, controlled clinical trial to determine the 
effectiveness of a test compound for gingivitis treatment. Saliva samples were collected over a period 
of time during gingivitis induction (day 1, 7, 9, 12 and 14) where gingivitis induction was through 
brushing abstention.  
For the proof-of-concept work presented here, six samples were obtained (out of the 40 participants). 
Saliva samples from these six individuals were analysed blinded to the treatment regimen. Patients 
were either on a daily mouthwash routine of either water (negative control), chlorhexidine (positive 
control) or a proprietary test compound. Ideally, saliva samples should have been selected after 
unblinding the randomisation code but this was not possible due to time restrictions. Since the primary 
aim of this PhD was to detect biomarkers that increase with gingivitis, it was of most interest to 
analyse the negative control population (patients on the water mouthwash) where the gingivitis 
symptoms would be expected to increase the most. Due to confidentiality restrictions, it was not 
possible to include data for patients who were treated with the proprietary test compound. 
Both the saliva supernatant and the residue were investigated for each of the 30 samples obtained from 
six individual subjects on day 1, 7, 9, 12 and 14 of gingivitis induction. The 60 samples (30 
supernatant, 30 residue) were analysed by shotgun proteomics and protein abundance was estimated 
by spectral counting. Sample fractionation (e.g. SDS PAGE) was not practical in terms of available 
instrument time and each saliva sample was digested in-solution. The whole saliva digest was 
subsequently analysed in a single 2 hour LC-MSMS run. 
For each saliva supernatant sample, around 600 proteins were identified. In total, 977 proteins were 
identified for all 30 samples combined with a FDR <1 % at the protein level. The total unique peptide 
count was 6,454 and the total peptide count was 209,539. Of the proteins identified, 894 were human, 
79 were from bacteria and 2 were from archaea ( Figure 5.4). For each saliva residue sample, around 
1,000 proteins were identified in each run. In total, 2654 proteins were identified for all 30 samples 
combined with FDR <1 % at the protein level. The total unique peptide count was 11,807 and the total 
peptide count was 287,380. Of all the proteins identified, 1378 were human, 1267 were from bacteria 
and 7 were from archaea. A total of 198 bacteria species were identified (Table 5.3) although many of 
these may be redundant through the similarity of proteins present in similar species and the 
incomplete sequencing of bacterial genomes (Appendix T).   
Almost half of all the proteins identified in the saliva residue were bacteria proteins. This represents a 
much greater proportion than that found from the saliva residue from a single healthy individual. 












The bacteria from the phyla Proteobacteria (gram-negative) and Firmicutes (mostly gram-positive) 
dominate in both the saliva residue and the supernatant (Figure 5.5). The genera Neisseria and 
Streptococcus are in the phyla Proteobacteria and Firmicutes respectively and have very high spectral 




























































   Residue Supernatant Residue Supernatant 
Neisseria meningitidis  121 1 917 1 
Neisseria flavescens 95 0 382 0 
Neisseria gonorrhoeae  94 2 1026 10 
Streptococcus pneumoniae  65 3 780 15 
Streptococcus salivarius  34 3 199 69 
Haemophilus influenzae  32 0 214 0 
Actinomyces odontolyticus   22 2 584 14 
Veillonella dispar  21 3 216 29 
Bacteroides caccae  17 0 259 0 
Streptococcus agalactiae  17 1 296 1 
Bacteroides fragilis 16 0 273 0 
Selenomonas flueggei   16 2 121 42 
Streptococcus gordonii   15 0 291 0 
Haemophilus ducreyi  14 0 46 0 
Streptococcus thermophilus   14 2 119 3 
Streptococcus sanguinis   13 4 224 47 
Bacteroides vulgatus   12 0 187 0 
Lactococcus lactis 12 1 158 1 
Streptococcus mutans  12 0 135 0 
Streptococcus equi 11 1 62 2 
Fusobacterium nucleatum  10 1 91 9 
Porphyromonas gingivalis   10 1 115 5 
Streptococcus pyogenes serotype  10 1 111 1 
Acinetobacter baumannii   9 1 111 18 
Escherichia coli O139:H28   9 1 221 6 
Kocuria rhizophila  9 0 95 0 
Actinomyces urogenitalis   8 1 70 1 
Bifidobacterium longum   7 1 12 3 
Eikenella corrodens 7 0 43 0 
Eubacterium ventriosum   7 1 133 4 
Kingella oralis   7 0 16 0 
Ralstonia solanacearum   7 0 24 0 
Streptococcus infantarius  7 0 39 0 
Burkholderia cenocepacia   6 0 37 0 
Enterococcus faecalis   6 0 37 0 
Porphyromonas uenonis  6 0 26 0 
Bacteroides coprocola   5 0 42 0 
Bacteroides thetaiotaomicron  5 2 62 38 
Bifidobacterium animalis  5 1 98 21 
Bordetella avium  5 1 139 15 
Delftia acidovorans  5 1 58 24 
Ralstonia pickettii  5 0 24 0 
Streptococcus equinus   5 1 75 13 
Streptococcus suis 5 2 55 12 
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5.3.2.1 Induced gingivitis: spectral count comparison of human proteins  
Previous literature reports comparing saliva from healthy individuals to that from 
gingivitis/periodontitis patients have reported particular proteins that were found to be higher in 
gingivitis/periodontitis compared to healthy. To determine whether these proteins were present in 
increasing quantities during gingivitis induction, the spectral count profile of particular proteins was 






















Several notable proteins which have been previously associated with gingivitis show upward trends 
upon gingivitis induction.  First, an increase in the abundance of cystatin proteins was observed in this 
study. For cystatin 4, a large increase was observed in the later part of gingivitis induction (day 7 to 













































decrease on day 12. Cystatins are cysteine proteinase inhibitors that reduce tissue damage in 
inflammation and are elevated in patients with gingivitis/periodontitis368-369. 
Also, the abundance of MMP9 (matrix metalloproteinase 9) was found to increase with gingivitis 
induction, and whilst MMP8 was identified, the spectral count was low and accurate quantitation was 
not possible. This is consistent with published data linking MMP8 and MMP9 to connective tissue 
breakdown in gingivitis356. MMPs are zinc dependent endopeptidases associated with 
polymorphonuclear neutrophils that are known to be expressed in many inflammatory diseases362 The 
abundance of cathepsin (CTS) proteins C, D and G was increased in the saliva supernatant, which is 
consistent with previous finding370-372. Cathepsins, along with MMPs are proteases associated with 
polymorphonuclear neutrophils (PMNs)371. 
Various cytokines were also identified including interleukins. The cytokine IL1F5 increased 
dramatically during the second half of gingivitis induction (day 7 to 14). Whilst various annexins were 
identified, the spectral count was too low for accurate quantitation and no significant trend was 
observed.  Annexin is another member of the calcium binding family that is involved with the defense 
and inflammatory response373. Annexin1 is thought to be a negative regulator of various pro-
inflammatory mediators including cyclooxygenase, IL-1 and IL-6374. The balance between protease 
activity and inhibition is essential for the maintenance of healthy tissues. Increased protease activity 
and/or decreased inhibition may result in tissue inflammation and ultimately tissue destruction. 
There was a clear, consistent increase in S100 protein abundance during gingivitis induction. S100 
proteins are calcium binding proteins that are expressed in inflamed epithelial cells and macrophages 
and decrease in saliva following treatment of periodontitis375. Therefore, the increased abundance of 
S100 proteins with gingivitis induction in this study is consistent with the expected response to 
gingivitis. 
Haptoglobulin (HP), an acute phase protein, was increased in the gingivitis samples, which is 
consistent with previous work where increases in HP were observed in saliva and in the serum of 
periodontitis patients376. Transketolase (TKT) and transaldolase (TALDO1) were also increased with 
the duration of gingivitis induction. Whilst TKT and TALDO1 are not known to have a direct role in 
the immune response, a previous proteomics study comparing the salivary proteome of individuals 
before and after periodontal treatment found these proteins to be higher in the diseased state361. 
Glutamic-oxaloacetic transaminase (GOT), gama glutamil transferase (GGT)  and lactate 
dehydrogenase (LDH) are enzymes associated with cell injury and cell death and were found to 
increase with gingivitis induction, consistent with previous reports357.  
The majority of literature studies on the investigation of gingivitis/periodontitis biomarkers have been 
performed on saliva, with a few have been performed on gingival tissue. To the author’s knowledge, 
no studies have been published on analysis of the saliva residue with respect to gingivits.  However, 
because a significant portion of saliva residue contains sloughed-off and lysed gingival cells, the 
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analysis of saliva residue would likely give similar results to direct analysis of gingival tissue, which 
is more difficult to obtain. The profile of proteins in the saliva residue which have previously been 





the all  the days of gingivitis  induction and gives an estimation of protein abundance. Selected proteins  taken 
from literature where they were reported to be higher in patients with gingivitis/periodontitis.  
 
The correlation of proteins reported to be increased in gingivitis/periodontitis with those found in the 
saliva residue appears poorer than the correlation for the proteins in the saliva supernatant (Figure 5.6 
and Figure 5.7). This may be due to several factors. Firstly, comparing literature ‘saliva supernatant 
biomarkers’ with saliva residue is not a fair comparison and many of the proposed biomarkers 
identified in gingival tissue using transcriptomics (such as PROK2, CSF3, IL8) were either not 
identified in the proteomic analysis of the saliva residue or were too low abundance for accurate 
quantitation. Secondly, a significant proportion of the saliva residue comprises bacterial cells, and 
therefore the abundance of a particular protein is measured against the background of total human and 
total bacterial proteins (Figure 5.8b, discussed in Section 5.3.2.2). While a particular human protein 
may increase with induction of gingivitis, it may appear to decrease with respect to the overall number 
of proteins present due to large changes in bacterial protein concentrations. However, despite 













































certain proteins reported to be associated with gingivitis including cystatins (CST1, 2, 4 and 5), 
cathepsins (CTSD and CTSG) and interleukins (IL1F5, IL1F6). 
Whilst many of the previously reported biomarkers for gingivitis/periodontitis increase with the 
induction of gingivitis in these data, several inconsistencies are present. For example, neutrophil 
defensin 1 (DEFA1) was observed to increase in both the saliva supernatant and the saliva residue 
(data not shown). Defensins are cytotoxic peptides and are abundant in neutrophil granules in the 
epithelia of mucosal surfaces, and it has previously been postulated that the progression of 
gingivitis/periodontitis may be linked to a decrease in the defensin barrier377-378. However, DEFB4 
was previously reported to be downregulated in gingival tissue in transcriptome pattern profiling of 
gingivitis induction364. The inconsistency with literature could be due to the different sample type 
(saliva residue vs. gingival tissue) along with the low statistical power of this study. 
Despite this, during the course of gingivitis induction, the majority of the proposed biomarkers are 
shown to increase. These results provide evidence that our techniques are valid and may be used as a 
tool for further gingivitis biomarker discovery.  Despite the lack of statistical power in our data, this 
proof-of-concept work illustrates several potentially novel protein indicators of gingivitis.   
Many new proteins not previously reported show correlations with the progression of gingivitis (Table 
5.4).  Although more patient data is clearly necessary for any reliable conclusions to be drawn, these 
data suggest that the combination of a longitudinal clinical trial with high throughput proteomic 
analysis is a powerful tool for disease biomarker discovery. Most significantly, many more proteins 
were identified and quantified in this study than in previous studies and proteomic comparisons358, 360-
362, 366. This technique would increase the number of candidate proteins associated with gingivitis and 
allow for high-throughput screening of potential biomarkers.  
Several notable proteins increase with gingivitis induction and have not previously been reported. In 
the saliva supernatant, Cysteine-rich secretory protein 3 (CRISP3) was observed to have a high 
correlation coefficient with the length of gingivitis induction. CRISP3 is present in neutrophilic 
granulocytes and exocrine secretions and is thought to play a role in the innate host defense379. 
CRISP3 has previously not been associated with gingivitis/periodontitis but was shown to be 
downregulated in patients with Sjogren’s syndrome380 and in patients with oral tongue squamous cell 
carcinoma381. CRISP3 has also been associated with prostate cancer382 and chronic pancreatitis, a 
progressive inflammatory process, where increased levels were observed in chronic pancreatitis tissue 
compared to normal pancreatic tissue383. The exact function of CRISP3 is unknown but it has been 
postulated to act as an anti-infection agent383 and therefore it might be expected to increase with 
during gingivitis. 
Calumenin (CALU) is a calcium-binding protein located in the endoploasmic reticulum secretory 
pathway. Calumenin has been implicated in several diseases including cardiovascular, cancer and 
neuromuscular384 but the in vivo function has been little studied. Data from a study of calumenin in 
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Caenorhabditis elegans suggests that it is important in calcium signalling pathways385 and is 
upregulated in ‘stress’ conditions384 which may be present in gingivitis. 
Endoplasmic reticulum oxidoreductin 1-L (ERO1L) is thought to be involved in the formation of 
hydrogen peroxide in the endoplasmic reticulum386 and is associated with endoplasmic reticulum 
stress-induced apoptosis where knock down of ERO1L in endoplasmic reticulum in stressed cells was 
shown to suppress apoptosis 387. Although ERO1L has previously not been associated with 
gingivitis/periodontitis, endoplasmic reticulum stress-induced apoptosis is involved in many diseases 
including diabetes, atherosclerosis and neurodegenerative disease387. Inflammation in 
gingitivitis/periodontitis is known to be associated with activation of the NF-κB pathway and 
antiapoptotic genes367. Therefore, an association of ERO1L and gingivitis/periodontitis may be 
possible. 
Glyceraldehyde-3 phosphpate dehydrogenase (GAPDH) was shown to be activated in T lymphocytes 
which are involved in adaptive immunity by interacting with the antigen and secreting cytokines388. 
Whilst no previous reports have highlighted the link between GAPDH and gingivitis/periodontitis, an 
activation of T cells is known to occur in gingivitis inflammation. Glia maturation factor-gamma 
(GMFG) has been shown to be preferentially expressed in inflammatory cells389 and its increased 
abundance with gingivitis induction is logical. 
A variety of immunoglobulins were observed to increase with gingivitis induction, where IGHA1, 
IGHV1OR15-1 and IGJ had high correlation coefficients. In addition, IGLV7-46, IGKV3-20, IGLL1, 
IGLV2-18, IGHG2, IGKV3D-11, IGKV3D-15, IGKV4-1, IGL, IGLV3-25 all showed positive 
correlation with gingivitis induction. Previous studies have reported a higher abundance of 
immunoglobulins in periodontitis saliva and/or gingival crevicular fluid194, 359-360, 390-391. This is 
consistent with the intuitive notion that inflammation of gingival tissues leads to migration of 
leukocytes and may lead to increased immunoglobulin secretion. 
In the saliva residue, leukotriene A4 hydrolase (LTA4H) and Peptidase inhibitor 3 (PI3) both had 
good correlation with the length of gingivitis induction (correlation coefficient of 1, p<0.02). LTA4H 
is an enzyme that is involved in inflammation and catalyses the synthesis of leukotriene B4, a potent 
proinflammatory lipid mediator392. PI3 is an antimicrobial peptide against both gram-positive and 
gram-negative bacteria and is known to be upregulated by bacterial lipopolysaccharide and cytokines. 
Despite no previous association of either LTA4H or PI3 with gingivitis/periodontitis, their increased 
abundance with increased inflammation of the gingiva would appear logical and these could be 
promising indicator of gingivitis severity in the saliva residue. 
The use of single mass spectrometry runs on in-solution digests of single samples has enabled the 
profiling of many proteins during the course of gingivitis induction. Spectral counting was used as a 
means of quantitation. To enable more accurate quantitation of lower abundance proteins, an isotopic 
labelling method (e.g. dimethylation) would be appropriate. Despite poor statistical power and the 
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clear need to investigate a greater number of subjects, several biomarkers previously proposed in the 
literature were found to increase with gingivitis induction, providing support for the presented 
method. Several proteins, previously not associated with gingivitis/periodontitis, show good 
correlation with length of gingivitis induction and merit further investigation.  These proteins include 
CRISP3, CALU and ERO1L in the saliva supernatant and LTA4H and PI3 in the saliva residue. 
 











CRISP3  1.00  0.02 ARPC2 1.00 0.02 
CALU  0.97  0.03 BRPF1 1.00 0.02 
ERO1L  0.97  0.03 LTA4H 1.00 0.02 
GAPDHS  0.97  0.03 PI3 1.00 0.02 
GMFG  0.97  0.03 PSMA4 1.00 0.02 
PODXL  0.97  0.03 YWHAE 1.00 0.02 
HMG1L10  0.90  0.08 TCN1 0.97 0.03 
IGHA1  0.90  0.08 AHCY 0.90 0.08 
IGHV1OR15‐1  0.90  0.08 ALDH3A1 0.90 0.08 
IGJ  0.90  0.08 ATP6V1B2 0.90 0.08 
LOC390006  0.90  0.08 CES2 0.90 0.08 
PEBP1  0.90  0.08 DDAH2 0.90 0.08 
PSMA2  0.90  0.08 DSC2 0.90 0.08 
RETN  0.90  0.08 GAPDH 0.90 0.08 
S100A12  0.90  0.08 GDI2 0.90 0.08 
S100A4  0.90  0.08 GPI 0.90 0.08 
S100P  0.90  0.08 GSS 0.90 0.08 
ECGF1  0.87  0.07 HSPA4 0.90 0.08 
TXN  0.87  0.07 LCN1 0.90 0.08 
ACTA1  0.80  0.13 LOC643997 0.90 0.08 
ACTR2  0.80  0.13 LRRFIP1 0.90 0.08 
PSMA3  0.80  0.13 MAPK1 0.90 0.08 
SLPI  0.78  0.20 MDH2 0.90 0.08 
SPRR2C  0.78  0.20 NP 0.90 0.08 
YWHAE  0.78  0.20 PDIA6 0.90 0.08 
ANXA5  0.71  0.40 PFN1 0.90 0.08 
CD55  0.71  0.40 PGD 0.90 0.08 
IGLV7‐46  0.71  0.40 PGLS 0.90 0.08 
SDCBP  0.71  0.40 PSMA1 0.90 0.08 
ADSS  0.70  0.23 PSMA3 0.90 0.08 
CD9  0.70  0.23 REEP5 0.90 0.08 
CFL1  0.70  0.23 RPLP1 0.90 0.08 
CST2  0.70  0.23 S100A7 0.90 0.08 
CST3  0.70  0.23 SPINK5 0.90 0.08 
CST4  0.70  0.23 FLJ25715 0.87 0.10 
CTSC  0.70  0.23 LAD1 0.87 0.10 
DKFZ  0.70  0.23 PFDN2 0.87 0.10 
DMBT1  0.70  0.23 SCAMP2 0.87 0.10 
EDARADD  0.70  0.23 ACPP 0.80 0.13 
FAM3D  0.70  0.23 CAP1 0.80 0.13 
FOLR1  0.70  0.23 CAT 0.80 0.13 
HMGN2  0.70  0.23 DECR1 0.80 0.13 
IGKV3‐20  0.70  0.23 DSTN 0.80 0.13 
IGLL1  0.70  0.23 ENO1 0.80 0.13 
IGLV2‐18  0.70  0.23 ENO2 0.80 0.13 
KLK1  0.70  0.23 ETFA 0.80 0.13 
LOC729708  0.70  0.23 GLOD4 0.80 0.13 
MMP9  0.70  0.23 IGKV4‐1 0.80 0.13 
MSN  0.70  0.23 KLK7 0.80 0.13 
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MYL6  0.70  0.23 MUC2 0.80 0.13 
NPC2  0.70  0.23 NDUFB10 0.80 0.13 
PAM  0.70  0.23 NIPSNAP3A 0.80 0.13 
PFN1  0.70  0.23 NPEPPS 0.80 0.13 
PGAM4  0.70  0.23 PGAM4 0.80 0.13 
PIGR  0.67  0.27 PGK1 0.80 0.13 
PSMA5  0.67  0.27 PITPNB 0.80 0.13 
RAB10  0.67  0.27 PLS3 0.80 0.13 
RDX  0.67  0.27 PPP2R1A 0.80 0.13 
SERPINB1  0.62  0.30 PRDX1 0.80 0.13 
SERPINB3  0.62  0.30 S100A2 0.80 0.13 
ARPC1B  0.60  0.35 SOD1 0.80 0.13 
AZGP1  0.60  0.35 SPRR1B 0.80 0.13 
C6orf58  0.60  0.35 ST13 0.80 0.13 
CD59  0.60  0.35 TGM3 0.80 0.13 
CORO1A  0.60  0.35 TPM4 0.80 0.13 
CST1  0.60  0.35 TUBB2C 0.80 0.13 
CYBB  0.60  0.35 VIL2 0.80 0.13 
FABP5  0.60  0.35 CTSA 0.71 0.40 
GDI2  0.60  0.35 NDUFA11 0.71 0.40 
GRN  0.60  0.35 PKP1 0.71 0.40 
HDGF  0.60  0.35 PLTP 0.71 0.40 
HP  0.60  0.35 PLUNC 0.71 0.40 
IGHG2  0.60  0.35 PRH2 0.71 0.40 
IGKV3D‐11  0.60  0.35 THBS1 0.71 0.40 
IGKV3D‐15  0.60  0.35 ACTN4 0.70 0.23 
IGKV4‐1  0.60  0.35 ACTR2 0.70 0.23 
IGL  0.60  0.35 ALDOA 0.70 0.23 
IGLV3‐25  0.60  0.35 ANXA4 0.70 0.23 
KLK11  0.60  0.35 ARHGDIB 0.70 0.23 
KRT75  0.60  0.35 ARPC3 0.70 0.23 
LGALS3BP  0.60  0.35 ARPC5 0.70 0.23 
LOC440786  0.60  0.35 AZU1 0.70 0.23 
LOC643997  0.60  0.35 CALML3 0.70 0.23 
M6PRBP1  0.60  0.35 CAPG 0.70 0.23 
MFI2  0.60  0.35 CFB 0.70 0.23 
RNASET2  0.60  0.35 CS 0.70 0.23 
SPARCL1  0.60  0.35 CST2 0.70 0.23 
TALDO1  0.60  0.35 CYC1 0.70 0.23 
TPM4  0.60  0.35 DDAH2 0.70 0.23 
VIL2  0.60  0.35 DMBT1 0.70 0.23 
WFDC2  0.60  0.35 DSG1 0.70 0.23 
LTA4H  0.56  0.40 ELA2 0.70 0.23 
NCF4  0.56  0.40 EPX 0.70 0.23 
NME1  0.56  0.40 F3 0.70 0.23 
P4HB  0.56  0.40 HSPA8 0.70 0.23 
ALDOA  0.50  0.45 HSPD1 0.70 0.23 
AMY1A  0.50  0.45 IDH1 0.70 0.23 
BPIL1  0.50  0.45 IGHA1 0.70 0.23 
C7orf24  0.50  0.45 IGJ 0.70 0.23 









5.3.2.2 Induced gingivitis: spectral count comparison of bacterial proteins 
Various bacterial species are associated with gingivitis and periodontitis. As well as considering the 
human portion of the saliva samples from the induced gingivitis trial, the change in abundance of 
bacterial proteins and species was also investigated. The majority of research has concentrated on 
identifying periodontal pathogens using classical culturing techniques or using targeted DNA 
approaches on small sets of putative periodontal pathogens393,394-396. Most studies analysing mouth 
bacteria have used tooth biofilm (plaque). This is the first study to investigate the proteomic 
composition of bacteria in saliva in health and disease states.  
Samples were analysed by correlating the abundance of each bacterial protein to the length of 
gingivitis induction. Many changes in bacterial protein abundance over the course of the induced 
gingivitis trial are observed (Figure 5.8).  Notably, the percentage of bacterial proteins in the saliva 














the  internal standard protein  (rabbit KCM), added prior to protein precipitation,  followed by normalisation to 
the  sum of  the  spectral  counts across all days of gingivitis  induction. Only proteins  that had a  total  spectral 

































































Various bacterial species and genera have been reported to be associated with periodontitis including 
Eubacterium397, Eikenella corrodens393, Bacteroides397, Treponema398, Fusobacterium nucleatum, 
Streptococcus mutans393 and Porphyromonas gingivalis399. As an estimate of the abundance of the 
species and genera, the number of proteins identified for each general/species was used to profile the 
abundance of the bacterial genera/species with the progression of gingivitis. No normalisation of the 
data was performed since ‘protein count’ rather than spectral counting was used as a measure of 
abundance. Whilst there is variation with the progression of gingivitis, a slight increase in a few 
putative periodontal pathogens was observed (Figure 5.9). In previous literature, biofilms of dental 
plaque are used and therefore larger changes might be expected when compared to saliva. Sampling of 
the bacterial biofilms can allow a more complete picture of the microbial ecology whilst analysis of 
the bacteria from saliva is probably only sampling a portion of the bacteria and may underestimate the 
abundance of bacteria present deep in the biofilm/plaque or those which adhere strongly to mouth 
surfaces. Despite this, a positive correlation of many of the periodontal pathogens was obtained. 
 
Figure 5.9   Profile of bacterial abundance with progression of gingivitis. The number of proteins matched  to 
bacterial  species  or  genera  is  used  as  a  measure  of  protein  amount.  No  normalisation  of  the  data  was 
performed since  ‘protein count’  rather  than spectral counting was used as a measure of abundance. Bacteria 
species/genera were selected  from proposed putative periodontal pathogens. Data are  from patient 1  (water 
mouthwash) 
 
The abundance of certain individual bacterial species often rose in parallel with the length of the 
gingivitis induction period (Figure 5.10). Many bacterial species were observed to increase with 
gingivitis progression and, in many cases, species from the same genera cluster together: in particular 






























plotted in Figure 5.11. Of particular interest, the species Haemophilus influenzae and Haemophilus. 
ducreyi show good correlation with induced gingivitis. The Haemophilus genera is in the Gram-
negative proteobacteria phyla and is known to be a key bacterium in the development of bacterial 
biofilms400-401. H. influenzae is known to be found in the upper respiratory system402 and can lead to 
pneumonia and bacterial meningitis, amongst a wide range of diesases. Whilst Haemophilus species 
have not been reported as a periodontal pathogen, H. influenzae has been found in the periodontal 
pockets in immunocompromised patients403, and elderly patients with periodontitis are more 
susceptible to aspiration pneumonia from H. influenza and S, pneumonia infections402. The level of H. 
influenza may therefore be expected to increase with the induction of gingivitis. Interestingly, S. 
pneumoniae was also observed to increase with the induction of gingivitis. 
Various species of Bacteroides increased during gingivitis induction including B. caccae, B. vulgatus, 
B. coprocola. Bacteroides species are anaerobic and have previously been associated with 
periodontitis, particularly B. forsythus216. Porphyromonas gingivalis was previously classified in the 
Bacteroides genera404 and is known to be a key bacterium in the development of periodontitis405-407. 
Very few studies have been performed on bacterial profiling of patients with gingivitis, but P. 
gingivalis is reported to have good correlation with the severity of periodontitis393 and therefore a 
small increase with gingivitis induction may be expected. There are no previous reports linking B. 
caccae, B. vulgatus or B. coprocola with gingivitis/periodontitis and the species are generally 
associated with the intestine and faecal samples408-409. 
Fusobacterium nucleatum was observed to increase with gingivitis induction and is known to be 
involved with dental plaque formation on account of their coaggregation with other oral bacteria. 
Moreover, F. nucleatum has previously been reported to be a key bacterium in periodontitis 216, 287. 
Fusobacterium are gram-negative anaerobes and are involved in the activation of neutrophils410.  
Whilst the mouth is not a natural habitat for E. coli and there are no links with gingivitis, several 
reports have identified the presence of E. coli in periodontal pockets396, 411-413. N. flavescens increases 
to a great extent on day 14 of gingivitis induction. Neisseria are commensal, Gram-negative bacteria 



































































bacterial  species  or  genera  is  used  as  a  measure  of  protein  amount.  No  normalisation  of  the  data  was 
performed since  ‘protein count’  rather  than spectral counting was used as a measure of abundance. Bacteria 
species/genera were  selected  from  the  cluster  diagram  in  Figure  5.10 which  had  good  correlation with  the 
length of gingivitis induction. Data are from patient 1 (water mouthwash). 
 
One potential drawback of this method is that the accurate profiling of bacterial abundance in saliva 
using the single mass spectrometry run in combination with protein number as a measure of bacteria 
abundance suffers from low numbers of proteins identified per species. This may be remedied in the 
future by using spectral counting or isotopic labelling. 
Despite this potential drawback, this proof-of-concept work to investigate bacterial proteins in saliva 
with induced gingivitis has shown that it is possible to profile the abundance of many bacteria in a 
single 2-hour mass spectrometry run per sample. Various bacteria known to be present in greater 
abundance in gingivitis/periodontitis were also increased with the length of gingivitis induction in 
these data. This finding validates this method of quantitating bacterial protein populations in saliva 
and suggests such a method could have future potential in bacterial biomarker discovery. The 
numerous bacteria species correlated with gingivitis induction in these data, but not previously 
reported, suggest that the proliferation and interaction of bacteria with gingival tissues may be more 
complex and widespread than previously believed. The accurate profiling of bacterial abundance in 
saliva using the single 2 hour mass spectrometry run suffers from low numbers of proteins identified 




































5.3.2.3 Induced gingivitis: kinase activity profiling of saliva samples 
Traditional proteomics focuses on protein abundance quantitation. Protein activity levels, as discussed 
in Chapter 4, complement the quantitation of protein abundance and provide an additional avenue of 
exploration. Kinase activity was previously shown to be present in saliva (Chapter 4) and the saliva 
samples from the induced gingivitis trial reported here were subsequently analysed using KAYAK to 
















A general trend of increased kinase activity with the induction of gingivitis was observed in both the 
saliva supernatant and residue. A large decrease in activity was observed on the last day of gingivitis 
induction (day 14). A possible reason for this decrease is that because of the rapidly accelerating 
gingivitis severity in this final sampled day, a greater proportion of the sample was comprised of 
bacterial proteins. Previous proteomic analysis (Section 5.3.2.2) showed that the number of bacterial 
proteins identified on day 14 in the saliva residue was twofold higher than previous samples (Figure 
5.8). Therefore, the lysate on day 14 would be expected to contain a lower proportion of human 
proteins. Assuming the kinase assay only measures the human kinase activities with no contribution 
from bacterial kinases, this observed decrease is logical. The decrease in kinase activity on day 14 was 
particularly evident in the saliva residue, consistent with the large increase in proportion of proteins 
matched to bacteria. To allow easier comparison of the different kinase profiles, day 14 was omitted in 
the final analysis and days 1 to 12 were profiled and clustered together (Figure 5.13).  
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In the saliva residue a large increase in kinase activity from day 1 to day 7 was observed, particularly 
for PKA and kinases targeting the basophilic substrate peptides (AA and BB respectively). PKC 
activity (CC substrate peptides) increased during days 7 to 9 of gingivitis induction. In the saliva 
residue, the kinase activities were generally higher than those in the supernatant (Figure 5.13c and d) 
and large increases in kinase activities were observed on the last day (day 12) compared to the 
supernatant, where a more gradual increase in kinase activity was observed. 
The observed increase in kinase activity with gingivitis induction is likely to be as a result of 
activation of inflammatory signal pathways. Various kinases are thought to play a significant role in 
the activation and expression of inflammatory mediators, including the kinases IKK2, MAPK and PI3 
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kinase which can regulate inflammation through the activation of pro-inflammatory transcription 
factors such as NF-κB (nuclear factor κB) and AP-1 (activating protein-1). Porphyromonas gingivalis 
is known to activate the proinflammatory transcription factor NK-κB pathway, partly through the PI3 
kinase/AKT pathway415. This is known to be followed by increased expression of anti-apoptotic genes 
and in the later stages of infection by increased pro-apoptotic genes415-417.  
The origin of kinase activity in the saliva supernatant is likely to be due to lysed cells, either through 
apoptosis or necrosis. Increased inflammation can lead to increased apoptosis which may explain the 
increased kinase activity in the saliva supernatant. Increased kinase activity in the saliva residue may 
be due to the presence of greater numbers of neutrophils in gingival tissue as well as the ‘sloughing 
off’ of gingival cells due to increased inflammation.   
Various kinases were observed in the saliva supernatant and residue. In order to determine putative 
kinases responsible for the kinase activities observed during the course of gingivitis induction, the 
kinase activity and kinase abundance profiles were compared. Unfortunately, good correlation was not 
obtained on account of very low spectral counts of the kinases (data not shown). For future studies, 
the low-abundance kinases may be enriched by using hexapeptide libraries on beads (Proteominer, 
Biorad)107, through immunodepletion of highly abundant proteins to allow better quantitation, or via 
fractionation of the saliva. Alternatively, more accurate quantitation methods (e.g. using AQUA 
peptides for each of the kinases) could be performed. 
This proof-of-concept work indicates that kinase activity may be useful in investigating the changes in 
kinase activities during the course of gingivitis, and illustrates the potential of KAYAK to be 
performed in body fluids. For future studies it would be informative to separate the bacterial and 
human cells in saliva prior to cell lysis to enable the concentrations of human and bacterial proteins to 
be determined separately. Also, kinase activity profiling of gingival cells (cell culture) infected with 
putative periodontal pathogens could help elucidate the effect of the pathogen on the signalling 
pathways in the gingival cells. 
 
5.4 Conclusions 
The discovery of accurate biomarkers linked to the severity of gingivitis and periodontitis has 
important implications for patient care and management of the disease, as well as for the evaluation of 
different treatments and oral care hygiene. Various proof-of-concept techniques for the discovery of 
gingivitis biomarkers are reported here: saliva supernatant and saliva residue were evaluated using 
proteomics and the protein abundance of both the human and bacterial proteins were considered. 
Kinase activity profiling was performed on both the saliva supernatant and residue. 
In the analysis of the first set of clinical samples from an internal Procter & Gamble clinical trial, the 
saliva samples from the healthy and gingivitis subjects were pooled, the saliva was fractionated into 
165 
 
10 gel pieces and analysed by GeLC-MSMS as well as being analysed individually by in-solution 
digestion and LC-MSMS. A large degree of individual variation was found and no significant changes 
in protein abundance in saliva between control and gingivitis subjects were clearly identified. In the 
induced gingivitis longitudinal clinical trial performed at the Eastman Dental Institute, inter-person 
variability was reduced and a time-profile of the changes in protein abundance in both the saliva 
supernatant and residue was obtained. On account of the large number of samples, fractionation was 
not feasible in terms of instrument time and analysis was performed using in solution LC-MSMS.  
Various proteins previously reported to increase with gingivitis/periodontitis were also observed to 
increase with the induction of gingivitis; these proteins included MMP9, LDH, IL1F5, IL1F6, various 
members of S100, cystatin and cathepsin protein families, as well as various bacteria including 
Fusobacterium nucleatum and Porphyromonas gingivalis. Various new potential salivary biomarkers 
that merit further investigation include CRISP3, CALU and ERO1L proteins in the saliva supernatant, 
and LTA4H and PI3 proteins and Haemophilus influenza and H. ducreyi in the saliva residue.  
Ideally, measuring the abundance of numerous human and bacterial biomarkers would allow for the 
accurate diagnosis and assessment of the severity of gingivitis. Utilising both host-response and 
pathogen biomarkers is likely to lead to the most accurate predictions of disease state and to allow the 
effectiveness of new drugs/oral care additives to be evaluated. Although not all the data from the 
induced gingivitis study could be included due to confidentiality, the analysis of one patient on a 
water treatment demonstrates the viability of this technique.  These results suggest that a 2-hour mass 
spectrometric analysis of one sample can provide adequate information (around 600-1000 saliva 
proteins) for protein profiling of human and bacterial proteins.  
To the author’s knowledge, this is the first reported comparison study of induced gingivitis in humans 
using mass spectrometry based proteomics, as well as the first time that the saliva residue and bacteria 
have been assessed for biomarker discovery using proteomics. Kinase profiling of saliva in health and 
disease has not previously been attempted and may offer a promising alternative technique for 
biomarker discovery in saliva. These novel techniques lay the foundation for further development of 
diagnostic and prognostic tools and may provide fundamental insights into the cellular dynamics of 








The specific aims of this PhD project were the application of mass spectrometry technology to:  
a) investigate the salivary proteome and develop a workflow for salivary biomarker discovery, 
and  
b) optimise and develop a functional protein assay for measuring multiple kinase activities for 
kinome profiling. 
With respect to the first aim, a number of methods were utilised to quantify various aspects of protein 
abundance within different portions of saliva.  A saliva sample from a single individual was analysed 
using GeLC-MSMS proteomics. The saliva was split into the soluble portion, termed supernatant, and 
the insoluble portion, termed residue; and the two fractions were analysed for both human and 
bacterial proteins. A total of 834 and 1,426 human proteins in the saliva supernatant and residue 
respectively were identified. A large degree of overlap was observed between the saliva supernatant 
and residue, indicating that a significant proportion of the salivary supernatant proteins may originate 
from lysed cells.  
By further examining the origins of the identified proteins (human or bacteria) revealed surprising 
numbers of bacterial species present in salivary fluids.  Individual saliva samples from six patients 
were collected during a two week period of gingivitis induction in which five saliva samples were 
taken for each subject. Of the 2,654 proteins identified in the saliva residue, 1,378 were of human 
origin and 1,274 were from bacteria. Proportionally, the number of proteins of bacterial origin 
identified in saliva from a single healthy individual (9%) was almost five times lower than the number 
identified in six individuals in whom gingivitis was being induced.  In the analysis of the saliva 
residue from six patients taken over a course of two weeks almost half of all the proteins identified in 
the saliva residue were from bacteria (48%). The high proportion of bacterial proteins in the saliva 
residue is likely due the effects of gingivitis inductions as well as the greater diversity of bacterial 
species between individual subjects. In this analysis, a total of 198 bacterial species were identified; 
this value is much higher than values previously reported by Xie, et al. (2008) in which 34 bacterial 
species were identified211. Proteomics research has, up until now, largely ignored the potential clinical 
and basic-science benefits of studying saliva residue and the bacterial proteome using proteomic tools. 
This study highlights the potential of using the saliva residue as a sample for biomarker studies and 
identifies that the bacterial component is a significant contributor to the proteins identified in the 
saliva residue. This indicates that future saliva studies may benefit from considering both bacterial and 




The presence of protein complexes in saliva was also investigated to gain insight into intracellular 
protein interactions. Following successful proof-of-concept work to profile protein complexes in 
whole cell lysate using BN PAGE and LC-MSMS278, this technique was applied to investigate the 
presence of protein complexes in saliva. The presence of two main protein complexes were observed: 
one comprising predominately immunoglobulins, amylase and the kinase RIPK4, and the second 
containing mainly enzymes including LPO, MDH2, GADPH, CAT, ALDOA, CA6, PP1B and LTF. 
The technique of protein correlation profiling using BN PAGE was extended to measure the relative 
protein turnover of proteasomal proteins present in different proteasomal subunits using a modified 
SILAC experiment. The result of the extended BN PAGE SILAC experiment showed that the 
formation of the BP1 complex was faster than that of the 26S proteasome. This supports the previous 
finding that PSMD5 is a molecular chaperone involved in the formation of the BP1 complex 
(Appendix A.1)278.  The success in identifying such protein complexes validates the BN PAGE protein 
correlation profiling technique, and demonstrates that this approach can be useful for investigating the 
protein composition of complexes and native protein-protein interactions. Furthermore, estimation of 
specific protein/protein-complex turnover rates in conjunction with isotopic labelling may be 
performed utilising BN PAGE protein correlation profiling. 
To address the second major aim of this PhD project, a mass spectrometry based assay that measured 
multiple kinase activities analysis (KAYAK) was further developed and optimised. A new set of 
substrate peptides for the assay was investigated and the use of KAYAK was extended beyond that of 
human cell lysate to applications on various organisms including mouse, Drosophila and yeast. 
Significant kinase activity was also observed in both the saliva supernatant and residue using 
KAYAK. The success in applying KAYAK to a range of organisms and body fluid types 
demonstrates the tractability of the KAYAK method. The ease of application of KAYAK is 
significant for future applications of the method; production of test-kits for disease and cancer 
diagnosis, or a high-throughput 96-well plate assay for high throughput drug and kinase inhibitor 
screening are two possible applications of KAYAK. It is important to note that protein 
phosphorylation is not the only disease-relevant form of protein modification. Hundreds of different 
intracellular protein modifications exist, and a long term goal of the KAYAK method is to modify the 
assay to profile other types of activities, such as phosphatases and proteases. 
To combine traditional proteomic analysis with this new KAYAK technique, in-gel kinase 
activity/kinase abundance correlation profiling using BN PAGE was performed. Kinase activity was 
observed following BN PAGE and various known kinase-substrate pairs were identified. 
Unfortunately, this procedure suffered due to the poor resolution of the BN PAGE but was useful for 
samples of lower complexity. For global proteome samples an alternative approach using AEX protein 
separation kinase activity/kinase abundance correlation profiling was used in this study. Using AEX 
separation the protein fractions were analysed using KAYAK to obtain kinase activity profiles, and by 
shotgun proteomics to obtain kinase abundance profiles. The kinase activity and kinase abundance 
profiles were correlated to match up substrate peptides and responsible kinases. Candidate kinases for 
168 
 
a number of documented hyperphosphorylated mitotic proteins from a recent phosphoproteomics 
study176 without an identified cognate kinase were identified using this correlation profiling approach. 
After identification of potential kinase-substrate pairs using correlation profiling, pairs were validated 
using several different techniques.  Putative kinase-substrate pairs were validated using in vitro kinase 
assays, overexpression of recombinant kinase, and siRNA knock down of the endogenous kinases. 
PAK3 was identified as the most likely candidate kinase for phosphorylation of the peptide substrate 
HFRNVHsEDFENR derived from the protein ADNP. The proposed phosphorylation of ADNP by 
PAK3 is of interest since PAK3 is thought to have some effect in neuronal cells and ADNP is known 
to be critical for brain and neuron development and this work could offer a link between these two 
proteins. PLK1 is the candidate kinase for the phosphorylation of the peptide substrates 
DDFKLNSsIVEPK, IEKLNSsLHFLQQ and AQHPDYsFGELSR that are derived from the proteins 
NFKB2, CAMSAP1L1 and PB1 respectively. PLK1 is highly upregulated in mitosis but has not 
previously been associated with the phosphorylation of NFKB2, CAMSAP1L1 or PB1. The putative 
phosphorylation of NFKB2 could be an important finding, since NFKB2 is a key transcription factor 
and very little is known about the transcriptional control of the cell cycle. This study has shown that 
by starting with a ‘hit’ from a phosphoproteomics experiment, kinase activity/kinase abundance 
correlation profiling can lead to the identification of putative kinases responsible for the protein 
phosphorylation. 
As a way of applying these aforementioned techniques for potential gingivitis biomarker discovery, 
saliva samples from an induced gingivitis trial were analysed using proteomics to examine protein 
abundance and using KAYAK to obtain kinase activity profiles. The changes in the abundance of 
human and bacterial proteins in both the saliva supernatant and residue were profiled using spectral 
counting label-free proteomics. The kinase activities in both the supernatant and residue were 
determined using KAYAK. This work is ongoing, however preliminary data is promising. Several 
protein abundances and activities show a clear trend after the induction of gingivitis. Specific 
examples include the induction of MMP9, LDH, IL1F5, IL1F6, various members of S100, cystatin 
and cathepsin protein families, which have all been previously documented as induced or increased 
upon gingivitis/periodontitis. Similarly, various bacteria documented to increase in gingivitis, 
including Fusobacterium nucleatum and Porphyromonas gingivalis, were also increased in this study. 
Although the statistical power of this study was low (one patient) and clearly needs to be performed 
with a greater number of subjects, the confirmation of similar trends observed in the literature helps to 
validate this method and offers the opportunity for new biomarkers to be identified. In particular, 
CRISP3, CALU and ERO1L proteins in the saliva supernatant, and LTA4H and PI3 proteins and the 
species Haemophilus influenza and H. ducreyi in the saliva residue show good positive correlation 
with gingivitis induction and merit further investigation as potential new gingivitis biomarkers.  
To discover not only protein abundance biomarkers, but potential protein activity biomarkers for 
gingivitis, a KAYAK assay was performed using these same saliva samples.  A general increase in 
kinase activity was observed in both the saliva supernatant and residue with the induction of 
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gingivitis. This may be explained by the increased inflammation gingivitis causes as it progresses. 
Inflammation leads to an influx of leukocytes into gingival tissues, an activation of inflammatory cell 
signalling pathways, a release of inflammatory cytokines, and results in increased apoptosis/lysis. The 
increase in kinase activity in the saliva supernatant may be explained by this increase in gingival cell 
lysis, whilst the increase in kinase activity in the saliva residue is likely to be due to greater activation 
of inflammatory cell signalling pathways. We would expect different signalling pathways to be 
regulated differently during gingivitis induction, which is consistent with the varying kinase substrate 
activity profiles seen in the results presented in this thesis. This proof-of-concept work indicates that 
kinase activity profiling may be useful to monitor the extent of inflammation with gingivitis induction 
and could be useful in other inflammatory diseases like atherosclerosis, arthritis and autoimmune 
diseases. 
It is important to note that the saliva residue contains many different cell types and is not a 
homogeneous mixture. Future profiling of the saliva residue would benefit from characterisation and 
separation of the human and bacterial cells to enable more accurate quantitation of changes in protein 
abundance against a background of human and bacterial proteins, respectively. With kinase activity 
profiling, it is especially important to determine an accurate human protein amount, since kinase 
activity originates predominately from human cells. It would also be of interest to profile the different 
types and proportions of human cells comprising the residue, for example leukocytes and gingival 
cells.  
This PhD project has involved mass spectrometry to study a variety of systems using both ‘classical 
proteomics’ to quantitate protein abundance and ‘functional proteomics’ to profile kinase activities. 
Although the project has been based around gingivitis biomarker discovery in saliva, a wide variety of 
projects have evolved, merged and mixed with this original project aim. The merging of the KAYAK 
project with saliva biomarker discovery not only shows that KAYAK can be performed in body fluids 
and diagnostic information can be obtained on the state of inflammation, but it also offers huge 
potential for the functional protein profiling in saliva for other enzyme classes since the KAYAK 
strategy can be adapted to other enzyme classes. By utilising this project as a foundation, a long-term 
goal is the development of a ‘gingivitis spit test’. Further development of a gingivitis spit test would 
benefit greatly from the expansion of the KAYAK method to a protease activity assay, which is the 
aim of the next stage of the KAYAK project.   
Many diseases, not only gingivitis and periodontitis, involve a complex interplay between bacterial 
and host responses. Therefore, to obtain a full picture of the diseases, it is useful to consider both the 
human and bacterial protein changes, along with protein activity measurements. The combination of 
both a functional protein assay and proteomic data is a unique way to search for biomarkers and offers 
great potential for future biomarker studies, as well as affords greater accuracy and specificity in 
biomarker analysis and diagnostics. 
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6.2 Concluding remarks 
My time was divided between two main projects: a) investigating the salivary proteome and b) the 
development and optimisation of a multiplexed kinase assay using mass spectrometry: Kinase 
ActivitY Assay for Kinome profiling (KAYAK). Whilst these two seemingly disparate projects 
appear to have little in common, each of the projects has benefited from the other: the application of 
KAYAK to saliva has shown the presence of significant kinase activity in saliva, which has been 
previously unseen. This expands the future potential use of KAYAK on body fluids as well as 
showing the application of a new technique that can be applied to salivary biomarker discovery.   
 
6.2.1 A short chronology of my PhD 
I have been extremely fortunate to have had the opportunity to be based in two different mass 
spectrometry research groups: Dr Perdita Barran’s group in the Chemistry Department at The 
University of Edinburgh (UoE) and Prof. Steven Gygi’s group in the Cell Biology Department at 
Harvard Medical School (HMS). The first two years of my PhD were spent in the Barran group at 
UoE and involved familiarising myself with various different mass spectrometry and HPLC 
equipment. I was able to gain experience using an Applied Biosystems MALDI Voyager, a Waters 
Ultima QTOF, a Bruker High Capacity Ion trap and a Bruker 12T FTICR mass spectrometer. HPLC 
systems used included a Waters CapLC, Dionex Ultimate, Eksigent nano, Proxeon’s ‘Easy’ nanoLC 
and the Dionex 3000 system. My subsequent two years work in the Gygi lab balanced this useful 
experience in Edinburgh of ‘hands-on’ mass spectrometry with a greater focus on biological 
application. The instrument set up at HMS comprised predominately Thermo LTQ Orbitrap mass 
spectrometers and Agilent HPLC systems. 
In the course of my first year at Edinburgh I experimented with analysing my own saliva on the 
MALDI Voyager and Waters QTOF and investigating different ways to prepare saliva. This was 
helped by a week’s trip to Prof. Joe Loo’s lab at UCLA (University of California, Los Angeles) in 
December 2006 where they were working on the salivary proteome. I compared the saliva from 
several healthy people qualitatively using SDS-PAGE gels, and the amount of variation between 
people was clearly evident. During my second year at Edinburgh, I used predominately the Bruker 
HCT and FTICR mass spectrometer and focused on label-free quantitation to establish a work flow 
for biomarker discovery. Since the aim was to develop a platform for the analysis of a large number of 
samples, the plan was to use intensity based label-free quantitation. I attempted a comparison of three 
label-free software packages to determine which one would be most appropriate for the available mass 
spectrometers. Near the end of my second year I obtained saliva samples from healthy people and 
gingivitis sufferers from an internal P&G clinical trial. Knowing that the bacteria played a significant 
role in gingivitis, I became interested in analysing both the supernatant and the pellet remaining after 
centrifugation (the residue) as I thought that the most dramatic changes might be observed in the pellet 
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which contained the majority of the bacterial cells. One of the problems in the analysis of the pellet 
was the ‘contamination’ of the bacteria with insoluble human proteins, such as mucin, and it was 
difficult to obtain adequate separation. Through collaboration with the Eastman Dental Institute in 
London, I was able to investigate the bacterial portion more thoroughly by analysing the bacterial 
pellicle obtained from an artificial mouth model of gingivitis. Saliva was also cultured to increase the 
proportion of bacterial proteins over the ‘contaminating’ human ones. These initial analyses of 
salivary bacteria led to the probable detection of archaea in saliva. Realising that the salivary 
proteome was too complex to be analysed quantitatively in a single run, and that intensity based label-
free quantitation with fractionation was currently too complicated for the equipment and 
bioinformatics resources available, I then considered analysing only a fraction of the salivary 
proteome, the phosphoprotein portion of saliva.  
I moved to HMS in September 2008 and spent the third and fourth year of my PhD in the Gygi 
laboratory, where my time was spent both on saliva and a functional protein assay to measure kinase 
activities. For saliva, the proteome of both the supernatant and residue was investigated using GeLC-
MSMS on an LTQ-Orbitrap. I carried out a comparison of the healthy and gingivitis saliva from the 
P&G internal trial. For quantitation I used spectral counting which allowed the fractionation of the 
sample and the identification of more proteins, whilst also the ability to quantify them, rather than the 
ion intensities method previously used at UoE.  
Alongside my work on saliva, I worked on the new Kinase ActivitY Assay for Kinome profiling 
(KAYAK) technique which was being developed in the Gygi laboratory. The original assay used a 
collection of 90 substrate peptides. My projects involved evaluating a new substrate set comprising 60 
peptides and applying the assay to a variety of systems and biological problems. Kinase activities in 
12 human cell lysates were profiled and many differences were observed, each having a unique kinase 
activity signature. Kinase activity profiles in mice, Drosophila and yeast were also profiled under 
various biological conditions. 
As well as the ‘standard’ KAYAK reaction, one of my projects involved proof-of-concept work to 
determine whether in-gel KAYAK was feasible and whether kinase activity/kinase abundance 
correlation profiling could be performed using blue native gels. One of the first steps in evaluating the 
method was to determine whether protein complexes remained intact following blue native 
polyacrylamide electrophoresis. The profiles of the proteins in the proteasome complex were 
investigated and, as well as showing that the complex remained intact, the method provided 
confirmation of the presence of the BP1 complex278. However, one of the main problems with this 
correlation technique was the poor resolution of the blue native gels which limited applicability of the 
correlation profiling method. An alternative chromatographic separation technique, anion exchange 
chromatography, was used instead to search for kinase-substrate pairs. The candidate kinase-substrate 
pairs were evaluated using several molecular biology techniques including overexpression using 
Gateway cloning and siRNA knock down. A slight variation of the kinase activity/kinase abundance 
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correlation profiling method was investigated using mouse tissues where the kinase activities in nine 
mouse tissues were compared with the kinase abundance. 
During my tenure in the Gygi lab, I received saliva samples from an induced gingivitis clinical trial at 
the Eastman Dental Institute (London, UK). Having gained experience with the kinase acitivity assay, 
KAYAK, I applied this assay to monitor the changes in kinase activities during the induction of 
gingivitis. The induced gingivitis saliva samples were also investigated using proteomics: both the 
saliva supernatant and residue being analysed using LC-MSMS. The protein abundance was 
calculated using spectral counting and both human and bacterial proteins investigated. 
 
6.2.2 Collaborative work 
One of the advantages of working in a research area which involves highly technical instrumentation, 
such as mass spectrometry, is that the facilities are very much in demand by research groups needing 
analysis of their samples. This stimulates various collaborations with more biologically orientated 
research groups. In both the Barran and Gygi lab, I was involved in a variety of collaborations; many 
such collaborations were closely related to my work while others were often very different.  
During my time with the Barran laboratory, I was involved with a Caenorhabditis elegans proteomics 
project which was part of the SCIBS (Selective Chemical Intervention in Biological Systems 
Initiative) project (involving the Walkinshaw group at Edinburgh, the Page group at the Institute of 
Comparative Medicine at Glasgow and the Turner group at Manchester); a sputum proteomics project 
with Dr Robert Gray of the Western Hospital in Edinburgh; a urine proteomics exosome project with 
Dr James Dear at the Edinburgh Royal Infirmary, and a mass spectrometry cross-linking project with 
Dr Malcolm Lyon in Manchester. 
During my time in the Gygi group, I was also involved with several collaborations. A collaboration 
with the Finley lab (Cell Biology, HMS) involving the proteasome evolved from my work studying 
complexes with BN PAGE278. Another collaboration involved investigating the pupylome (the 
proteome of PUPylated proteins where PUP is a ubiquitin-like protein in prokaryotes) with the Darwin 
group at NYU School of Medicine418. I was involved with various collaborations directly related to 
KAYAK: a collaboration with the Perrimon lab (Genetics, HMS) involving Drosophila, the 
Weinstock lab (Dana Farber Cancer Institute, Boston) on leukaemia, and the Flier lab (HMS) on mice 
treated with fibroblast growth factor. I was also involved in a collaboration with Merck Research 
laboratories to develop an assay for atypical PKCs along with a post-doctoral fellow in the Gygi lab, 




6.2.3 Final remarks 
The original objective on starting this PhD was to find biomarkers for gingivitis. Whilst the ‘perfect 
solution’ of a gingivitis assay has not yet been achieved, the skills developed along the way may form 
the foundation for future development of such tools. This work may allow for methods which move 
beyond the traditional large scale proteomics ‘healthy’ versus ‘diseased’ comparison. Development of 
the functional protein assay for kinase activities using mass spectrometry (KAYAK) uses a strategy 
that can be applied to any enzyme class. The development of an assay for protease activity would 
offer huge diagnostic potential for gingivitis because saliva is highly abundant in such proteases.  
Protease activity can lead to receding gums, one of the symptoms of gingivitis, and quantifying this 
activity may be an efficient method of measuring the severity of the condition. Future work will 
concentrate on developing such a diagnostic tool. While the projects pursued in the course of this PhD 
may at first glance seem relatively unrelated, taken together, they add novel and fundamental pieces to 
the puzzle of the eventual development of sensitive and specific body fluid assays.  In particular, a 
saliva based ‘gingivitis assay’ may benefit from the techniques presented here, and potential new 
biomarkers for the progression of this disease.  
Whilst gingivitis does not appear at first sight to be a very exciting disease in comparison to diseases 
with higher mortality or morbidity, gingivitis affects a very large proportion of the population. The 
majority of treatments and investment are targeted towards reparative dentistry, rather than 
preventative measures, predominately due to fiscal incentives and the dental healthcare system. With 
good biomarkers and a better understanding of gingivitis and its progression to periodontitis, it is 
hoped that in the future dentistry products and care will focus more on preventative measures rather 
than expensive reparative ones. As with many medical treatments, early diagnosis and investment at 
the start should reduce the need for expensive late-stage care. It is likely that the oral microbiome 
plays a key role in the development of gingivitis and periodontitis. Once the key bacteria for a healthy 
mouth flora are determined, it may be envisioned that following an oral cleansing with chlorhexidine 
or a broad spectrum antibiotic, the oral microbiota could be repopulated with ‘healthy bacteria’ either 
in the form of a ‘probiotic’ drink or by direct coating of the mouth surfaces.  
A note on the ‘evolution’ of the induced gingivitis project: during my ‘Year In Industry’ at P&G’s 
Brussels Innovation Centre in 2004/05 I had a keen interest in undertaking a PhD which had the 
potential for translation into practical useful applications. After P&G kindly offered to support my 
PhD there were numerous ideas for projects: from the development of an ‘active’ to put into 
detergents to kill bed bugs, to a ‘probiotic’ drink’ containing certain bacteria that could be given to 
children to reduce their risk of developing allergies. Having no real understanding of what a 
biomarker was, a telephone call with P&G suggesting a project in oral biomarkers led me to believe 
they desired something similar to the ‘blue tablet’ given by the dentist to stain the plaque on your teeth 
blue (which you then spend time trying to remove by brushing your teeth very thoroughly). However, 
a better understanding of the very wide uses of biomarkers made the project very appealing and has 
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given me exposure to a wide variety of fields. My original degree from the University of Edinburgh in 
‘Chemistry with Industrial Experience’ included very little biology, which I had previously only 
studied to AS level at secondary school. This PhD project has stimulated me to study independently 
relevant areas of the subject and led to appreciate the application of chemical methodology to 
biological problems. My future contribution to biological research is strengthened, I feel, by my 
knowledge of chemistry. It can be strengthened further by combining this knowledge with the 
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A. Collaborative work 
Aside from the two main projects on saliva and KAYAK, I was involved with various collaborative 
projects. A short description of my contribution to the main collaborative projects is given below. 


















This was a collaboration with Dr Jeroen Roelofs at Harvard Medical School investigating the 
proteasome. As part of the work on the blue native PAGE gels for the in-gel KAYAK correlation 
profiling project (Section 2.7.7.1), one of the preliminary steps was to determine what complexes were 
observed. By plotting the spectral count of each of the proteins against each of the gel fractions it was 
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possible to detect various protein complexes. All proteasome subunits could be identified in fractions 
1 and 2, indicating that completely assembled proteasomes were present in these fractions (Figure 
A.1). Many of the proteasome subunits were also present in different fractions of lower molecular 
weight. Further analysis showed that proteasomal proteins known to belong to a specific subcomplex 
have similar profiles (Figure A.1 a-d). For example, all subunits of the proteasome core particle (CP) 
were abundant in fractions 1 and 2 as components of assembled proteasomes (26S), but also in 
fraction 3. Fraction 3 lacks proteasome subunits from the other proteasome subcomplexes, the base 
and the lid, suggesting that this complex is assembled CP. All lid components showed a similar 
pattern to one another and could be found in fractions 1, 2 and 4, indicating that in fraction four we 
identified assembled lid. A base complex was not detected but, interestingly, four proteins that are 
thought to comprise the BP1 complex, an intermediate in base assembly, were detected in fraction 4 















Coommassie  blue  and  the  lane  was  divided  into  ten  equal  size  pieces;  all  pieces  were  analyzed  by mass 
spectrometry and protein abundance was determined using spectral counting. Graphs (a‐d) display the results 
for  most  proteasome  subunits  and  graph  (e)  comprises  an  average  of  all  the  proteins  in  the  different 
proteasomal components. Profiles of abundance can be divided into four groups: CP (alpha 1‐7 and  beta1‐7); lid 
(Rpn3‐11); base2  (consisting of Rpt3,4,5,6 and  rpn2);   Base1    (consisting of Rpt1,2, and Rpn1). All groups are 
present  in  fractions  1  and  2, where  26S  proteasomes  are  expected  to migrate.  Fraction  3  contains  a  high 
abundance of CP, while  the other  groups have  a  very  low  abundance,  indicating  the  location of  free CP.  In 
fraction 4  there  is a specific high abundance of  the subunits  from group base1, while other subunits  (base 2 
group) are very  low  in abundance. S5b  (PSMD5) shows a unique profile, being absent  for the  fractions where 
26S proteasomes migrate and only abundant  in the fraction where base 1  is present. These data suggest that 







Subsequent to publication of the paper, further work was carried out to investigate the BP1 complex in 
more detail. 26S proteasome consumes BP1 and therefore it would be expected that the turnover of 
BP1 would be faster than that of the 26S proteasomes. It has previously been shown by pulse-labelling 
in yeast that 35S-labelled BP1 decreases significantly compared to the other proteasome proteins in 
just 30 mins and is thought to be an in vivo assembly intermediate1. Several SILAC experiments were 
performed to determine the rate of turnover of the various proteins that comprise the BP1 complex. 
The traditional method for measuring protein degradation is to use a ‘pulse-chase’ type of experiment 
where cells are ‘pulse’-labelled with radioactive elements such as 35S which is present in the growth 
media. Following sufficient labelling, the cells are then ‘chased’ with normal media containing no 
radioactive elements. By collecting cell lysate at periodic time points, isolating the protein of interest 
(immuno- or affinity tag purification) and determining the amount of radioactivity (scintillation 
counting) over time, it is possible to determine the rate of degradation of a particular protein. During 
the ‘chase’ part of the experiment, the radioactive-labelled proteins are degraded and replaced with 
proteins that do not contain radioactive elements and, therefore, are not included in the radioactive 
measurements. 
An alternative approach is to use SILAC where, instead of the ‘pulse-labelling’ being with radioactive 
35S, stable isotope labels are used. By measuring the ratio of heavy to light peptides, the protein flux 
can be determined. This is slightly different from measuring the degradation rate using the radioactive 
pulse-chase since in the ‘chase’ part of the experiment as the cells grow, newly synthesised proteins 
effectively ‘dilute’ the original ‘pulse’-labelled proteins, and therefore the protein flux is measured 
rather than the protein degradation rate. However, by considering the growth rate of the cells, an 
estimate of the protein degradation can be obtained as described2. 
My contribution to the project was to determine the rate of incorporation of the four proteins into the 
BP1 complex, and involved a small modification of the classic SILAC protocol. HeLa lysate was run 
on a BN gel to preserve complexes. The rate of incorporation of heavy leucine in the BP1 complex, as 
well as in the full proteasome complex, was determined for the four proteins of interest (PSMC1, 
PSMC2, PSMD2 and PSMD5), the percentage incorporation of ‘heavy’ leucine over time being 
determined. HeLa cells were grown in ‘light media’ (containing naturally- light leucine) and were 
switched over to ‘heavy media’ (containing ‘heavy’ leucine) at the start of the time course. Cells were 
harvested and lysed at different time points. By measuring the heavy/light ratio of the leucine 
containing peptides, an indication of protein degradation rate and turnover was obtained. It would be 
expected that the proteins in the BP1 complex would have a higher turnover rate than the proteins in 
the proteasome.  
In total, three modified SILAC experiments were performed. The first SILAC experiment used time 
points between 0 and 150 min (0, 5, 15, 30, 60 and 150 mins) but unfortunately very little heavy 
leucine incorporation was observed. The second SILAC experiment used time points between 0 and 
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1440 min (0, 60, 105, 150, 195 and 1440 mins) but heavy leucine incorporation was only observed for 
the later time points. The third SILAC experiment used time points of 0 to 48 hours (0, 4, 8, 12, 18, 24 
and 48 hours). It was originally thought that the turnover of the BP1 complex would be fairly fast, 
hence the short time frames chosen initially. However, the delayed uptake of heavy amino acids might 
explain the slower dynamics2. Various rationales have been postulated to explain this delay in the 
uptake of heavy amino acids, although the exact reasons for this are not known. It could be due to 
amino acid recycling, since if the intracellular stores of light leucine are significantly high at the start 
of the ‘chase’ phase this could result in a ‘blurred’ transition between the ‘pulse’ and ‘chase’ phases. 
Another reason could be that some nascent proteins are more unstable than the more mature 
equivalent proteins which are already in complexes (and which contain light leucine). This has, for 
example, been shown for proteins that have problematic tertiary folding3-5. Other cellular functions 
that could explain the delay in uptake and the delay in synthesis include mRNA transport and 
regulated translation intitiation6-7. However, since the HeLa cells were asynchronous, these factors 
should not have had a significant effect. 
The main challenge with this experiment was data extraction and quantification. The data were 
initially quantitated using Vista, an in-house software suite for quantitation of isotopically labelled 
proteins2, 8. Another challenge was that the proteins comprising the BP1 complex were not particularly 
abundant and therefore it was not always possible to identify them for all the time points. Even if a 
protein is identified at every time point, the particular peptides detected might be different. It is not 
ideal, and it is actually invalid to assess protein degradation from the labelling of different component 
peptides across the different fractions. To improve detection of all the BP1 complex proteins at all 
time points, an inclusion list of the peptide m/z values (2+, 3+) was generated and the samples run 
with the inclusion list to try to ensure that the same peptides were identified in each fraction. Despite 
identifying many more peptides, all the time points were still not covered. 
A solution to the data analysis problems was to use an alternative method of analysis: to quantitate 
using a specific heavy/light peptide using the peptide EIC in Quanbrowser (Xcalibur), similar to the 
method used for KAYAK quantitation, rather than relying peptide detection by MSMS. This manual 
approach was time consuming and therefore only one/two peptides per protein were quantitated. 
However, it meant that the proteins could be quantitated at each time point and the initial results were 
very promising (Figure A.2). The percentage incorporation of heavy leucine was determined for 
PSMC1 and PSMC2 in both the BP1 complex (gel slice 5: PSMC1_5, PSMC1_5) as well as in the 
26S proteasome (gel slice 2: PSMC1_2, PSMC1_2). The rate of heavy leucine incorporation was 
much faster for the proteins in the BP1 assembly complex compared to the 26S proteasome, 
suggesting that the formation of the BP1 complex is much faster than that of the 26S proteasome 
complex. PSMD5 was only found in the BP1 complex and not in the 26S proteasome, which is 
consistent with the hypothesised molecular chaperone function of PSMD5. The rate of heavy leucine 
incorporation into PSMD5 is similar to that of the proteins in the 26S proteasomes, which was 
expected, since PSMD5 is a molecular chaperone and is ‘recycled’ and does not end up in the final 
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26S complex. Therefore, PSMD5 was expected to have a lower heavy leucine incorporation rate than 
the other constituents of the BP1 complex (that end up finally in the 26S proteasome) and for this 
reason would need to have a higher synthesis rate. This is consistent with the model for base assembly 














Figure A.2   Percentage  incorporation of heavy  leucine over a period of 48 hours. Av PSMC1_2  indicates  the 















As part of a collaboration with Professor Heran Darwin at the New York University School of 
Medicine, I was involved in identifying which protein sites had been modified with pup, a 
postranslation modification. My contribution included sample preparation and mass spectrometric 






A.3 Selective Chemical Intervention in the Proteome of 
Caenorhabditis elegans 
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Abstract 
We present the first study of protein regulation by ligands in C.elegans.  The ligands were peptidyl-
prolyl isomerase inhibitors of cyclophilins. Up-regulation is observed for several heat shock proteins 
and one ligand in particular caused a greater than two-fold enhancement of cyclophilin CYN-5. 
Additionally several metabolic enzymes display elevated levels.  This approach, using label free 
relative quantification, provides an extremely attractive approach to the effect of ligands on an entire 
proteome, with minimal sample pre-treatment, which could be applicable to large- scale studies. In 
this initial study, which compares the effect of three ligands, 54 unique proteins have been identified 
that are up (51) or down (3) regulated in the presence of a given ligand.   A total of 431 C. elegans 
proteins were identified. Our methodology provides an intriguing new direction for in-vivo screening 
of the effects of novel and untested ligands at the whole organism level.   
 
I was involved in carrying out the mass spectrometry work for the LCMS label free comparison and 










The Orbitrap mass analyser was developed by Alexander Makarov and it is a modified version of the 
ion trap that Kingdon developed in the 1920s.12-13 An Orbitrap is different to a conventional ion trap in 
that the ions are trapped in an electrostatic field: there is no magnet or RF used to trap ions. The 
Kingdon trap comprises a thin wire central electrode, an outer coaxilal cyclindrical electrode along 
with two endcap electrodes. Similar to the Kingdon trap, the Orbitrap comprises inner and outer 
coaxial electrodes. However, in the Orbitrap, the inner electrode is spindle-shaped.14 In the Orbitrap, 
tangentially injected ions are attracted electrostatically to the inner electrode but this is balanced by 
the centrifugal force of the ions. The electrostatic field inside the Orbitrap causes the ions to cycle the 
central electrodes where the axial frequency of these oscillations is inversely proportional to the 
square root of the m/z ratio and is independent on the energy or spatial spread of the ions.13 Similar to 
in FTICR, the trap can be used as a mass analyser. The Orbitrap is surrounded by an outer electrode 
that is split in the middle by an insulating ring. The ions induce an image current and this is detected 
by a differential amplifier between the two sides of the outer electrode surrounding the Orbitrap.15 The 
m/z ratio of the ions is determined by a fast fourier transformation (FFT) carried out on the oscillating 
frequencies. 
The LTQ Orbitrap hybrid mass spectrometer (Figure B.1) is ideally suited to ‘bottom up’ proteomics. 
Both mass analysers can work in parallel: while the high resolution/high mass accuracy MS scan of 
the precursor ions is acquired in the Orbitrap mass analyser, many fast MSMS spectra can be obtained 
on the lower resolution/lower mass accuracy LTQ mass analyser. The parallel operation of both the 
LTQ and the Orbitrap is achieved as the initial part of the high resolution spectra is used for the data-
dependent precursor selection which are subsequently fragmented while the high resolution Orbitrap 














C. Peptide Library approach to identify peptide 
substrates 
C.1 Phosphorylation site determination for peptide libraries 
Three peptide libraries were used: acidic, basophilic and proline directed (Table C.1). A modified 
KAYAK assay was performed on three peptide libraries. The acidic library and the proline directed 
library were incubated with 3 different cell lysates: nocodazole arrested HeLa, and HEK 293 treated 
with EGF and treated with PMA. The basophilic library was incubated with 3 different cell lysates: 
MCF7, and HEK 293 treated with EGF and treated with PMA. Details of lysate preparation are 
provided in the Section 2.7.2 For each KAYAK assay 20 µg of cell lysate was, individual 
concentrations of the peptide libraries were approximately 2.6 µM, 1.5 µM and 3.2 µM for the acidic, 
basophilic and proline directed libraries, respectively. The KAYAK protocol used for the peptide 
library assays is the same as described in Section 2.6.2.1 with the following exception: no internal 
standard (‘heavy library’) was added. Internal standard was not added since the focus of the first 
experiment was to determine which sites are phosphorylated rather than their quantitation. The 
peptides were analysed by LC-MS/MS (LTQ-Orbitrap) (details in Experimetal Procedures Section 
2.5) and searched using the SEQUEST algorithm 16against a reversed database containing all the 
sequences in the libraries and a concatenated  E. coli database. Peptides were filtered to a peptide FPR 
< 0.1%. The phosphorylated peptides for each library were submitted to MotifX17 to generate 











C.2 Relative KAYAK using peptide libraries 
A relative KAYAK assay was performed using the three libraries and HEK 293 cell lysate with and 
without EGF treatment. The same procedure as in Section C.1 above was performed except that 
following incubation of the libraries with the lysate, the appropriate internal standard (‘heavy library’) 
was added to the reaction mix following quenching. Following database searching, the heavy to light 
ratios were quantified using Vista (an in-house quantitation software suite) and the amount of 




C.3 Peptide library approach to identify substrates for KAYAK 
For kinase activity profiling using KAYAK it is critical to have good peptide substrates. Designing 
good peptide substrates is not straightforward. One approach that can be used to identify peptide 
substrates is to use peptide libraries which are generated using combinatorial peptide chemistry. 
Three different combinatorial libraries were investigated: acidic, basophilic and proline directed 
(Table C.1), to screen for interesting peptide substrates for KAYAK. The first experiment involved 
incubating the libraries with various different lysates and determining how many of the peptides were 
phosphorylated. In total, 50, 218 and 134 phosphorylated peptides were observed for the acidic, 
basophilic and proline directed libraries, respectively (Table C.2). Motif consensus software was used 
(Motif-X17) to generate putative phosphorylation motifs for each of the libraries using the 

























  HeLa – nocodazole arrested 8 












  MCF7 114 
















HeLa – nocodazole arrested 93 

















For the acidic library 50 peptides were phosphorylated, which is of particular interest since it is 
unusual to observe the acidic peptides being phosphorylated. Only one acidic kinase is currently 
known (casein kinase).  
A relative KAYAK experiment was carried out comparing the change in phosphorylation of the 
library peptides in two different samples: cells (293T) with and without EGF stimulation. Substrates 
displaying a change in the degree of phosphorylation between cells treated in different conditions are 
desired. One of the difficulties with the relative KAYAK quantitation was that many of the peaks had 
the same or similar m/z in the same time window due to the nature of the peptide sequences in the 
library. The peptides that showed a significant degree of phosphorylation (light/heavy ratio), and 
where the degree of phosphorylation was different between samples with and without EGF treatment, 




L/H ratio, EGF 
treatment 
L/H ratio, no EGF 
treatment 
Acidic     
pept_lib_1_57 JLDDDALsDLELEK 1.4 0 
pept_lib_1_552 JEDNDAEsDLENLK 0.89 0 
      
Basophilic     
pept_lib_2_104 KLARSJsAEDLAA 0 0.2 
pept_lib_2_594 PKKRRJsSPLLAA 0 0.2 
pept_lib_2_657 PLARKJsAPLLAA 0 0.09 
      
SP Directed     
pept_lib_3_117 KLKJPEsPKKVVK 0 1.4 
pept_lib_3_141 KLKJPEtPKKVVK 0.2 0.4 










D. Quantitation using targeted spectral counting 
 
Comparison of normal and targeted spectral counting approach for kinase quantitation with spectral 
counting. 
Table D.1  List of kinases and their spectral counts using a normal and targeted spectral count approach. A list of 
m/z  kinase  peptides  (from  previous  analyses) was  used  as  an  inclusion  list.  Three  gel  bands  (B,  C, D) were 
analysed using  target  approach  (shown  in  grey)  and  a  TOP  10  data  (shown  in white) dependent  acquisition 
strategy. A greater number of kinases and spectral counts were observed using the target approach. 
Gene symbol  MB_Target  MB_Top10  MC_Target  MC_Top10  MD_Target  MD_Top10  MBCD_Target  MBCD_Top10  Target/Top10 
CDC2  44  4  64  5  63  4  171  13  13.2 
CDK2  1  0  1  0  2  0  4  0  #DIV/0! 
CDK3  4  0  23  2  16  2  43  4  10.8 
CDK4  6  1  6  1  5  1  17  3  5.7 
CDK9  4  0  0  0  0  0  4  0  #DIV/0! 
CSK  0  0  0  0  1  1  1  1  1.0 
CSNK1A1L  8  1  9  1  4  0  21  2  10.5 
CSNK2A1  51  11  43  5  0  0  94  16  5.9 
CSNK2A2  50  5  24  2  0  0  74  7  10.6 
EGFR  0  0  23  3  0  0  23  3  7.7 
EPHA2  0  0  1  0  5  0  6  0  #DIV/0! 
ERBB4  0  1  0  1  0  0  0  2  0.0 
FGFR1  6  1  6  1  5  1  17  3  5.7 
GSK3B  1  0  1  0  0  0  2  0  #DIV/0! 
ILK  3  0  0  0  0  0  3  0  #DIV/0! 
MAP2K1  0  0  0  0  11  1  11  1  11.0 
MAP2K2  0  0  1  0  12  1  13  1  13.0 
MAP2K3  0  0  0  0  1  0  1  0  #DIV/0! 
MAP3K1  0  0  0  0  1  0  1  0  #DIV/0! 
MAPK1  0  0  1  1  25  1  26  2  13.0 
MAPK15  0  0  0  0  3  0  3  0  #DIV/0! 
MAPKAPK2  2  0  3  1  0  0  5  1  5.0 
MAPKAPK3  0  0  0  0  1  0  1  0  #DIV/0! 
MASTL  0  0  2  0  0  0  2  0  #DIV/0! 
NEK11  0  1  0  0  0  0  0  1  0.0 
NEK7  1  0  3  0  1  0  5  0  #DIV/0! 
NRBP1  7  1  1  0  0  0  8  1  8.0 
OXSR1  1  0  31  4  92  9  124  13  9.5 
PAK1  0  0  0  0  5  0  5  0  #DIV/0! 
PAK2  0  0  0  0  45  3  45  3  15.0 
PAK3  0  0  1  0  18  2  19  2  9.5 
PBK  0  0  7  0  41  3  48  3  16.0 
PIK3R4  0  1  0  0  0  0  0  1  0.0 
PKN2  1  0  63  8  4  0  68  8  8.5 
PLK1  20  2  4  5  0  0  24  7  3.4 
PRKACA  0  0  8  1  34  4  42  5  8.4 
PRKACB  0  0  0  0  4  1  4  1  4.0 
PRKACG  0  0  0  0  1  0  1  0  #DIV/0! 
PRKDC  511  101  1  0  0  1  512  102  5.0 
RIOK1  1  0  5  0  0  0  6  0  #DIV/0! 
RIOK2  0  0  4  0  0  0  4  0  #DIV/0! 
RIPK2  0  0  0  0  1  0  1  0  #DIV/0! 
ROCK1  2  3  0  0  0  0  2  3  0.7 
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ROCK2  52  9  0  0  0  0  52  9  5.8 
RPS6KA3  0  0  0  0  9  0  9  0  #DIV/0! 
RPS6KA6  0  0  0  0  0  1  0  1  0.0 
SCYL1  2  1  0  0  0  0  2  1  2.0 
SCYL2  0  0  1  0  0  0  1  0  #DIV/0! 
SLK  22  10  0  0  0  0  22  10  2.2 
SRPK1  1  0  2  1  0  0  3  1  3.0 
STK10  0  0  1  0  0  0  1  0  #DIV/0! 
STK24  0  0  13  1  33  4  46  5  9.2 
STK25  0  0  0  0  4  1  4  1  4.0 
TGFBR1  1  0  7  0  6  0  14  0  #DIV/0! 
TRIM28  318  43  54  6  11  1  383  50  7.7 
TRIM33  0  1  0  0  0  0  0  1  0.0 
TRRAP  0  0  0  0  0  1  0  1  0.0 
TTBK2  5  1  0  0  0  0  5  1  5.0 
TTK  0  0  2  0  0  0  2  0  #DIV/0! 












































KAYAK Assay for B4 and C2 and SC BN Gel 





















































































































E. Label free software packages 
E.1 XCMS 
XCMS was written using R, which is an open source statistical programming environment. 












E.1.1 Peak detection 
Since many peaks may be split between two bins, adjacent chromatographic slices are combined. 
Following generation of the combined chromatograms a matched filtrate algorithm is employed using 
a second-derivative Gaussian as the model peak shape18. Whilst the boundaries for peak integration 
are determined using the zero-crossing points of the filtered chromatograms, it is the unfiltered 
chromatograms that are actually integrated. Where the data resolution is very high and the m/z peak 
width is narrow compared to the 0.1 m/z bin size or where the data is centroided where the peak width 
is infinitely thin, the maximum signal intensity from adjacent slices can be overlapped. Where the 
resolution is low and the m/z peak width is large compared to the 0.1 m/z bin, XCMS’s vicinity 









E.1.2 Peak matching 
To overcome the problem of splitting due to arbitrary bin boundaries, peaks from overlapping bins are 
later removed in the postprocessing operations. Following mass binning (mass bins of width 0.25 m/z 
are used), the peak matching algorithm groups peaks from different samples into each bin by 
calculating the overall distribution of peaks in chromatographic time. This is determined using the 
kernel density estimation method which is effectively creating a smoothed histogram by applying a 














E.1.3 Retention time alignment  
If there are regions of the spectra where no well behaved peak groups exist, XCMS uses an algorithm 
to estimate the retention time deviation. For those peak groups which are missing a sample, XCMS 
adds in intensity values by using integration data from the raw LCMS runs. XCMS generates EIC for 
significant peaks where the alignment can be observed. 
Work is currently in progress to standardise LCMS data to be able to combine and compare LCMS 
data obtained from different instrument platforms. The Annotated Putative Peptide Markup Language 
(APML)20 along with the Corra framework20 are such initiatives are currently under development. 
 
E.2 MS-Xelerator 
The software from MsMetrix is user-friendly and comparison can be performed either manually or 
using algorithmic techniques to identify changes. Manual comparisons can be carried out by 
comparing the TCMs (Total Chromatogram Mass spectra), which are the average spectra of an LC-
MS run, or by comparing the TIC (Total Ion Chromatograms) for specific mass ranges. The advantage 
of using ‘mass spectra’ is that alignment problems are minimal. The disadvantage is that it is difficult 
to detect small differential peaks in the presence of larger peaks having the same or similar m/z 
values. It is also possible to set up automatic detection of differences. Another method is to scan all 
the 2D-LC-MS surfaces simultaneously, creating a binary map of m/z vs. retention time and then 
unique peaks can be identified. 
In MSX it is possible to normalise the spectra based on area, a unit vector or a specific peak. The 
disadvantage of using normalisation using the area of the TIC or that of a single peptides is that it is a 
single measurement and therefore may not be reliable. Also, if sample comparison is based on total 
protein abundance, then it is not accurate to correlate the TIC with total protein since there are likely 
to be other compounds present such as lipids and small molecules that make up the TIC.   
 
E.3 Progenesis 
Nonlinear Dynamics (UK) They offer a series of packages for biomarker discovery for different 
instrument platforms: 1D/2D gel quantitation, MALDI and LCMS. and it is particularly useful to 
visualise the error bars for the peak abundance both in and between the groups. The peptides are 
ranked by ANOVA p-value and PCA is possible. 
Following quantitation of the EIC from the LCMS trace it is possible to export the significant peaks 
into a file that can be exported to Mascot (or Sequest or Phenyx). Following database searching, the 
Mascot results can be exported into xmL format and imported back into Progenesis and the peptides 
are automatically matched to the MSMS spectra and protein identifications. Where one peptide 
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matches several proteins, all the possible protein identifications are listed. One of the advantages of 
Progenesis is that the link between LCMS and LCMSMS is not restricted to a single LCMSMS run, or 
indeed to the same instrument. LCMS experiments can be performed on an FTICR mass spectrometer 
and quantitatively processed whilst LCMSMS can be performed on an ion trap. Following alignment 
and quantitation of the FTICR LCMS, the LCMSMS spectra can be aligned ‘on top’ of the FTICR 


























F. Protein complexes in saliva 
 


















the  fractions.  (a) Profile of protein complexes  for each gel slice. Hierarchical clustering grouped proteins with 
































by  GeLCMSMS.  Spectral  counts  of  the  proteins  give  an  estimate  of  the  protein  abundance  in  each  of  the 
fractions. Hierarchical clustering grouped proteins with similar spectral count profiles  together. Proteins were 




































G. Kinase correlation profiling of saliva on BN 
PAGE 
Kinase activity profiles (obtained using KAYAK) were correlated with kinase abundance profiles 





(c) Heatmap of Pearson correlation coefficients bewteen kinase abundance  (SC) and activity  (KAYAK)  in saliva 













H.  Optimisation of parameters for label free 
software packages 
There were various label-free software packages available at the time of analysis, both open source 
and commercial. Three of these software packages were investigated: MS-Xelerator, Progenesis and 





0.1  111 2.61 1.52 
0.2  92 2.63 1.62 
0.3  57 2.26 0.46 
0.4  34 2.16 0.40 
0.5  26 2.07 0.28 
0.6  18 2.00 0.22 
0.7  9 1.99 0.21 
0.8  6 1.98 0.24 
0.9  0 0 0 
 





0.1  772 2.24 0.63 
0.2  498 2.20 0.44 
0.3  269 2.18 0.41 
0.4  134 2.12 0.38 
0.5  60 2.08 0.35 
0.6  29 1.99 0.35 










10  79 81.00 247 158 56  8.03
20  123  2.44 1.28 190 2.78  1.30
30  136  2.30 0.75 247 2.46  0.91
40  138  2.31 0.86 237 2.23  0.70
50  141  2.29 0.77 244 2.33  0.65
60  262  2.16 0.79 244 2.33  0.65
80  130  2.21 0.49 237 2.31  0.55
100  221  2.11 0.56 ‐ ‐ ‐ 












10  83 3.11 1.90 28 7.37  12.4
20  33 5.71 13.40 231 2.78  1.85
30  162  2.49 3.00 277 2.58  1.06
40  179  2.25 0.82 342 2.44  0.84
50  183  2.16 0.54 ‐ ‐ ‐ 
60  169  2.14 0.51 ‐ ‐ ‐ 
80  166  2.13 0.47 ‐ ‐ ‐ 
100  152  2.13 0.49 ‐ ‐ ‐ 










10  267  1.97 0.50 267 1.97  0.49
20  400  1.90 0.39 400 1.90  0.39
30  383  1.86 0.34 94 1.83  0.24
40  363  1.82 0.32 363 1.81  0.32
50  353  1.79 0.33 353 1.79  0.33
60  325  1.77 0.24 325 1.76  0.24
80  302  1.72 0.24 294 1.72  0.21
100  261  1.70 0.22 261 1.69  0.22










10  14 2.04 0.46 14 2.04  0.46
20  28 2.04 0.48 28 2.04  0.47









I. Kinase activity profiling in Drosophila 
This is an ongoing collaboration is with the Perrimon lab in the Genetics department at HMS and 
involves investigating the dynamics of early embryonic phosphorylation-dependent signalling in 
Drosophila melanogaster. The Perrimon lab has developed a method to knock down genes in embryos 
by embedding mRNA targeting sequences within a microRNA. Previous transgenic Drosophila lines 
used for knock down gene studies were inefficient in the germLine because the long dsRNA hairpins 
relied on processing by the siRNA pathway. This pathway appears non-functional in the Drosophila 
germLine and the Perrimon lab has circumvented this issue by exploiting the microRNA pathway. Dr. 
Richelle Sopko in the Perrimon lab uses these short hairpin microRNA (shmiRNA) lines to map 
phosphorylation-dependent signalling networks. By using well-characterised phospho-specific 
antibodies to assess the altered distribution and intensity of phospho-proteins in embryos where 
kinases and phosphatises have been knocked down with shmiRNA, the contribution of the kinome and 
‘phosphatosome’ to early embryonic signalling pathways that trigger these particular phosphorylation 
events has begun to be assessed. In a similar and more quantitative manner, KAYAK performed on 
shmiRNA embryos lacking a particular kinase or phosphatase should enable a more refined 
assignation of a specific kinase or phosphatase to a specific pathway. Following identification of the 
responsible kinase and phosphatase, epistasis analysis with other pathway component mutants will be 
used to determine the hierarchy of phospho-relay.  
Of the K60, only 18 shared more than 20 % sequence identity with the corresponding Drosophila 
homolog. The overall plan in the future is to determine a kinase activity profile using KAYAK for 
each stage of development (0 to 24 hours in 2 hours increments) for each mutant kinase. This type of 
analysis has already been carried out examining mRNA (Figure I.1). However, only the kinase 
expression based on mRNA is known and there is no indication of the kinase activity. Performing the 
same experiment using KAYAK would involve a very large number of reactions if all protein kinases 
(~350) were considered, and currently this would not be practical in terms of instrument time. 
Particular kinases of interest in specific temporal windows, such as 0-2hrs, have been selected when 
the proteomic complement is simpler. Only 100-150 of the approximately 300 kinases in the fly 




























gene     function  human ortholog  pathway 
csw   corkscrew  ppase  SHP2  MAPK 
dsor   downstream of raf   kinase  MEK1/2  MAPK 




w  white  neg control       
wts  warts  kinase  LATS1/2  Hippo 
yki  yorkie   TF  YAP/TAZ  Hippo 
egfr 
epidermal growth factor 
receptor  kinase  EGFR  MAPK 
pten  pten   ppase   PTEN  PI3K/Akt 
Tor  Target of rapamycin  kinase   TOR  PI3K/Akt 
S6K  p70 S6 kinase  kinase   S6K  PI3K/Akt 




src42A Src oncogene at 42A  kinase  SRC  RTK 
cnk 
connector enhancer of kinase 
suppressor of Ras     CNKSR1/2/3  RTK 
dos  daughter of sevenless  SH2 domain binding  no orthologue   RTK 
drk 
downstream of receptor 
kinase  SH3/SH2 adaptor  GRB2  RTK 
gap1  GTPase‐activating protein 1  Ras GTPase activator  RASA2/3  RTK 
ksr1  kinase suppressor of ras     KSR1  RTK 
shc  SHC‐adaptor protein     SHC1/2/3/4  RTK 
InR  insulin‐like receptor  kinase  IGF1R  RTK 
phl  polehole  kinase  Raf  MAPK 
ras85D Ras oncogene at 85D  GTPase  Kras/Hras/Nras  MAPK 
rl  rolled  kinase  ERK1/2  MAPK 









I.1.1 Drosophila crosses 
 
Virgin female UAS-shmiRNA flies were crossed to male MTD-Gal423 flies. The transgenic MTD-
Gal4 flies are homozygous for P(Gal4-nos.NGT)40, P(COG-GAL4:VP16) and P(nos-Gal4-VP16) on 
three different chromosomes. These P-element insertions enable expression of Gal4 (a yeast 
transcription factor) under the regulation of NGT, cog, and nanos transcriptional elements. These three 
genes are expressed in the germLine.  
The germLine of female progeny generated from this cross bear both Gal4 protein (expressed from 
NGT, cog, and nanos promoters) and one copy of a chromosome bearing mRNA for the gene we 
desire to knock down (a kinase or phosphatase) targeting sequences embedded within a microRNA 
(shmiRNA).The shmiRNA is preceeded by a UAS (upstream activating sequence) for Gal4 (derived 
from yeast). During oogenesis, Gal4 can bind the UAS sequence, invoking transcription of the 
shmiRNA. Upon folding, the shmiRNA hairpin is directed to the microRNA machinery, resulting in 
the down-regulation (or knock-down) of the gene the shmiRNA is targeting. The second cross is 
merely to induce fertilisation and consequent release of eggs from virgin females bearing eggs with 
the kinase or phosphatase of interest knocked down. 
I.1.2 Drosophila embryo extract preparation 
Adult flies were discarded after 2 hours in molasses agar/yeast paste vials. Embryos laid on agar/yeast 
paste were treated for 2 minutes with 50% bleach with shaking and delivered to a small mesh basket 
in bleach; washed with copious amounts of 0.1% Triton X-100, then water; then transferred with a 
paintbrush to a 1.5 mL siliconised Eppendorf tube containing 1mL cold KAYAK buffer. After the 
embryos settled, the buffer containing agar bits was removed under vacuum with a 23gauge needle. 
Embryos were resuspended in 1mL cold KAYAK lysis buffer with a cut P1000 tip and delivered to 
1mL glass dounce homogeniser.  All buffer was removed using a vacuum/23gauge needle, avoiding 
embryos. 100ul KAYAK buffer was added to ~20 µL packed embryos. Following 11 strokes of tight 
pestle, lysate was transferred to a cold 1.5mL Eppendorf tube. The crude extract was spun at 13kprm 
for 10min in a cold microfuge. The supernatant was removed and transferred to a new Eppendorf tube. 
1µL and 2 µL was taken for a Bradford assay and extract frozen in 20µg aliquots of 20µL (topped up 
with KAYAK buffer) in liquid N2. Frozen aliquots were stored at -800C. 
28 
 
I.1.3 Drosophila cell culture extract preparation 
Kc167 and clone8 Drosophila cells were plated at 2x106 cells/mL in a 6 well plate. The following day 
insulin was added to 25 μg/mL for 10 minutes. Cell culture medium was aspirated andthe cells washed 
1x with 1mL PBS. Cells were suspended in 0.5mL cold KAYAK buffer and incubated on ice for 5 
minutes. Crude extract was transferred to a 1.5mL Eppendorf tube and spun at 13krpm for 10 min at 
40C in a cold microfuge.The supernatant was removed and transferred to a new Eppendorf tube. 1 µL 
and 2 µL was taken for a Bradford assay and extract frozen in 20 µg aliquots of 20 µL (topped up with 
























KAYAK had not previously been performed on Drosophila embryos. Initial ‘proof-of-concept’ 
experiments were performed to determine if significant kinase activity was present at different times 
of embryogenesis and whether significant differences were observed between the WT (wild type) and 
mutant samples. The samples included: WT embryos (w118) 0-2 hours and 0-4 hours, torso shmiRNA 
mutant embryos (0-2 hours) which had the Torso kinase knocked down, and corkscrew shmir mutant 
embryos (0-2 hours) which had the Corkscrew phosphatase knocked down. Significant kinase activity 
was observed for many peptides at (53 of the K60) and significant differences can be observed 



















KAYAK was also carried out on Drosophila Kc167 cells with and without insulin stimulation. Insulin 
is known to activate AKT, and increased kinase activity of A3, N6, and K11, which are known AKT 
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substrates, was observed with the insulin treated cells. Interestingly, AKT activation inhibits GSK3 
activity and reduced phosphorylation of P12, a GSK3 substrate peptide from glycogen synthase, was 













































Zinc finger protein 106
Tsc2 - Akt target
Tsc2 - Akt target
IRS1 - InR target 
Aktide
Nitric oxide synthase
>30% conservation of  peptide to 
f ly including phospho-site

















Various kinases and phosphatases were knocked down using shmiR, and the kinase activity was 
determined using the K60 substrate set (Table 1.1 and Figure I.2). In general, there is a correlation 
between knocked down genes in the same pathway, as would be expected since these would lead 
ultimately to similar kinase signatures. The knocked down genes torso, csw and dsor, all from the 
RTK signalling pathway, cluster together as do warts and hippo from the hippo pathway. Knocked 
down PTEN increases AKT activity, and indeed increased phosphorylation of the AKT substrates A3 
















The peptide substrates were designed as human target kinases, and yet many of the peptide substrates 
are phosphorylated by Drosophila kinases, so these proof of concept experiments show that KAYAK 
can be applied to this species to assess the activity of kinases. Many of the kinases and the motifs that 
they recognise are conserved throughout a wide range of relatively distantly related evolutionary lines, 
and the use of such peptide target approaches should be able to decipher the motif conservation in a 
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J. KAYAK in mice treated with fibroblast growth 
factor (FGF) and mice with targeted disruption of 
FGF 
J.1 Experimental 
Mouse livers were provided by Dr. Patty Chui from the Flier laboratory at HMS. Generation of mice 
treated with FGF21: Human FGF21 was expressed in E. coli and refolded in vitro as described21. For 
analysis of acute signalling events in the liver, recombinant FGF21 was administered via  the inferior 
vena cava to anesthetised adult mice. Briefly, mice were anesthetized via intraperitoneal injection of a 
ketamine/xylazine cocktail.  The peritoneal cavity was then exposed and either FGF21 (100 ng/gram 
of mouse weight) or saline was injected directly into the inferior vena cava in a total volume of 20 µL. 
After 10 minutes, the liver was dissected, flash frozen in liquid nitrogen and stored at -80ºC until 
further analysis.   Generation of mice with targeted disruption of Fgf21: FGF21 KO mice were 
generated by Eli Lilly (Lilly Research Laboratories, Indianapolis, IN).  To generate mice with targeted 
disruption of the Fgf21 locus, a 6.5 kb NheI genomic fragment containing all three exons of the mouse 
FGF21 gene was subcloned and used as a gene targeting vector by replacing part of exon 1 (30bp 
downstream of the ATG), all of exon 2, and the 5’ region of exon 3 with a neomycin resistance gene 
(pGTN29; New England Biolabs, Ipswich, MA), thus deleting approximately 1200 bp of the genomic 
FGF21 sequence.  Founder mice were subsequently backcrossed onto the C57Bl/6 line at least 10 
times before investigation. Mouse treatment: All procedures were approved by the Beth Israel 
Deaconess Medical Center Institutional Animal Care and Use Committee.  FGF21 signalling studies 
were carried out using male wild-type C57Bl/6 mice obtained from Jackson Laboratory (Bar Harbor, 
ME).  FGF21 , and FGF21 KO mice and their WT littermates were bred at Beth Israel Deaconess 
Medical Center.  All mice were maintained in a temperature-controlled environment at 24ºC on a 12-
hour light, 12-hour dark cycle (0600-1800h) with ad libitum access to food and water.  For the diet-
induced obesity signalling studies, mice were fed either regular chow (Harlan Teklad F6 Rodent Diet; 
Madison, WI) or an obesogenic high-fat high-sucrose diet (D12451, Research Diets, New Brunswick, 
NJ) for at least 22 weeks.  FGF21 KO mice and their WT littermates were fed regular chow as above, 
then euthanized between 24-32 weeks of age by cervical dislocation; they were then exsanguinated by 
cardiac puncture, and tissues were rapidly dissected and flash frozen in liquid nitrogen until further 
analysis.  Liver homogenate was prepared for KAYAK as described previously in Section 2.7.2. Two 
experiments were carried out (Figure J.1). Experiment 1: KAYAK on lean and obese mice with and 
without FGF21 treatment. KAYAK was performed (in triplicate) on two biological replicates for lean 
and obese, FGF21 treated and untreated mice, using 20 µg of tissue homogenate for each KAYAK 
reaction (Figure J.1). KAYAK was performed using the classical ‘eppendorf’ format as described in 
Experimental procedures Section 2.6.2.1. Experiment 2: KAYAK on wild type and FGF21 Knock out 
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mice. KAYAK was performed (in triplicate) on two biological replicates for wild type and FGF21 KO 
mice using 20 µg of tissue homogenate for each KAYAK reaction (Figure J.1). KAYAK was 











J.2 Kinase activity profiles in mice treated with fibroblast growth 
factor 
Kinase activity profiling was performed on livers from lean and obese, FGF21 (fibroblast growth 
factor 21) treated and untreated mice. The treated and untreated mice form two clusters based on their 
kinase activity profiles (Figure J.2). Overall, very few differences in kinase activities are observed. 
However, increased kinase activity for the peptides MM1, MM2, RR2 and PP1 are observed (Figure 
J.2). The kinase responsible for the phosphorylation of MM1 is thought to be Erk1 which is one of the 
downstream targets of FGF21. MM1 is increased 2.8 fold following treatment and has a very low p 
value of 2.4 x 10-11 (anova, 2 factor with replication). MM2, a MAPK substrate and RR2, a RSK 
substrate and PP1, a MEK substrate all have significantly greater activity in the FGF treated mouse 
and these kinases are in the FGF signalling cascade and should be activated with FGF treatment. 
Despite the inherent biological variability between the mice significant the treated and untreated mice 
clearly cluster into two groups based on the treatment and that subtle changes can be observed on a 
kinase activity background that is largely unchanging. A similar kinase profiling experiment was 
performed on mice with FGF21 knocked out and wild type. Very few differences were observed 
between the kinase activities and this is was in keeping with the knockout having a similar phenotype 
to that of the wild type. It is presumed that since FGF21 was a germline knockout, then other 






















Figure  J.2    Profile  of  kinase  activities  in mouse  livers  from  lean  and  obese mice  treated with  and without 
fibroblast  growth  factor.  (a)  Heat  map  of  kinase  activities  the  8  mice.  Analysis  by  Pearson  correlation 
hierarchical clustering was used to group similar responders together. Each row represents the phosphorylation 












MM1  STSTPTsPGPRTHPFR  Ataxin‐2‐like protein  Erk1  2.80  2.38x10‐11 
RR2  RKRLIsSVEDPFR  Tuberous sclerosis 2  RSK  1.83  5.96x10‐11 

























































































































































K. Kinase activity profiling in yeast 
 
KAYAK was performed in yeast (S. cerevisiae) and 39 out of the K60 substrate peptides were 
significantly phosphorylated. None of the tyrosine kinase substrate peptides were phosphorylated, as 
would be expected since there are no conventional tyrosine kinases in yeast. 
KAYAK was performed on asynchronous and nocodazole arrested yeast lysate (Figure K.1). Many 
differences were observed between the two states. The two MAPK substrate peptides (MM1 and 


















































































L. Correlation of KAYAK with phosphorylation of 
kinase activation loop 
 
 












Figure  L.2    Correlation  profile  bar  charts  of  selected  known  kinase‐substrate  pairs.  The  normalised  spectral 





M. Kinase activity correlation profiling 
KAYAK correlation profiling of HeLa nocodazole arrested cell lysate 
List of proteins for Figure 4.1.1. (too small to see in figure ) 
Number Kinase Number Kinase Number Kinase 
1 MYLK 65 MAP3K5 129 NPR1 
2 MYLK2 66 PKMYT1 130 AXL 
3 CSNK1A1L 67 STK25 131 BCR 
4 EPHB4 68 ROR1 132 PRKD3 
5 SCYL2 69 CDK3 133 EIF2AK4 
6 MAP2K1 70 EGFR 134 BUB1 
7 MAP2K2 71 ERBB4 135 JAK1 
8 EPHA5 72 FRAP1 136 SCYL1 
9 LYN 73 WNK1 137 SMG1 
10 CAMK1D 74 CCNB1 138 STK4 
11 STK38 75 DDR2 139 TRIM28 
12 PDPK1 76 INSR 140 CDC42BPA 
13 MAPKAPK2 77 TP53RK 141 IRAK4 
14 FGFR1 78 PRKAA1 142 CDC42BPB 
15 CDK4 79 PRKCB1 143 ROR2 
16 CDK6 80 CDK7 144 PRKCI 
17 MAPK1 81 LIMK2 145 TRIM33 
18 MAPK3 82 PKN1 146 GAK 
19 RIPK1 83 TRIO 147 GRK5 
20 CSK 84 STK24 148 MELK 
21 OXSR1 85 RP6-213H19.1 149 TRIM24 
22 STK39 86 ROCK1 150 MAP4K4 
23 PTK2 87 PKN2 151 ROCK2 
24 RIPK2 88 PIK3R4 152 NEK9 
25 STK38L 89 WNK3 153 STK3 
26 MAP3K3 90 MAPK9 154 NRBP1 
27 MERTK 91 TAOK1 155 BUB1B 
28 PDGFRB 92 CDC2 156 GRK4 
29 CHEK2 93 CDK2 157 CIT 
30 STK10 94 CDK5 158 TTBK2 
31 ILK 95 GSK3A 159 HSPB8 
32 RPS6KA3 96 GSK3B 160 IKBKB 
33 MAPKAPK3 97 MARK4 161 TNNI3K 
34 FYN 98 MLKL 162 BMP2K 
35 MAPK15 99 NEK7 163 RIOK3 
36 ACVR2A 100 RPS6KA1 164 RIOK2 
37 GUCY2D 101 MAP2K6 165 SRPK1 
38 CABC1 102 PTK2B 166 CCNT1 
39 MATK 103 PCTK1 167 CDK9 
40 OBSCN 104 SRPK3 168 CDC2L2 
41 RPS6KA6 105 TTN 169 CLK3 
42 YES1 106 STK31 170 MAP4K1 
43 AKT2 107 CSNK1A1 171 SRPK2 
44 PRKCD 108 PRKACB 172 EPHB1 
45 PRKCG 109 ADCK5 173 FLT3 
46 EPHA2 110 ARAF 174 KIAA0999 
47 MAP2K4 111 HIPK3 175 ADRBK1 
48 TAOK3 112 MAPK14 
49 PRKCA 113 ZAK 
50 EIF2AK2 114 PBK 
51 IGF1R 115 PLK1 
52 PAK2 116 TTK 
53 PAK3 117 MAP2K3 
54 PAK1 118 TGFBR1 
55 PRKACA 119 PRKDC 
56 PRKACG 120 CSNK2A1 
57 RIPK4 121 CSNK2A2 
58 AKT1 122 EEF2K 
59 MINK1 123 IRAK1 
60 CASK 124 ULK1 
61 SLK 125 MASTL 
62 CAMKK1 126 LRRK1 
63 MAST1 127 RPS6KA2 




N. Validation experiments – kinase activites in the 
presence and absence of lysate 
 
Table N.1   Kinase activities  for  recombinant kinases  (50 ng)  in  the presence and absence of HeLa nocodazole 
arrested lysate (20 µg). 
 
An interesting miscellaneous finding during this experiment was that for peptide 5B4, the combination 
of recombinant PBK and lysate (nocodazole arrested HeLa) led to a 7-fold increase in kinase activity 
compared to recombinant PBK or lysate alone. PBK was not one of the putative kinase hits for 5B4, 
which made this an unexpected finding. However, on examining the KAYAK profile, the 5B11 kinase 
activity had 2 peaks in its profile and the PBK protein profile overlapped with the second peak. A 
similar effect was also observed for the peptide 5B11, albeit to a lesser extent. There is currently no 
known explanation for this, but it is a very interesting observation due to the large fold increase in 
activity and warrants further investigation. Some chemical in the lysate is presumably responsible for 

























O. siRNA knockdown of kinases 
KAYAK K8 and K60 were performed on the lysates with siRNA knocked down kinases (Figure O.1). 
The knock down of TP53RK and TOPK does not appear to have any significant effect on either the 
K8 or K60 peptide substrate set. For KAYAK K60 on the knocked down lysates, decreased 
phoshphorylation of the peptide substrates for the knocked down kinases was not clear. For MAPK14, 
decreased phosphorylation of PP1, AM1 and CH2 was observed in the knocked down lysate and these 
peptides displayed increased phosphorylation with MAPK14 overexpression (Figure). However, there 
are very few examples of ‘expected outcomes’, and the results were difficult to interpret, so it is likely 
that the ‘knock downs’ were not efficient. No measure of the knock down efficiency of the lysates has 
currently been determined so it is difficult to assess how effective the knock down was. The knock 
down efficiency will be assessed in the future using western blotting or quantitative PCR for the 
kinases which have no commercially available antibodies. Also, there could have been contamination 
of the lysates with BSA from the cell media. This source of error would be exacerbated through the 
use of very small lysis volumes from the small culture dishes (12 well). Any media (which contains 
BSA) not completely removed may therefore ‘contaminate’ the protein assay which would not 












Figure O.1   Heat map of kinase activities  for K60 substrates  for HEK 293T cells with  five siRNA knocked down 
kinases.  Kinase  activity  is  normalised  to  control  cells.  Hierarchical  clustering  grouped  similar  responders 
together. Heat map  of  kinase  activities  for  K8  substrates  for HEK  293T  cells with  five  siRNA  knocked  down 





P. Presence of known interacting partners of PAK3, 
PLK1 and PBK 
 
P.1 Interactions with PAK3 
It is known that CDC42 and RAC stimulate Group I PAK activation. The current model for the 
activation involves a reversal of a negative regulatory effect by the binding of CDC42 and RAC24. In 
the absence of G protein binding, PAK activity is thought to be repressed by an intramolecular 
interaction between the regulatory and catalytic domains. On binding by CDC42, RAC and other 
proteins, the interaction is thought to be disrupted, resulting in an increase in kinase activity24. PAK is 
known to have several binding partners including αPix (Pak-interactive exchange factors), βPix  and 
p50Cool-1.  
PAK3/5B11 profiles overlap with part of the RAC3 profile but not with RAC1 or RAC2 which are 
very low in abundance. There is quite good overlap with CDC2 but the overlap with the other known 






















































































































































































































































































































































P.2 Interactions with PBK 
PBK was one of the top hits from the protein correlation profiling for peptides 5B6, 5B7 and 5B8. 
PBK is reported to form a complex with CDC2/cylin B25. However, the protein correlation profiling of 
PBK does not overlap with CDC2/Cyclin B complex, although there was some overlap between PBK 
and CDC2 where it is not complexed to CCNB1 (Figure P.2). In siRNA PBK knock down studies, 
cyclin B1 is reported to be reduced during mitosis whilst CDC2 expression increases slightly26. From 
mutation studies there is evidence that PBK expression and phosphorylation are important for mitotic 
cyclin B1 expression and it is postulated that PBK helps in recruiting CDC2/cyclin B to mitotic 
spindles. It is thought that MAPK14 could be a substrate of PBK resulting in MAPK14 activation26-27 
and the protein correlation profiles are very similar, both peaking in fraction 22 (Figure P.2), TP53 
(p53) is known to bind to PBK and whilst TP53 itself was not identified, the binding protein TP53BP1 
was identified and this fell within the PBK profile as shown in Figure 4.2 Many major substrates of 











































































P.3 Interactions with PLK1  
PLK1 associates with various proteins, including MCMs (mini chromosome maintenance proteins)28 
and proteins in the 20S proteasome29. There are several overlapping regions in the elution profiles of 
PLK1 and the various isoforms of the mini chromosome maintenance proteins (MCM) and the 








































































Q. Protein sequences of PLK1 substrates  
 
CAMSAP1L1 
>sp|Q08AD1|CAMP2_HUMAN Calmodulin-regulated spectrin-associated 
































































>sp|Q00653|NFKB2_HUMAN Nuclear factor NF-kappa-B p100 subunit 






























R. Details on induced gingivitis clinical trial 
R.1 Subject recruitment and selection 
This clinical trial can fulfil its objectives only if appropriate participants are enrolled. Healthy 
volunteers will be recruited from an existing database of health volunteers within the Eastman Clinical 
Investigation Centre.  Individuals will contacted by telephone to inquire of potential interest.  If 
interested, they will be sent a patient information sheet and advised to contact the centre if they would 
like to proceed with screening for eligibility. The following eligibility criteria are designed to select 
subjects for whom protocol treatment is considered appropriate.  All relevant medical and non-
medical conditions should be taken into consideration when deciding whether this protocol is suitable 
for a particular subject.   
 
R.1.1 Inclusion Criteria 
Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the trial: 
1. Males and females ≥ 18 years of age and in good general and oral health. 
2. Volunteers must read, sign and receive a copy of the Informed Consent Form after the nature of the 
study has been fully explained. 
3. A minimum of 20 natural teeth with scorable facial and lingual surfaces. Teeth that are grossly 
carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized 
cervical and/or enamel abrasion, or third molars will not be included in the tooth count. 
4. Absence of significant oral soft tissue pathology, excluding gingivitis, based on a visual 
examination. Absence of any object used for lip, tongue, or other form of oral piercing. 
5. Absence of moderate/advanced periodontitis based on a clinical examination. 
6. Absence of fixed or removable orthodontic appliance or removable partial dentures. 
 
R.1.2 Exclusion Criteria 
Subjects presenting with any of the following will not be included in the trial: 
 1. History of significant adverse effects following use of oral hygiene products such as toothpastes 
and mouthrinses. 
2. History of uncontrolled diabetes or hepatic or renal disease, or other serious medical conditions or 
transmittable diseases, e.g. cardiovascular disease or AIDS. 
3. History of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring 
prophylactic antibiotic coverage prior to invasive dental procedures. 
4. Antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding the baseline 
exam. 
5. History of alcohol or drug abuse. 
6. Participation in any dental plaque/gingivitis study involving oral care products, concurrently or 
within the previous 30 days. 
7. Self reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy 
and nursing which can affect interpretation of study results). 
8. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may 
increase the risk associated with trial participation or investigational product administration or may 
interfere with the interpretation of trial results and, in the judgment of the investigator, would make 
the subject inappropriate for entry into this trial. 
9. History of any known food allergies. 
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R.2 Löe and Silness Gingival Index (GI) 
Gingivitis will be assessed at baseline and 2 weeks (Final-Day15) by the Loe and Silness Gingival 
Index on three surfaces buccal and three surfaces lingual marginal gingivae and interdental papillae of 
all scorable teeth by the calibrated examiner: 
0 - Normal (absence of inflammation). 
1 - Mild inflammation (slight change in colour, little change in texture) of any portion of the 
gingival unit but no bleeding when running a periodontal probe along entrance to the 
gingival crevice 
2 - Moderate inflammation (moderate glazing, redness, edema, and/or hypertrophy) with 
bleeding of the gingival unit when running a periodontal probe along the entrance to the 
gingival crevice. 
3 - Severe inflammation (marked redness and edema/hypertrophy, or ulceration) with 
spontaneous bleeding of the gingival unit when running a periodontal probe along the 
entrance to the gingival crevice. 
 
R.3 Silness-Löe Plaque Index 
Plaque area will be scored at baseline and 2 weeks (Final-Day 15) by the calibrated dental examiner, 
using the Silness-Löe Plaque Index, three buccal surfaces and three lingual surfaces of all scorable 
teeth following disclosing: 
0 - No plaque. 
1 – No plaque can be observed by the unaided eye but the plaque is made visible on the point 
of the probe after it has been moved across the tooth surface at the entrance of the gingival 
crevice. 
2 – The gingival margin is covered with a thin to moderately thick layer of plaque visible to 
the naked eye. 
3 – Heavy accumulation of soft matter, the thickness of which fills out the niche produced by 














S. T-test of gingivitis vs healthy 
t-test p values for comparison of saliva from individual healthy and gingivitis subjects. No proteins 




value   
AZGP1 0.04 MCTP1 0.27 TXN 0.60 
IGKV3-20 0.06 NAIP 0.27 LYZ 0.64 
HP 0.10 OPA1 0.27 HBB 0.66 
LCN2 0.12 PGD 0.27 HBA1 0.67 
IGJ 0.12 PGLYRP1 0.27 ALB 0.68 
LOC124220 0.12 PIWIL1 0.27 SMR3B 0.72 
HIST2H2BE 0.14 POLR3GL 0.27 LTF 0.74 
AMY1A 0.15 RAD54B 0.27 PFN1 0.74 
TKT 0.16 RNF149 0.27 AMY2B 0.75 
PIP 0.16 RTN4IP1 0.27 LOC440786 0.76 
DSG3 0.17 SERPINB1 0.27 BPIL1 0.77 
CRISP3 0.17 SLC27A4 0.27 CSTB 0.77 
LYPD3 0.20 SYT8 0.27 IGHG2 0.78 
ACTB 0.20 TGOLN2 0.27 CASP3 0.80 
RIPK4 0.21 YEATS2 0.27 IGL@ 0.80 
IGHG1 0.21 ZNF433 0.27 IGHV@ 0.81 
IGHM 0.23 ZNF774 0.27 GSN 0.82 
PIGR 0.25 KLK1 0.28 S100A8 0.85 
IGHA2 0.27 AMY1A 0.29 ENO1B 0.86 
DEFA1 0.27 F7 0.29 ACTA2 0.86 
ADCY1 0.27 TF 0.31 CST2 0.86 
ALDOA 0.27 GSTP1 0.32 FABP5 0.89 
ARHGDIB 0.27 CST4 0.32 PPIA 0.93 
C3 0.27 HBB 0.32 PRTN3 0.93 
CA1 0.27 HIST1H4D 0.40 ENO3 0.95 
CA6 0.27 IGKV2-40 0.40 
CACNB1 0.27 JMJD3 0.40 
CLU 0.27 KIAA1843 0.40 
CNDP2 0.27 L2HGDH 0.40 
COL11A2 0.27 LCN1 0.40 
CRNN 0.27 LOC729708 0.40 
ENO1 0.27 LPO 0.40 
FGA 0.27 MPO 0.40 
FGB 0.27 NFIL3 0.40 
GOLGB1 0.27 NOL1 0.40 
GPI 0.27 SLPI 0.40 
HPR 0.27 TACC2 0.40 
HSPA8 0.27 TCN1 0.40 
IDH1 0.27 C6orf58 0.45 
IGHG4 0.27 CST1 0.48 
IGKV4-1 0.27 S100A12 0.49 
IGLC2 0.27 S100A9 0.50 
ITGA1 0.27 DKFZp686D0972 0.55 
KIAA0317 0.27 IGKV1-5 0.56 
KLHL34 0.27 GAPDH 0.58 
LCP1 0.27 HSPA1L 0.58 
MCM8 0.27 IGHA1 0.60 
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T. Bacterial species identified in induced gingivitis 
trial 
List of the proteins identified in six patient undergoing the induction of gingivitis. 
   Number of proteins Total Spectral count 
   Residue Supernatant Residue Supernatant 
Abiotrophia defectiva   2 0 2 0 
Acinetobacter baumannii   9 1 111 18 
Actinomyces coleocanis   4 0 19 0 
Actinomyces naeslundii  1 0 1 0 
Actinomyces odontolyticus   22 2 584 14 
Actinomyces urogenitalis   8 1 70 1 
Agrobacterium radiobacter  2 1 51 12 
Agrobacterium tumefaciens  4 0 95 0 
Anaerococcus hydrogenalis  1 0 6 0 
Atopobium rimae   2 1 31 1 
Atopobium vaginae   1 0 1 0 
Bacillus amyloliquefaciens   3 0 168 0 
Bacillus anthracis   3 0 92 0 
Bacillus cereus   1 2 8 10 
Bacillus halodurans  1 0 5 0 
Bacillus selenitireducens  1 0 2 0 
Bacillus sp. B14905  1 0 3 0 
Bacillus sp. NRRL B‐14911  1 0 25 0 
Bacillus sp. SG‐1  1 0 18 0 
Bacillus stearothermophilus  1 0 1 0 
Bacillus subtilis  1 0 1 0 
Bacillus thuringiensis   2 0 20 0 
Bacteroides caccae   17 0 259 0 
Bacteroides capillosus   4 0 17 0 
Bacteroides coprocola   5 0 42 0 
Bacteroides dorei   1 0 1 0 
Bacteroides eggerthii   1 0 2 0 
Bacteroides fragilis  16 0 273 0 
Bacteroides intestinalis   3 0 21 0 
Bacteroides ovatus   3 0 52 0 
Bacteroides pectinophilus   3 0 55 0 
Bacteroides plebeius   3 0 14 0 
Bacteroides stercoris   1 1 42 2 
Bacteroides thetaiotaomicron 5 2 62 38 
Bacteroides uniformis   4 0 33 0 
Bacteroides vulgatus   12 0 187 0 
Bartonella bacilliformis   1 1 111 13 
Bartonella henselae   1 0 1 0 
Bartonella quintana   1 0 61 0 
Bdellovibrio bacteriovorus  4 1 123 3 
Bifidobacterium adolescentis 2 0 4 0 
Bifidobacterium animalis  5 1 98 21 
Bifidobacterium catenulatum  1 0 2 0 
Bifidobacterium dentium   2 0 2 0 
Bifidobacterium longum   7 1 12 3 
Bordetella avium   5 1 15 139 
Bordetella bronchiseptica   2 1 43 3 
Bradyrhizobium japonicum  3 1 22 30 
Bradyrhizobium sp.   1 0 340 0 
Brevundimonas sp. BAL3  1 0 23 0 
Burkholderia ambifaria   4 0 6 0 
Burkholderia cenocepacia   6 0 37 0 
Burkholderia cepacia  2 0 12 0 
Burkholderia mallei   3 0 29 0 
Burkholderia phymatum   1 0 120 0 
Burkholderia phytofirmans   2 1 14 3 
Burkholderia sp.  1 0 1 0 
Burkholderia thailandensis   1 0 3 0 
Burkholderia xenovorans   2 2 113 119 
Campylobacter coli RM2228 1 0 1 0 
Campylobacter concisus   4 1 76 3 
Campylobacter curvus   2 0 12 0 
Campylobacter hominis   1 0 8 0 
Catonella morbi   1 0 6 0 
Caulobacter crescentus   3 0 56 0 
Clostridiales bacterium  3 0 9 0 
Corynebacterium aurimucosum    2 0 19 0 
Corynebacterium diphtheriae 1 0 3 0 
Corynebacterium glutamicum  2 0 4 0 
Corynebacterium jeikeium   1 0 1 0 
Corynebacterium kroppenstedtii   1 0 1 0 
Corynebacterium lipophiloflavum   1 0 9 0 
Corynebacterium matruchotii  1 0 7 0 
Corynebacterium urealyticum  1 0 3 0 
Delftia acidovorans   5 1 58 24 
Desulfovibrio desulfuricans   1 0 27 0 
Desulfovibrio magneticus   2 1 119 57 
Eikenella corrodens  7 0 43 0 
Enterobacter sp.   4 0 11 0 
Enterococcus faecalis   6 0 37 0 
Enterococcus faecium  1 1 3 3 
Enterococcus hirae  1 0 10 0 
Escherichia coli  3 0 13 0 
Escherichia coli O127:H6   1 0 1 0 
Escherichia coli O139:H28   9 1 221 6 
Escherichia coli O157:H7  3 0 20 0 
Eubacterium biforme   3 0 74 0 
Eubacterium dolichum   1 0 13 0 
Eubacterium eligens   2 0 15 0 
Eubacterium hallii   1 1 14 2 
Eubacterium rectale   3 0 10 0 
Eubacterium siraeum   2 0 16 0 
Eubacterium ventriosum   7 1 133 4 
Finegoldia magna    1 0 10 0 
Fusobacterium nucleatum  10 1 91 9 
Granulicatella adiacens  1 0 2 0 
Haemophilus ducreyi  14 0 46 0 
Haemophilus gallinarum  0 1 0 1 
Haemophilus influenzae  32 0 214 0 
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Haemophilus parainfluenzae 2 0 3 0 
Haemophilus parasuis  2 0 3 0 
Haemophilus somnus  4 0 12 0 
Helicobacter pylori   3 0 6 0 
Kingella oralis   7 0 16 0 
Klebsiella pneumoniae  1 0 5 0 
Kocuria rhizophila   9 0 95 0 
Lactobacillus amylophilus  1 0 1 0 
Lactobacillus brevis   1 0 3 0 
Lactobacillus casei   1 0 46 0 
Lactobacillus delbrueckii  2 0 42 0 
Lactobacillus gasseri   2 0 51 0 
Lactobacillus helveticus  1 1 17 1 
Lactobacillus jensenii  1 0 53 0 
Lactobacillus plantarum  1 0 2 0 
Lactobacillus sakei  1 0 2 0 
Lactobacillus salivarius   1 0 12 0 
Lactobacillus vaginalis   0 1 0 1 
Lactococcus lactis  12 1 158 1 
Listeria innocua  1 0 19 0 
Listeria welshimeri  1 0 1 0 
Mobiluncus curtisii   1 0 4 0 
Mobiluncus mulieris   2 0 10 0 
Mycobacterium abscessus   2 0 40 0 
Mycobacterium avium   1 1 2 1 
Mycobacterium bovis  2 1 40 11 
Mycobacterium leprae  1 0 1 0 
Mycobacterium smegmatis  2 1 64 47 
Mycobacterium ulcerans   1 0 10 0 
Mycobacterium vanbaalenii  1 0 1 0 
Mycoplasma capricolum  2 0 15 0 
Mycoplasma mycoides  1 0 1 0 
Mycoplasma pulmonis  2 0 15 0 
Neisseria flavescens  95 0 382 0 
Neisseria gonorrhoeae  94 2 1026 10 
Neisseria meningitidis  121 1 917 1 
Neisseria perflava  1 0 10 0 
Ochrobactrum anthropi   1 0 1 0 
Oribacterium sinus  2 1 8 13 
Porphyromonas endodontalis  4 1 56 1 
Porphyromonas gingivalis   10 1 115 5 
Porphyromonas uenonis  6 0 26 0 
Prevotella intermedia  1 0 1 0 
Prevotella loescheii  1 0 24 0 
Propionibacterium acnes  2 0 14 0 
Propionibacterium freudenreichii subsp. shermanii  1 0 2 0 
Proteus mirabilis   1 0 51 0 
Pseudomonas aeruginosa  2 0 22 0 
Pseudomonas fluorescens   1 0 29 0 
Pseudomonas mendocina   1 0 3 0 
Pseudomonas putida   1 0 28 0 
Pseudomonas sp. BG33R  1 0 11 0 
Pseudomonas stutzeri   2 0 22 0 
Ralstonia eutropha  2 1 126 92 
Ralstonia metallidurans   2 0 6 0 
Ralstonia pickettii   5 0 24 0 
Ralstonia solanacearum   7 0 24 0 
Rhizobium etli   1 0 2 0 
Rhizobium leguminosarum bv. trifolii  1 0 13 0 
Rhizobium loti   1 0 2 0 
Rhizobium tropici  1 0 5 0 
Selenomonas flueggei   16 2 121 42 
Selenomonas ruminantium  1 0 53 0 
Shuttleworthia satelles   2 2 24 6 
Sphingomonas sp. SKA58  1 0 1 0 
Staphylococcus aureus   1 1 10 6 
Staphylococcus cohnii  1 0 16 0 
Staphylococcus epidermidis  1 0 53 0 
Staphylococcus haemolyticus  1 0 2 0 
Stenotrophomonas maltophilia  1 0 5 0 
Streptococcus agalactiae  17 1 296 1 
Streptococcus canis  2 1 27 1 
Streptococcus equi  11 1 62 2 
Streptococcus equinus   5 1 75 13 
Streptococcus equisimilis  1 0 75 0 
Streptococcus gordonii   15 0 291 0 
Streptococcus infantarius  7 0 39 0 
Streptococcus intermedius  1 1 48 5 
Streptococcus mutans  12 0 135 0 
Streptococcus oralis  1 0 4 0 
Streptococcus parasanguis  2 0 33 0 
Streptococcus parauberis  2 0 8 0 
Streptococcus pneumoniae  65 3 780 15 
Streptococcus pyogenes serotype  10 1 111 1 
Streptococcus salivarius  34 3 199 69 
Streptococcus sanguinis   13 4 224 47 
Streptococcus suis  5 2 55 12 
Streptococcus thermophilus  14 2 119 3 
Streptococcus uberis   3 0 19 0 
Streptococcus vestibularis  2 0 6 0 
Treponema pallidum  1 0 6 0 
Treponema phagedenis  1 0 3 0 
Treponema saccharophilum 1 0 70 0 
Veillonella dispar   21 3 216 29 
Xanthomonas campestris  1 0 1 0 
Yersinia aldovae  1 0 19 0 
Yersinia enterocolitica   3 1 37 7 
Yersinia frederiksenii  1 0 3 0 
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